Skip to content
Regulatory news list Vol. 22 · 2026-11-16

Global Regulatory Monitor
Regulatory News, Week 3 · 2026/11

Period 2026-11-09 ~ 2026-11-16 Published 2026-11-16 Collected 142 · 82 cards Evidence A 32 · B 50 · C 0

20 cards in this issue cover Korean regulator documents. Company and institution names, and quoted source text, are shown in Korean exactly as they appear on the official record.

This week's key points
  • FDA issues a 6-observation Form 483 to a sterile drug site in Jecheon, Korea, citing manipulated microbiology records
  • FDA warns USV's sterile injectable site in India over 3 violations in aseptic design and visual inspection
  • MFDS suspends all manufacturing at a domestic company for 1 month for skipping required self-inspections
This week at a glance
51GlobalFDA 483 observation 44 items · Warning Letter 4 items · Regulatory news 2 items · Guidance 1 item
13KoreaAdministrative action 11 items · GMP inspection 2 items
18RecallRecall 12 items · Recall / sales suspension 3 items · Recall (Health Canada) 2 items · Recall (UK) 1 item
About AI-generated content

Summaries, translations, implications, check items, and in-depth analysis are written by generative AI; figures, quotations, links, and machine-extracted tables are provided as in the source. This is reference material — check the official source before making decisions.

Read in full ↓
82 cards

Global 51 cards

▫️ Other
[FDA 483 observation · FDA]Dr. Reddy's Laboratories Ltd. — Aseptic filling and EM deficiencies
FDA483

While loading sterile stoppers many touched an unsterilized part directly

Published 2026-11-13 · Inspection date 06/25/2026 · Drug Product Manufacturer · FEI 3014250111

7 observations
Findings
  1. 1Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate aseptic practices.
  2. 2Aseptic processing environmental monitoring procedures are inadequate in them filling line.
  3. 3Thewe drug substance manufacturing process lacks adequate controls to prevent microbial contamination of in-process intermediates.
  4. 4Aseptic practices observed in air visualization studies oe drug product filling operations are inadequate in that first air was obstructed in different m@ critical zones during aseptic processing interventions.
  5. 5The visual inspection program for @@ drug product is inadequate.
Show 2 more
  1. 6Your firm failed to review in-process bioburden testing results form@ drug substance, as microbial colony growth was detected in multiple in-processy@ samples.
  2. 7Your firm failed to ensure that operators working in aseptic manufacturing areas are adequately trained, as evidenced by deficient On-the-Job Training (OJT) records for personnel in them@ _ area.
Check points
  • Does the aseptic filling procedure still allow sterilized stopper bowls and parts to be assembled uncovered before the decontamination cycle? (Observation 1)
  • Does the procedure set contact time and rolling technique for fingertip plates, and is it followed? (Observation 2)
  • Are black and colored particles classified as critical defects in visual inspection? (Observation 5)
Observation detail · 7 observations · From the source
Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate aseptic practices.

During filling of [redacted] drug product batch number [redacted] on June 18, 2026, in the [redacted] filling line, inadequate aseptic practices were observed. Specifically, A. The oe and stopper bowl were assembled into the [redacted] and were uncovered prior to initiation of the oe decontamination cycle. As a result, these sterilized components were exposed to the [redacted] decontamination agent prior to filling operations, compromising the sterility of these items. Sterilized components introduced into the [redacted] should not be subjected to conditions that could compromise their sterility assurance. B. During loading of [redacted] sterilized stoppers into the [redacted], theme ow), which is not sterilized and is only exposed to the [redacted] decontamination cycle, is positioned directly above the [redacted] When [redacted], the [redacted] blocks unidirectional first air to the mw, exposing the sterilized [redacted] to potential microbial contamination. C. During loading of they sterilized stoppers into the [redacted], a large number of stoppers were observed making direct contact with an unsterilized [redacted] positioned above the [redacted] Contact between sterilized stoppers and an unsterilized surface compromise the sterility of the stoppers prior to their placement on vials. Drug Product and Drug Substance Manufacturer D. During installation of the [redacted], each me was assembled onto a non- sterileg [redacted] Although eac [redacted] _-was individually protected by a cover prior to installation, the top of each protective cover was observed contacting the unsterile [redacted] Upon removal of the protective cover, the cover was slid along the full length of these, such that the top portion of the cover contacted the entire length of the [redacted] _, including the mm This practice compromises the sterility of thes and presents a direct contamination risk to the drug product. E. The [redacted], under which vials are capped during the stoppering operation, is positioned such that it blocks unidirectional first air to all vials passing beneath it. The [redacted] is not sterilized and is only exposed to th [redacted] decontamination cycle. Because all vials must pass under this [redacted] during stoppering, this unsterilized surface is in direct proximity to open vials and exposed stoppers, representing an uncontrolled contamination risk to the drug product. F. During filling of [redacted] drug product batch number [redacted] on June 22, 2026, in the [redacted] Restricted Access Barrier System (RABS) vial filling line (Grade A within a Grade B environment), inadequate aseptic practices were observed. Specifically, 1. Operators were observed moving back and forth between the Grade B area and the Grade A air-supplied area outside the RABS through which stoppered vials transit via conveyor belt to the capping machine. Although a [redacted] is present between the operators and the stoppered vials on the conveyor, operators were observed reaching [redacted] ow) into the Grade A zone to manually discard vials identified as lacking stoppers or as m™ [redacted]. This practice introduces personnel, who have been present in the lower-classified Grade B environment, into direct proximity with potentially [redacted] vials within the Grade A zone, compromising the sterility Drug Product and Drug Substance Manufacturer of the drug product. The repeated ingress and egress of operator arms [redacted], as well as operators extending over the [redacted], disrupts the integrity of the GradeA air supply and increases the risk ofmicrobial contamination of the drug product. This inadequate aseptic practice is visible at minute 10:59:19 in airflow simulation video IMNO9, titled "Removal of unstoppered or [redacted] or fallen vials over [redacted] conveyor (Smoke Study, [redacted])", filmed on August 22, 2025.

Observation 2

Aseptic processing environmental monitoring procedures are inadequate in them filling line.

Specifically, A. On June 24, 2026, following filling of [redacted] drug product batch number 0), environmental monitoring failed to include viable surface monitoring of the [redacted] 0) and stopper bowl. The inadequate [redacted] design does not allow for effective monitoring strategies for these indirect product-contact surfaces, which compromises sterility assurance of the drug product as the potential microbial load on these components during filling operations remains unknown. B. On June 23, 2026, following filling ofmm drug product batch number 0) and [redacted] drug product batch number [redacted],imprope [redacted] fingertip contact plate monitoring technique was observed, as approximately only one second of non-rolling finger contact with the contact plates was observed. This inadequate contact time undermines the reliability of environmental monitoring data. C. On June 23, 2026, during environmental monitoring of the [redacted] ow) module of the [redacted] following filling of [redacted] drug product batch numbe [redacted] complete absence of a non-viable particle monitor in the transfer conveyor Drug Product and Drug Substance Manufacturer area durings) [redacted] unloading was observed. This constitutes a critical gap in the environmental monitoring program as adequate air quality control during a sterility-critical operation cannot be demonstrated.

Observation 3

Thewe drug substance manufacturing process lacks adequate controls to prevent microbial contamination of in-process intermediates.

Specifically, 0) microorganism, was identified in the [redacted] (batch numbe [redacted] indicating contamination events across multiple unit operations.

Observation 4

Aseptic practices observed in air visualization studies oe drug product filling operations are inadequate in that first air was obstructed in different m@ critical zones during aseptic processing interventions.

Specifically, 1. Airflow visualization (smoke) studies conducted on 17/12/2024 (December 17, 2024) for Intervention: Filling machines adjustment vial maximum loa [redacted] atw [redacted], show that ame positioned above the [redacted] would likely block first air to all vials as they are transported in the [redacted] il. Airflow visualization (smoke) studies conducted on 19/12/2024 (December 19, 2024, 19:22:22) for Intervention: Adjustment of stoppering machine parts [redacted], Show that a [redacted] positioned above the mw and ame hand blocked first air to exposed stoppers. Drug Product and Drug Substance Manufacturer The we and/oig) [redacted] hand were positioned such that they blocked first air to either open vials or exposed stoppers (direct product-contact surfaces) in Grade A critical zones within the [redacted] during inherent and non-inherent interventions, increasing the risk of microbiological contamination of the sterile drug product.

Observation 5

The visual inspection program for @@ drug product is inadequate.

Specifically, A. The classification of defect categories (1.e., critical, major, and minor) is not adequately justified. For example, black and colored particles, which present a significant risk to patient safety and are indicative of potential contamination, have been inappropriately classified as major defects rather than critical defects. B. Visual inspection qualification kits include vials marked with numbers visible to personnel performing qualification testing. This practice compromises the integrity of the qualification process, as inspectors may become familiar with the identity and location of defective vials prior to qualification testing.

Observation 6

Your firm failed to review in-process bioburden testing results form@ drug substance, as microbial colony growth was detected in multiple in-processy@ samples.

The microorganism recoveries were not identified, and root cause investigations were not performed. Specifically, OX).;. A. Batch No. [redacted]: Bioburden testing conducted on April 25, 2025, yieldede [redacted] microbial colonies. Drug Product and Drug Substance Manufacturer B. [redacted] Batch No. [redacted]: Bioburden testing conducted on May 2, 2025, yielded [redacted] microbial colony. C. [redacted] Batch No. [redacted]: Bioburden testing conducted on May 10, 2025, yielded mw microbial colonies.

Observation 7

Your firm failed to ensure that operators working in aseptic manufacturing areas are adequately trained, as evidenced by deficient On-the-Job Training (OJT) records for personnel in them@ _ area.

Specifically, Review of the On-the-Job Training Record (record numbe [redacted] for Employee ID: p shows that individual skill training sessions for critical aseptic manufacturing operations were documented as lasting as few as 29 minutes (Participate in BPR execution and closure activity, documented November 10, 2025, mw and 9 minutes (Procedure for operation and cleaning of [redacted] LAF, documented November 10, 2025, [redacted]. These session durations do not provide reasonable assurance that the employee received sufficient training to competently perform complex aseptic operations, including equipment cleaning and sterilization activities that are critical to product sterility assurance.

See all 3 findings in this document
[FDA 483 observation · FDA]Qingdao Kangyuan Pharmaceutical Co., LTD — API test methods and stability gaps
FDA483

Product returned from the USA put back into release inventory without QA check

Published 2026-11-13 · Inspection date 01/25/2013 · API Manufacturer · FEI 3006512854

11 observations
Findings
  1. 1From 12/10 to 7/12, quantities of@@ finished batches of bearing a labeling for use ir have been shipped to USA.
  2. 2There is no written and approved stability study protocol.
  3. 3There was no study protocol to for developing an impurity profile on the product nor there was an impurity profile on@@ for review.
  4. 4No forced degradation studies have been performed or®® _ produced at the current manufacturing site.
  5. 5The contract laboratory performs the residual solvent test for detectinga@ in the finished product.
Show 6 more
  1. 7The Crude product used to produce the finished product is produced byg@ different suppliers.
  2. 9The pw step requires the use of oa i apparatus).
  3. 10The BPR does not document the duration of the, _—step of the 4) 4 during production; for example, at | | ?
  4. 12SOP 10-103 requires QA to check and sample products that are returned to the site.
  5. 14SOP 09-301 requires analytical balances to be placed on a vibration proof surface.
  6. 15There was no identification, calibration record, or usage log on a scale found in the raw material weighing and dispensing room.
Check points
  • When using a different pharmacopeial method, is equivalence shown for every test? (Observation 1)
  • Does QA check quantity and sample returned goods before restocking them? (Observation 12)
  • Are balances checked with weights matching the actual sample weight range? (Observation 14)
Observation detail · 11 observations · From the source

Inspectors: Jose R. Hernandez

Observation 1

From 12/10 to 7/12, quantities of@@ finished batches of bearing a labeling for use ir have been shipped to USA.

The finished product shipped to the USA was tested based on the Chinese Pharmacopeia method. On December 27-31, 2012, a study was performed comparing only the potency method listed the Chinese Pharmacopeia with the USP (lot [redacted] but no lot number of a) used were recorded.

Observation 2

There is no written and approved stability study protocol.

The three PV batche [redacted]) were reportedly placed on stability studies. However, the samples for these batches were initially stored in a refrigerator. The samples were moved from the refrigerator to two other stability storage study units, but there is no written explanation as to how, when, and why the samples were managed when moved out each of the stability study storage units.

Observation 3

There was no study protocol to for developing an impurity profile on the product nor there was an impurity profile on@@ for review.

Observation 4

No forced degradation studies have been performed or®® _ produced at the current manufacturing site.

Observation 5

The contract laboratory performs the residual solvent test for detectinga@ in the finished product.

This test is reportedly performed in accordance with the Chinese Pharmacopeia method. There is no information to determine whether this method is equivalent to the USP <467> method. Also, there is no information to determine whether the Chinese Pharmacopeia method had been qualified by performing at least linearity and specificity with equipment used for testing. Moreover, 4 is used in the process butneither the intermediate or the finished product is tested for this solvent.

Observation 7

The Crude product used to produce the finished product is produced byg@ different suppliers.

Reportedly, these suppliers do not have the capability of testing the crude product and the product is received untested. QKP tests the crude product. However, review of test records for the potency test performed found no data to allow traceability of lot numbers and expiration dates on reagents and solutions (i.¢., standard solution, water, and [redacted] used when the test is performed; for example, Crude supplicr’s lot #5,4 tested on 3/20/12. 8. ree type apparatuses used te) a the product in the ‘a [redacted] step,’ generate noticeably different 4. despile,)4. apparatuses being essentially the same. No investigation or experiment has been done to determine why the 4,4 from these apparatuses look different. j i

Observation 9

The pw step requires the use of oa i apparatus).

It was reported that44. is fixed at 6a but the a has not been qualified to assure that the its 4)4 is accurate, precise, linear, and robust. Also, the lot number of the 4 [redacted] use during the manufacturing is not documented; for example during the Processing of process Validation batches [redacted] H

Observation 10

The BPR does not document the duration of the, _—step of the 4) 4 during production; for example, at | | ?

OO) j thei stage’ the iS i 1]. Anentry in pagew of the BPR for the 4 processing step documents that 9 ofthe aes were collected and measured. However. while auestioning this BPR entry itwasreported that the operator measures the amount of The measurement is done oe The actual steps as to how the operator came up with the 4 value, documented in the BPR, are not documented in the BPR or explained in an operating instruction procedure. i

Observation 12

SOP 10-103 requires QA to check and sample products that are returned to the site.

However, there is no data to show that QA checked the amount of batch 4) returned to the firm on 2/28/11 and 3/16/11, respectively. It was reported that this product was returned from the USA due to the product cost being too high. The product was accepted by warehouse personnel and returned to product release inventory. ini —— Food and Drug Administration, CDER/OC/DMPQ/ICT, HFD-325 j January 21-25, 2013 10903 New Hampshire Avenue, Building 51, Room 4218 \ 1117-77ac sons Silver Spring, MD 20993 PH: +1 301 276-8261 ATTN: Ms. Elizabeth Philpy NUMER,: 3006512854 industry Information: www.fda.gov/oc/industry NAME AND TITLE OFINDIVIDUALTO WHOM REPORTISISSUED=———C——OSS—~—~<“‘<=<; OC! PS LNA ENS PIE Ae To: Mr. Naishan Liu, President and General Manager Uy a a ‘ail Mee en ee esaner ee Qingdao Kangyuan Pharmaceutical Co., LUD 43 Yinghai Industrial Area, Jiaozhou City CITY.STATEAND ZIPCODE — TYPE OFESTABLISHMENT INSPECTED a Qindao, Shandong, China 266300 APt Producer 13, A physical inspection of thegs water system revealed the following: Oo Oe type valves Were MOUNLEC) in the water distribution line installed. after the Watley a storage tank. These 4oy valves were installed in such a way that may not allow for complete drainage. 7 All valves observed at the use water use points are they, valve type. The was a water leak al the connection of the tubing to a pressure gauge after the [redacted] No TOC test is performed.

Observation 14

SOP 09-301 requires analytical balances to be placed on a vibration proof surface.

However, inspection of the table used to hold Metter Toledo analytical balance #JY-TP-12-01 revealed that the table vibrated to the touch. Also, one of the legs of the table appeared to be shorter than the other 3 legs and was supported by what appeared to be a folded carton. Also, the gy check of the balance was performed using dg Mass grams weight when in fact the sample weight uscd in testing is in milligrams.

Observation 15

There was no identification, calibration record, or usage log on a scale found in the raw material weighing and dispensing room.

Reportedly, this scale is used to weigh gm used in the product formulation and recorded in the BPR. 16, There were several undated loose pages ofpartially completed batch production records for processing stages Oa steps) in a drawer of a desk in the office used by production operators and management.; a, ae "|

See all 6 findings in this document
[FDA 483 observation · FDA]Avaria Health & Beauty Corp — Raw material ID and validation gaps
FDA483

Raw material spec cited the pharmacopeia for an in-house microbial limit test

Published 2026-11-13 · Inspection date 04/30/2024 · OTC Drug Manufacturer · FEI 3014583374

8 observations
Findings
  1. 1Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that conform to appropriate standards of identity, strength, quality and purity.
  2. 2The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.
  3. 3Verification of the suitability of the testing methods is deficient in that they are not performed under actual conditions of use.
  4. 4Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
  5. 5The quality control unit lacks the responsibility and authority to approve and reject all components.
Show 3 more
  1. 6Routine calibration of electronic equipment is not performed according to a written program designed to assure proper performance.
  2. 7Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.
  3. 8The number of containers to be sampled is not based upon appropriate criteria.
Check points
  • Is at least one identity test performed on every incoming raw material lot? (Observation 2)
  • Do raw material specs cite the actual test basis (USP or in-house)? (Observation 5)
  • Is the number of containers sampled based on statistical criteria, with amounts recorded? (Observation 8)
Observation detail · 8 observations · From the source

Inspectors: Jose M Cayuela

Observation 1

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that conform to appropriate standards of identity, strength, quality and purity.

Specifically, The quality control unit fails to ensure that the raw material, ed for the manufacturinsof OTC dis products shipped to the U.S. hassafety limits 0 ontamination.

Observation 2

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.

Specifically, The quality control unit fails to ensure that at least one test is performed to verify the identity of the _—'rawmaterialsused forthemanufacturingofOTC drugproducts shipped totheU.S.

Observation 3

Verification of the suitability of the testing methods is deficient in that they are not performed under actual conditions of use.

Specifically, The quality control unit failed to ensure that the analytical test method used for the quantification of contaminationa in manufacturing drug products is veri 1 conditions of testing. Withow od verification there is no assurance that the test results are accurate, precise, and reliable.

Observation 4

Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, The firm failed to validate the manufacturing process and equipment that are used to manufacture the following OTC drug products for the U.S. market.

Observation 5

The quality control unit lacks the responsibility and authority to approve and reject all components.

Specifically,. op:... [redacted] The quality control unit failed to ensure that the Raw Material Specification for the of drug products (documentNo version tb) effective date) does not depict misleading information regarding to the Microbial Limit Test (i.e., Total Plate Count and Yeast and Mold) making erroneously reference to the USP when in reality, the test is an In-house test.

Observation 6

Routine calibration of electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically, The quality control unit fails to establish a calibration program for the following electronic devices used to support the manufacturing and release of OTC drug products: a. Temperature and humidity devices used to monitor the environmental conditions of the: accelerated stability chamber, long term stability area, compounding area, and retain storage area. [redacted]. tor. [redacted]. b. pH meter used to monitor and report the pH of the used for the manufacturing of C drug products. we) SP a.. se [redacted]. c. conductivity meter used to monitor and report the conductivity of the used for the manufacturing ofOTC drug products. d, OM OE device used to report Microbial Limit ofWater.

Observation 7

Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.

Specifically, The quality control unit fails to establish annual product reviews for OTC drug products.

Observation 8

The number of containers to be sampled is not based upon appropriate criteria.

Specifically, The quality control unit fails to establish an appropriate sampling criteria such as statistical criteria for component variability, confidence levels, degree ofprecision required, past quality history of supplier, quantity needed for analysis and reserve of in-coming raw materials and active ingredients. For example, sb)), [redacted] a. Gee i22/2022, the firm receivedyay drums A) kg each) ofthe raw material, USP, lot from where"6 drum was sampled without a sampling m d criteria. Additionally, the quality control unit failed to record the amount of sample taken and the drum sampled. Standard Operating Procedure AQSP-MTRL-01, Raw Material Receiving, Sampling, Testing, Approval, Storage, and Disposition, revision 00, effective date 01/03/2023 is deficient establishing a sampling method and criteria.

See all 5 findings in this document
[FDA 483 observation · FDA]Guangxi Yulin Pharmaceutical Group Co. Ltd. — Unvalidated test methods, no audit trails
FDA483

Finished-product assay results not assessed against the label claim

Published 2026-11-13 · Inspection date 03/21/2025 · OTC Drug Manufacturer · FEI 1000589993

8 observations
Findings
  1. 1Testing and release ofdrug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
  2. 2Laboratory controls do not include the establishment ofscientifically sound and appropriate specifications, standards, and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.
  3. 3There is no written testing program designed to assess the stability characteristics of drug products.
  4. 4Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
  5. 5There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Show 3 more
  1. 6Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality, or purity of the drug product.
  2. 7Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.
  3. 8Strict control is not exercised over labeling issued for use in drug product labeling operations.
Check points
  • Are finished-product assay results judged as a percentage of label claim? (Observation 1)
  • Does lab software keep an audit trail that is reviewed before release? (Observation 2)
  • Is a third-party suspension notice on equipment handled as a deviation? (Observation 5)
Observation detail · 8 observations · From the source
Observation 1

Testing and release ofdrug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically, a) Your firm does not perform 1 i i ions foo ive ingredients in the nished OTC drug product atches of this drug product were distributed to the US in July 2023. b) Percentage concentrations ofthe active ingredients in finished dosage units of th TC drug product have not been determined. The finished product test results of the active ingredient assay are reported in units of milligra T milliliter (mg/mL) and no evaluation has been made to assess if this concentration meet centration label claim forww active ingredients. For example batch L packaging size) has finished pr assay test results reported as g/mL, respectively. atches o have been distributed to the US since December 2020,

Observation 2

Laboratory controls do not include the establishment ofscientifically sound and appropriate specifications, standards, and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.

SEE EI yp (S) Specifically, a) Your firm has not validated or verified i iate/in- i ‘analytical textmethodsperfomedod0) Me aac drug products. Test methods including but not limited to the following, have not been validated or verified: e| Active ingredient raw material component testing: fo) ssay [gas chromatography (GC)] fo] identification test (UV-visible spectroscopy and infrared spectroscopy) fe) related substances test (GC) e ntermediate/in-process testing: assa e finished product testing: ssay b) Your firm follows the Chinese Pharmacopoeia (ChP) for the test procedures, specifications, and reference standards used in component, intermediate/in-process, and finished product testing of the eis bet oe drug products distributed to the US. In accordance with the; e The acceptance criteria for the assay o active ingredients in finished pcoducts, "...contains no less than g " for each individual active ingredient (yourfirm's internal standard is, "...no less than 2/mL"). e The identification tests for component testing of [redacted] active ingredient are performed through colorimetric analysis rather than gas chromatography. e Component testing for active ingredient assay has an acceptance criteria of9%, c) The method validation performed on the finished product in-house test methodoem assay by gas chromatography fore OTC drug product is inadequate: e Accuracy: It is unclear how the results ofpercentage of the recovery of the known added amount yi Si in the sample injections were calculated. e Specificity: Assay test results are reported as a ratio of mg/mL with no evaluation or calculation of the percentage concentration of the [redacted] active ingredients. As such, this test method does not provide meaningful test results providing information on the potency of the analytes in these samples. d) System suitability testing is inadequate for the assay o [redacted] active ingredients by gas chromatography in raw material component testing and in the assay of these active ingredients in finished product testing o [redacted] e There is no blank injection. e The percent relative standard deviation is not calculated for the peak areas of the [redacted] reference standard injections. e System suitability testing in the method validation for [redacted] assay by gas chromatography in [redacted] finished product testing consists Ofma “eference standard injections, however, testing of finished product batches consists of [redacted] reference standard injections. e) Your firm lacks controls to ensure data integrity is implemented and maintained over analytical instruments and corresponding analytical software. For example: e There is no audit trail feature for the IRSolution software used in infrared (IR) spectroscopy. e There is no audit trail feature for the UVProbe software used in UV-Vis spectroscopy. Both analytical software systems are used for the component identification tests ofthe [redacted] active ingredient. e Raw data electronic files generated from the IR and UV-Vis software and saved locally on to the computer system can be deleted by QC personnel. e There is no review of the audit trail of the gas chromatography OpenLab software after completion of finished product testing and prior to finished product approval and release of each batch o [redacted] OTC drug product. This software is used for the assay of (4) active ingredients in finished product testing. e There is no documentation or record of the review and comparison of electronic raw data to the SEE E OYEE(S} printed, physical copy ofthe data.

Observation 3

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, (A)You have failed to establish how your stability testing methods are stability indicating. You do not have data to show your stability test methods meet the appropriate identity, strength, and quali attributes to support the helflife ofyour OTC GUNMEN products, (B) Microbial content and identification testing are not performed at appropriate intervals during your stability studies for yourOTC6 pros Microbiological and identity testing is only performed at the beginning of your stability study at the end of your study at St yo. do not have scientific rational to support this test frequency. (C) Stability testing for [redacted] does not testing for the active contents and you do not have scientific rational to justify not performing this test.

Observation 4

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, a) The production processes for the OTC dru products have not been validated for a specific batch size. The validated batch size for i ou, b) Your firm's calculation for percentage oftheoretical yield has an acceptance criteria fom %. The theoretical yield is based on a batch size o [redacted] which can be exceeded by the actual yield due to the variation of production batch sizes.

Observation 5

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, You did not open a deviation investigation following issues identified with you equipment. In September 2022, you received a third-party suspension notification for your SN on 4, equipment ID 130301011. However, upon receipt ofthis notification you failed to open a deviation to establish if the equipment was adequate for use and continued using tank 4 equipment ID 130301011 until it was replaced in April 2023. From September 2022 to April 2023, you manufactured apart lan SEAM, scches ofOTC) [redacted] Which were distributed to the U.S. market. In addition, no preventive actions were assessed or proposed for deviation PC-20250201 in which an unplanned power outage led to a loss ofpower to your firm’s stability chambers.

Observation 6

Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality, or purity of the drug product.

a Ff OYEE(S) TURE Specifically, Your firms cleaning validation studies to justify the cleaning in your reparation system are g J g In yOu [redacted] prep y inadequate. For example, (A) You do not have records to show you have validated the cleaning procedures for extended clean hold times. (B) You failed to establish how the methods used for your cleaning validation studies are adequate to detect the number of residual contaminants in your rinse samples.

Observation 7

Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.

Specifically, (A) Your firm failed to maintain records for routine supplier audits of your active pharmaceutical ingredient supplier. Records for the las [redacted] supplier audits for your [redacted] active pharmaceutical ingredient supplier could not be found. ‘The last record your facility has of a routine supplier audit was dated 2016. [redacted] is oneofthe active pharmaceutical ingredients for your m [redacted] drug products. (B) Your quality unit failed to implement appropriate change control procedures following changes to your supplier qualification process. For example, you changed your procedures for conducting routine supplier audits. However, these changes were not included in a change control process, and you do not have justification for why these changes were not incorporated into a change control.

Observation 8

Strict control is not exercised over labeling issued for use in drug product labeling operations.

SEE View BF NATURE Specifically, a) There is no label reconciliation in the packaging record for the OFC drug product. b) Reconciliation of labeling materials is inadequate as the starting quantity of packaging and labeling materials is not always confirmed to be accurate, therefore, resulting in inaccurate calculations for reconciliation. see wan

See all 6 findings in this document
[FDA 483 observation · FDA]Packagina On Demand, Inc. — No final ID testing, weak cleaning validation
FDA483

No identity test of the active ingredient before finished-product release

Published 2026-11-13 · Inspection date 09/27/2024 · Contract OTC Drug Manufacturer · FEI 3004758248

8 observations
Findings
  1. 1Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
  2. 2Drug product reserve samples are not stored in the same immediate container-closure system as the marketed product and an immediate container-closure system that has essentially the same characteristics as the marketed product.
  3. 3Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
  4. 4Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
  5. 5The persons performing and double-checking the cleaning and maintenance are not dating and signing or initialing the equipment cleaning and use log.
Show 3 more
  1. 6In-process specifications are not derived from previous acceptable process average and process variability estimates where possible.
  2. 7The number of containers to be sampled and amount of material taken from each container is not based upon appropriate criteria.
  3. 8Records fail to include an individual inventory record of each component and reconciliation of the use of each component with sufficient information to allow determination of any associated batch or lot of drug product.
Check points
  • Is an identity test of the active ingredient done before finished-product release? (Observation 1)
  • Does the cleaning validation recovery study show the methods detect residues? (Observation 4)
  • Are high-risk components sampled and tested from every container of each lot? (Observation 7)
Observation detail · 8 observations · From the source

Inspectors: Kham Phommachanh · Pearl C Ozuruigbo · Wenzheng Zhang

Observation 1

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

Specifically, identification testing of the active pharmaceutical ingredients has not been performed on final finished OTC drug products. For examples but not limited to the following: 1. No identification test was performed on the final release active ingredient of [redacted] that was used in the final finished OTC drug product [redacted] - [redacted] Lot No.: [redacted] - [redacted] that was produced on [redacted] and expires on [redacted] with [redacted] total finished goods produced and released by the quality unit on 04/30/2024. 2. No identification test was performed on the final release active ingredient of [redacted] that was used in the production of final finished drug product [redacted] Lot No.: [redacted] Manufactured on [redacted] ~—s and expired on [redacted] with total of (6) [redacted] finished goods produced and released by the quality unit on 04/03/2024. 3. No identification test was performed on the final release active ingredient of [redacted] that was used in the final finished OTC drug product [redacted] Lot No.: [redacted] that was produced on [redacted] and expires on [redacted] with [redacted] total finished goods produced and released by the quality unit on 06/28/2024. 4. No identification test was performed on the final release active ingredient of [redacted] that was used in the final finished OTC drug product [redacted] Lot. No.: [redacted] that was produced on [redacted] and expires on [redacted] with (6) [redacted] total finished goods produced and released by the quality unit on 03/14/2024.

Observation 2

Drug product reserve samples are not stored in the same immediate container-closure system as the marketed product and an immediate container-closure system that has essentially the same characteristics as the marketed product.

Specifically, OTC drug products retain samples are not maintained in the same immediate container- closure system as the marketed product. For examples, OTC drug products [redacted] lot [redacted] (»)(4) manufactured on [redacted] and [redacted] lot [redacted] manufactured on [redacted] were observed not in the same container closure in the retain sample room. FACILITIES AND EQUIPMENT SYSTEM

Observation 3

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Specifically, your firm's equipment qualification is inadequate. For example, your attempt of performance (PQ) references Batch production records: [redacted], Lot # [redacted], manufactured on [redacted] _, [redacted], Lot # [redacted] manufactured on " [redacted] - [redacted], and [redacted], Lot # [redacted] manufactured on [redacted], for the qualification is inadequate in that it does not provide full documentation of IQ, OQ, and PQ for compounding tanks. For filling equipment there is no IQ, OQ, and PQ used in the qualification of OTC drug products.

Observation 4

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

Specifically, your firm’s cleaning validation for the equipment used to manufacture and package the over-the-counter (OTC) drug products is deficient. Your firm used [redacted] and [redacted] methods to test cleaning procedures in the equipment cleaning validation (Validation Report: Cleaning and Sanitization of Production Equipment, Document Number: VR-12-03, Approved Date: September 18, 2014). However, the recovery study conducted in your equipment cleaning validation demonstrates that [redacted] and [redacted] testing failed to detect the dirty and clean surfaces of the production equipment. As a result, your firm’s proper equipment cleaning procedures cannot be assured. Without validated cleaning procedures for the equipment, the potential contamination that would alter the safety, identity, strength, quality, or purity of the drug products cannot be prevented.

Observation 5

The persons performing and double-checking the cleaning and maintenance are not dating and signing or initialing the equipment cleaning and use log.

Specifically, Your equipment cleaning and sanitization log which is your firm's confirmation of which equipment was used have discrepancies with information on the batch production record. For example: 1. Batch production record for [redacted] Lot # [redacted] manufactured on [redacted] indicated Tank & as the production tank, and this lot is not on the cleaning log. 2. Batch production record for [redacted] Lot # [redacted] manufactured on [redacted] indicated Tank [redacted] as the production tank, and this lot is not on the cleaning log. 3. Batch production record for [redacted] Lot # [redacted] —_—smanufactured on [redacted] indicated Tank as the production tank, and this lot is not on the cleaning log. 4. Batch production record for [redacted] Lot # [redacted] manufactured on [redacted] indicated Tank as the production tank, and this lot is not on the cleaning log. 5. Batch production record for [redacted] Lot # [redacted] manufactured on [redacted] indicated Tan [redacted] as the production tank, and this lot is not on the cleaning log. PRODUCTION SYSTEM

Observation 6

In-process specifications are not derived from previous acceptable process average and process variability estimates where possible.

Specifically, process validation is inadequate. There is no data to assure that bulk blends are uniform. For examples, 1. Your firm does not perform blend uniformity testing during the manufacturing process which prevents your firm from detecting potential variability in the homogeneity of active ingredients throughout the batch. 2. Your firm has not fully established appropriate time-based and temperature-based process control during manufacturing for example: a. The batch production record for [redacted] ’ Lot # [redacted] manufactured on [redacted] states " [redacted] - [redacted] " Stabilized temperature was not recorded for this batch, and thermometer ID and Calibration due date were also not recorded. b. The batch production record for [redacted] Lot # [redacted] manufactured on [redacted] states " [redacted] " 3. Your firm relies solely on content uniformity testing as the primary method for process validation and it is not consistent. For example: a. The batch production record for [redacted] Lot # [redacted] manufactured [redacted] - [redacted] was distributed to the customer on 7/9/2024. Samples of finished drug products were collected from the [redacted] of filling operation and tested separately for assay content. “Special Instructions: Drug Uniformity” b.The batch production record for [redacted] Lot # [redacted] manufactured [redacted] - () (4) was distributed to the customer on 9/28/2024. Samples of finished drug products were collected from the [redacted] of filling operation and [redacted] for assay content. “Special Instructions: Drug Uniformity ( [redacted] — of Run)” MATERIALS SYSTEM

Observation 7

The number of containers to be sampled and amount of material taken from each container is not based upon appropriate criteria.

Specifically, Between January 2024 and August 2024, your firm used [redacted] as the drug component to manufacture different over-the-counter (OTC) drug products for wholesale and distribution. [redacted] is a high-risk drug component for [redacted] and [redacted] contaminations. However, your firm did not adequately sample and test [redacted] for [redacted] and [redacted] from each container of each lot of each shipment before the high-risk drug component was used in the manufacture of drug products. Without appropriate sampling and testing of drug components, the quality and safety of drug products could not be ensured.

Observation 8

Records fail to include an individual inventory record of each component and reconciliation of the use of each component with sufficient information to allow determination of any associated batch or lot of drug product.

Specifically, your firm has no inventory control records or reconciliation of the use of each lot of drug substances and excipients for any batch of the over-the-counter (OTC) drug products. Imestgsee Imesbpaer” Geagated Drg Cade

See all 5 findings in this document
[FDA 483 observation · FDA]Huangshi Hygenic Material Medicine Co. — Expiry dating without stability testing
FDA483

OTC drugs for the US market assigned expiry dates without stability testing

Published 2026-11-13 · Inspection date 08/30/2024 · Manufacturer · FEI 3005543486

8 observations
Findings
  1. 1An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
  2. 2Equipment and utensils are not cleaned and maintained at appropmiate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
  3. 3Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
  4. 4Laboratory records are deficient in that they do not include a statement of the results of tests and how they compare to the established specifications.
  5. 5The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Show 3 more
  1. 6Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
  2. 7Buildings used in the manufacturing and processing of a drug product are not maintained in a good state of repair.
  3. 8Laboratory records do not include the initials or signature of a second person showing that the original records have been reviewed for accuracy, completeness and compliance with established standards.
Check points
  • Is every marketed product's expiry date supported by stability data? (Observation 1)
  • Is each batch tested for identity and strength of every active ingredient before release? (Observation 3)
  • Does the quality unit review HPLC/GC audit trails before approving results? (Observation 5)
Observation detail · 8 observations · From the source
Observation 1

An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.

Specifically, Your firm has not tested OTC drug products manufactured for the US market for stability to determine the expiration date. The products: oe wo are assigned [redacted] expiration date from the date of manufacture. The product [redacted] is assigned [redacted] expiration date from the date of manufacture. Ovei [redacted] batches of products shipped to the US i [redacted] are still within expiry date.

Observation 2

Equipment and utensils are not cleaned and maintained at appropmiate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, Equipment and utensils used for the manufacture ofUS drug products are not cleaned and maintained to prevent contamination including the following: (4 A) [redacted] S02009 used for the formulation of drug product [redacted] S02008 used for the formulation of drug product [redacted] we C) [redacted] used for transferring formulated US drug product intermediates to the [redacted] machine room. D) [redacted] $01007 used for [redacted] raw ingredients. E) [redacted] S01031 used for processing raw ingredients. In additional you firm did not conduct risk assessment for sharing of equipment and/or [redacted] between US and Domestic drug products/intermediates without performing major cleaning. Some of the ingredients used exclusively for Domestic products include oe we

Observation 3

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically, You did not perform testing of your finished product for identity and strength of each active ingredient prior to release including for a total o [redacted] batches of the following products manufactured for the US market. OC)

Observation 4

Laboratory records are deficient in that they do not include a statement of the results of tests and how they compare to the established specifications.

Specifically, Your firm did not perform growth promotion studies on each batch of media used for microbial testing of your finished drug products [redacted]

Observation 5

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically, A) Your quality unit does not review electronic raw data including but not limited to identify testing of a finished product and APIs by HPLC and GC. B) Your quality unit does not review audit trails on test results including for HPLC (Waters Chromatography Data System Empower 3 and Lab Solutions) and GC (Chromleon and OpenLab) to ensure data integrity. HPLC and GC are used to perform identity testing of APIs anda finished product. C) Your firm has not designed and performed cleaning validation studies on equipment used in the manufacture ofUS drug products including for oe D) You do not follow your procedure for “ [redacted] operating Regulations” CZ-21-4114 for testing of [redacted] The procedure requires [redacted] testing of [redacted] including for microorganisms. Your last [redacted] testing was performed on [redacted] Thewe is used in the production ofUS drug products and for cleaning ofproduction equipment. E) You do not follow your procedure “Laboratory management regulations” GL-ZL-2026 for data backup. Your SOP requires [redacted] data backup including for HPLC and GC data. However, your records indicate that you perform data back up [redacted] F) Your procedures for cleaning and cleaning verification of [redacted] is inadequate as it does not involves cleaning the interior of theme between batches of products considered similar.

Observation 6

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

Specifically, Your firm did not perform microbial testing of the finished drug product [redacted] manufactured for the US market.

Observation 7

Buildings used in the manufacturing and processing of a drug product are not maintained in a good state of repair.

Specifically, The building used in the processing and storing of the raw materials was not maintained in a good state of repair including A) The ceiling of raw material storage room had water damage stains and peeling paint above the bags storing raw ingredients. B) A door of the ingredient (API, [redacted] room was damaged and had large holes with potential for rodent and pest entry. C) Paint on the light frames above the raw material processing area and on the [redacted] room doors was found to be peeling at multiple locations. D) In adequate lighting in the raw material [redacted] processing areas. E) Raw materia [redacted] room hada dripping pipe with apparent mold on the wall.

Observation 8

Laboratory records do not include the initials or signature of a second person showing that the original records have been reviewed for accuracy, completeness and compliance with established standards.

Specifically, The reviewer of microbiological test results does not verify the original raw data for accuracy and completeness.

See all 6 findings in this document
[FDA 483 observation · FDA]Tripak Pharmaceuticals Pty Ltd. — Failed excipients used, no final release tests
FDA483

Finished product made with an excipient that had failed testing and then released

Published 2026-11-13 · Inspection date 07/25/2025 · Finished Product (OTC) Manufacturer · FEI 3008549263

9 observations
Findings
  1. 1The quality control unit lacks the responsibility and authority to approve, reject all drug products.
  2. 2Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.
  3. 3Failure to establish adequate written procedures for production and process controls.
  4. 4Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications, identity, and strength of each active ingredient prior to release.
  5. 5There is no written testing program designed to assess the stability characteristics of drug products.
Show 4 more
  1. 6Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
  2. 7Laboratory controls shall include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, drug product closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity.
  3. 8Equipment and utensils shall be cleaned, maintained, and, as appropriate for the nature of the drug, sanitized and/or sterilized at appropriate intervals to prevent malfunctions or contamination that may alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements, Specifically, On 07/24/2025, during my walkthrough inspection at your manufacturing facility, I observed multiple 0) tanks and transfer tanks without proper status labels.
  4. 9Strict control shall be exercised over labeling issued for use in drug product labeling operations.
Check points
  • Is release of an excipient blocked until its OOS investigation is closed? (Observation 1)
  • Are materials accepted on a supplier COA still identity-tested lot by lot? (Observation 2)
  • Is finished-product release based on tests of the final dosage form? (Observation 4)
Observation detail · 9 observations · From the source

Inspectors: Nibin Varghese

Observation 1

The quality control unit lacks the responsibility and authority to approve, reject all drug products.

Specifically, Your firm manufactured several products using inactive ingredients that failed testing. Following are the examples I observed during my review, but are not limited to: a) On 09/24/2024, your firm opened an OOS investigation #122 for one of the inactive ingredients used in the manufacturing of oe mL), Lot # [redacted] #(Bulk Lot # [redacted] Ex [redacted] ‘-Your contract testing laboratory reported twice for failed [redacted] content in oe, Batch [redacted] Your firm proceeded with manufacturing of finished product Lot # [redacted] using the failed inactive ingredient. This product was later released to your customer and subsequently shipped to the US market. Capalaba, Queensland, Australia 4157 Finished Product (OTC) Manufacturer b) On 05/16/2024, your firm opened an OOS investigation #115 for the inactive ingredient used in [redacted] Tot He [redacted] and [redacted] Lot He [redacted] Your contract testing laboratory reported an OOS for impurity failure in [redacted] Lot # [redacted] Related substances were reported as more than [redacted] % for a specification of NMU [redacted] %. Your firm proceeded with manufacturing of finished products Lot # [redacted] and Lot # [redacted] using the failed inactive ingredient. These products were later released to your customer and subsequently shipped to the US market.

Observation 2

Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.

Specifically, a) Your firm failed to conduct identification tests for raw materials used in drug product manufacturing. Specifically, your firm failed to verify the identity of each component prior to use in manufacturing operations. For example, your firm used oe oe Lot [redacted] in the manufacture of [redacted] Lot # [redacted] Exp: [redacted] without performing the required identification testing to confirm these materials met established specifications. The failure to conduct proper identification testing creates a significant risk that incorrect, adulterated, or substandard raw materials may be incorporated into finished drug products, potentially compromising product safety, efficacy, and quality. b) From 01/31/2024 to 02/07/2025, your firm released [redacted] lots of [redacted] 4) to customer, and these lots were subsequently shipped to the US market. These lots Capalaba, Queensland, Australia 4157 Finished Product (OTC) Manufacturer were manufactured using [redacted] as an inactive ingredient. Your firm failed to conduct specific identity analysis for each lot of [redacted], which should include a limit test for oe and incorporate testing of samples from all containers of all lots received. Currently, your firm tests for [redacted] oe which does not ensure the safety and quality of each individual lot used in manufacturing. For example, [redacted] Lot Ho [redacted] (Bulk Lot # [redacted]. Exp. [redacted], was manufactured using [redacted] Lot # [redacted] which was accepted based solely on the supplier's Certificate of Analysis (COA) for [redacted] without independent verification testing.

Observation 3

Failure to establish adequate written procedures for production and process controls.

Specifically, Your process validation report VMP-VR0031.00 for the manufacturing of [redacted] bulk fails to demonstrate that written procedures designed to assure that drug products have the identity, strength, quality, and purity they purport or are represented to possess are adequate. The validation lacks sufficient details regarding critical process parameters, in-process controls, and acceptance criteria for manufacturing steps. Additionally, the validation scope is limited to bulk product testing and does not address process parameter controls to ensure consistent product quality throughout the manufacturing process. Moreover, your firm failed to validate the filling/packaging process. Capalaba, Queensland, Australia 4157 Finished Product (OTC) Manufacturer

Observation 4

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications, identity, and strength of each active ingredient prior to release.

Specifically, Your firm failed to test finished drug products for all required specifications prior to release. From 05/04/2022 to 05/19/2025, your firm manufactured and released approximately [redacted] batches to your customers without conducting comprehensive finished product testing. These lots were subsequently shipped to the US market. Your firm currently relies only on bulk drug testing results for finished product release, which is inadequate to ensure the quality and safety of the final dosage form. For example, the [redacted] Lot # [redacted] (Bulk Batch Lot # [redacted] Exp: [redacted] was released on 05/07/2024 without testing the finished dosage form, relying solely on bulk drug testing results. The absence of finished product testing creates significant risk that products not meeting quality standards may be released to the market, potentially compromising patient safety and product efficacy.

Observation 5

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, Your firm failed to establish a written testing program designed to assess the stability characteristics of oe Your firm currently proposes a [redacted] 4) expiration period without adequate supporting stability data. The proposed expiration Capalaba, Queensland, Australia 4157 Finished Product (OTC) Manufacturer date is based solely on 6-month accelerated condition (ACC) data for bulk, which is insufficient to support the claimed shelf life according to established stability testing. Additionally, your firm failed to place at least one (1) batch of each commercial product on long-term stability testing under recommended storage conditions. This deficiency prevents your firm from demonstrating that the products maintain their identity, strength, quality, and purity throughout the proposed shelf-life period.

Observation 6

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, Your firm failed to conduct hold time studies for products manufactured at your facility. For example, On [redacted], your firm compounded [redacted] Bulk Lot # [redacted]. but did not complete filling operations until [redacted] (final lot # [redacted], representing a hold time of approximately [redacted] between compounding and final packaging. Without proper hold time studies, your firm cannot demonstrate that the product maintains its identity, strength, quality, and purity during extended storage periods between manufacturing steps.

Observation 7

Laboratory controls shall include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, drug product closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity.

Capalaba, Queensland, Australia 4157 Finished Product (OTC) Manufacturer Specifically, From 05/04/2022 to 05/19/2025 your firm released approximatel [redacted] lots of products to customers without conducting [redacted] testing. These lots shipped to the US market. All your products contains [redacted] an inactive ingredient in the formulations, which significantly increases the microbiological risk profile and necessitates comprehensive microbiological testing to ensure product safety. For example, the [redacted], Lot # [redacted], Exp: [redacted] was released on 05/07/2024 without conducting testing for [redacted]

Observation 8

Equipment and utensils shall be cleaned, maintained, and, as appropriate for the nature of the drug, sanitized and/or sterilized at appropriate intervals to prevent malfunctions or contamination that may alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements, Specifically, On 07/24/2025, during my walkthrough inspection at your manufacturing facility, I observed multiple 0) tanks and transfer tanks without proper status labels.

Specifically, I observed [redacted] tanks in the warehouse and [redacted] tanks in the compounding area that lacked appropriate status identification. According to the cleaning logbooks, these tanks had been cleaned; however, the status was not clearly indicated through proper labeling. According to your written procedure no. 30022.04: Status Labeling in Production, new green cleaned labels should be attached after equipment cleaning. The absence of clear status labeling creates potential for cross-contamination and makes it difficult to verify equipment Capalaba, Queensland, Australia 4157 Finished Product (OTC) Manufacturer readiness for use. These tanks are being used in the manufacturing of several products including The we mL).

Observation 9

Strict control shall be exercised over labeling issued for use in drug product labeling operations.

Specifically, On 07/25/2025, during my walkthrough inspection, I observed inadequate label storage controls. Multiple different label rolls were stored together in plastic bags in an open warehouse environment accessible to all personnel, creating significant risk for label mix-ups, unauthorized access, and compromised chain of custody during labeling operations. Additionally, your firm failed to have a written procedure for the labeling issuance and control.

See all 5 findings in this document
[FDA 483 observation · FDA]Linhai Tianyu Pharmaceutical Co., Ltd. — OOS investigations and data review
FDA483

Electronic data checklists were ticked one after another with no software open

Published 2026-11-13 · Inspection date 09/15/2023 · Active Pharmaceutical Ingredient and Intermediate Manufacturer · FEI 3013345425

7 observations
Findings
  1. 1Written procedures are deficient for the cleaning and maintenance of equipment used in the manufacturing, processing, packing, or holding of a drug substance.
  2. 2Facilities and equipment used in the manufacturing of drug substances are not adequately maintained.
  3. 3Written records of investigation into unexplained discrepancies and the failure ofa batch or any of its components to meet specification do not always include the conclusions and follow-up.
  4. 4Laboratory records are not completed contemporaneously and do not include complete data derived from all tests to assure compliance with established specifications and standards.
  5. 5There is no written testing program designed to assess the stability characteristics of drug substances and intermediates.
Show 2 more
  1. 6Appropriate controls are not exercised over computers or related systems to assure that changes in quality control records are instituted only by authorized personnel.
  2. 7The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Check points
  • Are OOS root causes confirmed with hypothesis testing or other scientific evidence? (Observation 3)
  • Do reviewers open the original electronic data before signing review checklists? (Observation 4)
  • Does electronic data review reconcile data generated in every software package? (Observation 7)
Observation detail · 7 observations · From the source

Inspectors: Arsen Karapetyan · Anders W. Evenson

Observation 1

Written procedures are deficient for the cleaning and maintenance of equipment used in the manufacturing, processing, packing, or holding of a drug substance.

Specifically, Your firm’s clean hold time study and evaluation report (Confirmation report on the validity of the clean retention time of the crude roduction equipment GP-EV-PR-3-21 1203; Evaluation Report on Reasonableness0 Oo Area Equipment GR-EV-PR-3-220805) that are applicable for drug substances and intermediates, including [AMM conclude aPOF ican hold time inMM followingoe firm’s Equipment Cleaning Management Procedure SMP-PR-011 requires a clean for beyond thisamet time that is valid foryour firm’s Cleaning Managementoreo 1) and clean hold time study and evaluation (GP-EV-PR-3-211203, GR-EV-PR-3-220805) are deficient because they do not include adequate scientific justification for thePPA ctean hold time following a88 clean after) NNN clean, For example, we reviewed Equipment Operational Logbooks FOM-GDL-035-01 for 2022.05.09~2022.08.10 and 2022.08.18~2022.08.28 for JJ [redacted] 315 in Workshop On J mm completed a lean after a production campaign of later, your firm completed a clean on hes our tirm’s Cleaning Management Procedure (SMP-PR- - On August 16, 2022, your firm began 2 1OSbatch production campaign for) an intermediate used in the manufacturing of drug substance or the China and Europe market. Your firm has no scientific Linhai Tianyu Pharmaceutical Co., Ltd. No. 15 Donghai 5th Ave., Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai CITY, STATE, ZIP CODE, COUNTRY ZonESTABLSRSAENT INSPECTED Manufacturer. justification that confirmscen following aeerrnii hold time is sufficient on [redacted] quipment used between production campaigns ofwed erent products.

Observation 2

Facilities and equipment used in the manufacturing of drug substances are not adequately maintained.

Specifically, During our facility walk-through on 9/11/2023, we observe i itions in Workshops/ [redacted] andPena are used for drug substance manufacturing ofae other drug substances and intermediates intended for the U.S. market: ¢ Worksho fe) 15 with three ~2 feet segments of broken pipe insulation laying near utility nect to theSR PSain andPisin 18 with multiple reddish/brown areas on the ground and a puddle of water under the utility pipes that connect to thesasuaneana.atiii and the§§ [redacted] tank fe) omer with reddish/br surrounding utility pipes that run through the ae o Area between 14 and 15 with l)a 3-feet by 2-feet by 2- inch pan-like item placed under the utility pipes that connect to there station andsans 2) a~2 feet by 1 foot reddish/brown area of peeling floor under utility pipes connect to the EE Paton 3) a drooping clear coil with reddish/brown residue that connects to utility pipes that connect to the I [redacted] 17 with a drooping clear coil with reddish/brown residue that carries 0 utility pipes that connect to theIN stationander tan; 09/15/2023 Linhai Tianyu Pharmaceutical Co., Ltd. No. 15 Donghai 5th Ave., Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai CITY, STATE, ZIP CODE, COUNTRY ‘ Ln aR ISWENT INSPECTED Manufacturer crartecsiy We a detached floor area of~1 foot by foot with reddish/brown residue directly next to theBiank with a pipe running through it a oO 16 with nsulation on the outside of the station while production of= =aae Your firm uses Equipment Maintenance Management Procedure -EN-003 that requires il 9 patrol and documentation of facilities and equipment used in the production of drug substances in Workshops /))/ [redacted] and other workshops. Your firm did not adequately document) // [redacted] patrols nor the inadequate status ofequipment and pipelines in Workshop / [redacted] within the Equipment Inspection Record FOM-SMP-EN-003-03.03 for WorkshopMS hat is required per the Equipment Maintenance Management Procedure SMP-EN-003.

Observation 3

Written records of investigation into unexplained discrepancies and the failure ofa batch or any of its components to meet specification do not always include the conclusions and follow-up.

Specifically, Investigations initiated and performed by your Quality Unit in response to Out of Specification results, laboratory events, and market complaints related to intermediates and API manufactured by your firm are not always scientifically sound or comprehensive with respect to root cause determination. Additionally, Corrective Action/Preventive Action (CAPAs) as a result of investigations are not always comprehensive to address root causes documented to have been performed. For Example: A. -On or around 01/14/2021, OOS-205301-21001 was initiated forene batch number intermediate for [redacted] drug substance) for other single impurity with results as % andee versus specification ofNMTP2%%. Your firm’s Taizhou, Zhejiang 317016 China Active Pharmaceutical Ingredient and Intermediate Manufacturer; i igati ined the root cause to be “the tester did not change gloves after testing the olution and directly prepared theSUNN G*Psample solution, resulting in contamination”. d d 01/21/2021, OOS-10501-21001 was initiated for drug substanceLs aa..c number for PPL impurity HOS wi result as| ppb versus specification of LOD! [redacted] ppb. Your firm’s investigation determined the root cause to be “the tester did not wear gloves when weighing back, returning the control and transferring the test solution, resulting in contamination of the test solution’. -On or around 06/08/2021, OOS-10501-21003 was initiated for intermediate intermediate for rug substance), batch numberDe for test item tandard with result as|%pmM versus specification ofNMIfgper Your firm’s investigation determined the root cause to be “the inspector did not change his gloves when testingSe GPS resulting in some bottle caps being contaminated witha) -On or around 01/01/2022, OOS-10501-22001 was initiated for drug substance atch number 922 6-month accelerated stability test for mpurity ith result as{{{ [redacted] pb versus a specification ofLOD pb. Your firm’s investigation determined the root cause to be “the bottle cap used for the test did not differentiate between the use of samples and controls, and the tester got the /)/ [redacted] contaminated bottle cap, resulting in the test solution being contaminated with§ [redacted] For all OOS investigations performed by your firm, the assignable root cause was determined without performing hypothesis studies and without scientific justification. 2 Linhai Tianyu Pharmaceutical Co., Ltd. No. 15 Donghai 5th Ave., Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai CITY, STATE, ZIP CODE, COUNTRY LO gSWENT INSPECTED Manufacturer B. Starting from 04/01/2021 to 07/07/2022, your fi initiated 2 OOT and 7 OOS investigations for 11 batches with respect to intermediate product or test specifications for any individual impurity (NMTFOR dor total impurities (NMT 0). All batches involved were said to be destroyed as a result. Subsequent investigations performed by your firm’s QC and R&D units have resulted in the identification of a root cause for formation of the impurity, however no adequate CAPA has been implemented to address this root cause. Per your firm’s personnel, current action plan, should another OOS occur, is to destroy the batch. C. During our review of your Empower 3 chromatography software, interrupted sequences were observed, which generated “Data Incomplete” chromatographic data. Your firm documented these interrupted injections due to a power outage via investigation no. DR-3-22003R, dated 02/27/2022, owever, during the investigation, the interrupted sample injections were not adequately documented and/or investigated, in that your firm did not verify the incomplete data to evaluate if the interrupted sequence chromatogram for abnormalities. D. Complaint No. CH-3-23004, dated 02/20/2023 was initiated due to customercomplaint{00s results for 7tag onectit shipped to your customer. This intermediate is used for the manufacture o I, potentially intended for the U.S. Market. Based on your firm’s investigation, no issues were found, and the complaint wasnotjustified. After your firm communicated the results ofyour findings to your customer, your customer replied that their quality unit had released these batches for use to manufacture. There was no adequate follow up by your firm to determine why these batches were released, specifically what the root cause of your customers investigation revealed. During our inspection, your firm re-initiated communication with your customer to determine your customers investigation results. Linhai Tianyu Pharmaceutical Co., Ltd. No. 15 Donghai 5th Ave., Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai CITY, STATE, ZIP CODE, COUNTRY fone SISNET INSPECTED Manufacturer E. On or around 03/07/2019, 7 OOS investigations for 7 batches were initiated for intermediate| for OOS results with respect to specification other individual impurity NMT. Your firm’s investigations resulted in root cause determination as a damaged Your firm’s CAPA included replacing the damaged ith a new and retesting. No consideration was given to the establishment o management and maintenance procedure as part of your investigation and CAPA.

Observation 4

Laboratory records are not completed contemporaneously and do not include complete data derived from all tests to assure compliance with established specifications and standards.

Specifically, A. Electronic and physical laboratory records data review are not completed contemporaneously by your QC reviewers. During our walkthrough of your QC laboratory data review room on 09/11/23, observed your QC analyst/reviewer checking off boxes on a form titled “Checklist of Electronic Data” for approximately 5 analytical batch records for) resting ofWe [redacted] arr via Ion Chromatography test, one after another, without any software opened for review. In all, we counted approximately 18 analytical test records for six batches which the analyst confirmed to have performed during the observed review process from above. Your analyst stated that they had reviewed the electronic data on the software in another room approximately one hour before. B. Microbiology laboratory records and usage logbooks are not completed contemporaneously by your analysts. During our walkthrough ofyour microbiology laboratory, we observed a QC analyst filling out a form titled “Preparation and Use Records ofControl Medium” for preparation ofOe controlled media used for system suitability reference fortesting ofaes. Items observed in the process of being filled out included, but not limited to, reagents used, quantity of reference media andWH P [redacted] wvater used, stirring to dissolve operations, dispensing into a bottle operation, and; 09/15/2023 Taizhou, Zhejiang 317016 China Active Pharmaceutical Ingredient and Intermediate Manufacturer WE perations. Per your analyst, they had finished preparation ofthe [/™ [redacted] controlled media prior to my arrival to the room.

Observation 5

There is no written testing program designed to assess the stability characteristics of drug substances and intermediates.

Specifically, the assay and related substance test methods for intermediateused for stability testing are not stability indicating, where they can detect the change with time in chemical, physical or microbiological properties ofthe intermediate drug substance so that the content ofactive ingredients and degradation products can be accurately measured without interference. As a result, the validity of the stability ofthe process cannot be verified, in that your firm is not able to monitor results during stability studies in order to assure safety, efficacy and quality for your intermediate drug substance.

Observation 6

Appropriate controls are not exercised over computers or related systems to assure that changes in quality control records are instituted only by authorized personnel.

Specifically, GMP related computerized systems and equipment have not been validated/qualified to demonstrate the suitability of computer hardware and software to perform assigned tasks. Your firm appears to have performed Performance Verification and data integrity assessments for Empower 3 software, however the verification and assessments do not evaluate the consistent performance ofthe software/equipment over a specified period and operating environment. For Example, during our review of your Empower 3 chromatography software, interrupted sequences were observed, which generated “Data Incomplete” chromatographic data. Your firm has not demonstrated full understanding of the different types of 097157202 Taizhou, Zhejiang 317016 China Active Pharmaceutical Ingredient and Intermediate Manufacturer communication errors and circumstances which may lead to a “Data incomplete” or Bad Checksum/Data Missing chromatography considering the relationship between the Empower application and database server, Empower RDS servers, internet connection, Empower LAC/Es, and the instruments connected to LAC/Es. This discrepancy in your firm’s ability to review, document, and investigate all electronic data is a gap in your Data Integrity Program.

Observation 7

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically, Supervisory oversight over the laboratory electronic systems and data is deficient. Per your firm’s data review procedure, Quality Control (QC) personnel perform review electronic test data for all analytical batch records using an approved review procedure and checklist for HPLC/GC network equipment. This review process does not appear to be adequate, in that all potential data generated during that specific review period for that product are not reviewed. For example, your firm utilizes up to five different software’s for testing of intermediate and API products on HPLC and GC equipment, which include, Empower 3, Openlab CDS, LabSolutions, MassHunter. There is no software dedicated to testing of a particular intermediate or API, as the analyst may use whichever software is available at the time ofthe test. There is no adequate reconciliation of all generated electronic test data during the review process for HPLC/GC network equipment. 09/1 3 Taizhou, Zhejiang 317016 China Active Pharmaceutical Ingredient and Intermediate Manufacturer ———

See all 3 findings in this document
[FDA 483 observation · FDA]Glenmark Pharmaceuticals Inc USA — Quality unit authority and data integrity gaps
FDA483

Interim site quality head knew of only 7 of 20 points from a legal investigation

Published 2026-11-13 · Inspection date 05/19/2022 · Manufacturer · FEI 3011585599

16 observations
Findings
  1. 1The quality control unit lacks authority to fully investigate errors that have occurred.
  2. 2There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
  3. 3Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
  4. 4Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.
  5. 5Procedures for the preparation of master production and control records are not followed.
Show 11 more
  1. 6Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.
  2. 7Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.
  3. 8Written production and process control procedures are not followed in the execution ofproduction and process control functions and documented at the time of performance.
  4. 9Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
  5. 10Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.
  6. 11Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
  7. 12The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
  8. 13Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
  9. 14An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
  10. 15Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
  11. 16Routine calibration of equipment is not performed according to a written program designed to assure proper performance.
Check points
  • Are GMP allegations raised in legal or compliance investigations recorded in the quality unit's investigation records? (Observation 1)
  • Is there a procedure to verify that certificates issued by contract laboratories are authentic? (Observation 2)
  • Are electronic data and audit trails from standalone instruments such as liquid particle counters and TOC analyzers reviewed? (Observation 4)
Observation detail · 16 observations · From the source

Inspectors: Adam R Cooke · Steven A Brettler · Justin A Boyd

Observation 1

The quality control unit lacks authority to fully investigate errors that have occurred.

Specifically, Glenmark corporate received an anonymous complaint that resulted in a corporate compliance investigation which led to the involvement of Glenmark General Counsel (GGC) and an outside law firm, Alston and Bird LLP. Multiple times during the inspection FDA Investigators were told that Alston and Bird investigated occurrences of GMP failures, including data integrity lapses, in quality control. When FDA requested the comprehensive investigation into GMP quality system deficiencies including data integrity lapses, FDA was provideda single page list of 20 bullet points titled "Quality Related Facts from Legal Investigation". Of those 20 bullet points, on April 11 or 12, 2022, the interim Site Quality Head stated that he had some awareness of seven (7). This indicates that, at least, the site Quality Unit was unaware of allegations including: e Allegation that portable particle counters were being moved from ISOS to ISO7, but documentation indicates that the test was in ISOS. e Allegation that there were three inconsistent limits in water testing SOP. e Allegation that analysts were not performing the correct number of growth promotion tests on media, but this was not reflected in the records. e Allegation that growth promotion testing on media sometimes was not done before media was used. Allegation that expired media was used after being tested. e Unsigned validation reports, and no written protocols for validations. e Written sterility test SOP relates to ()(4) which is not yet in use. Does not comply with USP <71 and analysts do not use it. e Sterilization validation summary report serves as a written test method for sterility testing. e Allegation of issues with traming documentation, including backdating of training records. e BET results recalculated because wrong unit of measure used, and signatories were not involved in the recalculation. Findings i [redacted] report. e Allegation of testing into compliance, and deficient OOS investigations. e Allegation that SOPs do not align with actual practice, some are not well written, and some are missing information. e No lab notebooks. e [redacted] — is used in the lab even thoug [redacted] is in the cleaning SOP. e Lack of certified trainers. This contradicts statement in the April 22, 2022 letter from GGC stating “... the law firm contemporaneously shared the underlying facts relevant to the quality system with the interim site Quality director [interim Site Quality Head], Glenmark employees, and outside consultants.” Further details of these investigations into quality failures were not provided to FDA under the umbrella of attorney-client privilege. When asked on April 27, 2022 if a site investigation into these quality failures was opened the interim Site Quality Head referenced Issues 478, 480, and 522 which were signed by the interim Site Quality Head February 8 (478 and 480) and February 18, 2022 (522) - approximately two months prior to the conversation where he stated he was not aware of the above 13 bullet points. FDA recognizes that attorney-client privilege can exist outside of quality investigations which FDA has a right and responsibility to review. Furthermore, as the current interim Site Quality Head was unaware of the majority of the provided list, FDA cannot assess the quality of the investigation(s) nor can FDA determine if the Alston and Bird personnel who performed the investigations are qualified to make Quality determinations; there is no way for FDA or site Quality management to determine if the failures were adequately and completely investigated. Despite the findings of Alston and Bird’s investigation(s), you continued to manufacture drug products without knowing the full extent of the deviations, including data integrity lapses, and without implementing appropriate CAPA, includin [redacted] batches manufactured in March 2022 intended for commercial release.

Observation 2

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, 1. Investigations into data integrity deficiencies were not thoroughly investigated and did not assess the impact of the findings on the reliability of data used to support approved and pendin [redacted] applications. For example: a. Issue-0478 was initiated September 15, 2021, to investigate an internal complaint received August 11, 2021, including allegations that the Microbiology Laboratory Associate Director was pressuring employees to falsify documents. The Site Head was made aware of the complaint on August 12, 2021, and the initial investigation confirmed data generated by the microbiology laboratory was not reliable, resulting in the recall of all commercial products within expiry. The investigation by the quality unit was not thorough or extended to all relevant data. i. Interviews of microbiology analysts were conducted as part of two investigations outside of the quality system; one led by Glenmark’s Legal Counsel and a second led by a contracted law firm. The allegations of failure to comply with CGMP discovered during the interviews were not documented within the quality system and not fully shared with quality personnel. This prevented the Quality Unit from fully investigating all allegations, being able to determine the impact on data reliability in pending and approved applications, to determine the root cause, and to ensure the necessary corrective actions and preventive actions are taken. Allegations from the microbiologist interviews included, but were not limited to: e The Microbiology Laboratory Associate Director asked individuals to sign documents they had not completed. e The Microbiology Laboratory Associate Director asked individuals to sign for things they were not qualified to do. e Microbiology analysts were instructed to backdate records. e Analytical method validations fo [redacted] sterility included overwrites and changes from failing to passing results. e There was overwriting in endotoxin testing to changea failing result to passing. e Microbiology analysts were instructed to retest failing results without performing an adequate investigation. e Microbiology analysts were instructed to use unvalidated testing protocols. e Microbiology analysts were instructed not to follow testing protocols. e There was a failure to use laboratory notebooks or controlled documents for recording GMP data. e Documentation indicated non-viable sampling was conducted in ISO-5 areas, but the counters were located in the ISO-7 areas. e Growth promotion of media used for microbiological testing was not performed correctly, but this was not reflected in written records. ii. Issue-0478 did not identify and investigate the personnel, including analysts, managers, and others involved in these activities; determine all past and current CGMP activities those individuals perform; and determine the full extent of the unreliable data that was generated asa result of the activities performed by these iii. The Issue-0478 quality investigation did not include interviews of current and former employees including the Site Quality Head, Microbiology Laboratory Associate Director, Microbiology Manager, Senior VP & Cluster Head Formulations - Quality, or all analysts that worked in the microbiology laboratory. iv. The Issue-0478 quality investigation did not extend interviews to other areas including the chemistry laboratory, production departments, engineering, or metrology to determine if similar practices existed in other areas of the facility. v. Issue-0478 included conclusions that documented: “Systemic quality related gaps and concerns in the Microbiology Laboratory”, that the “Problem existed prior to 18Aug2021 and was recurrent”, and these conclusions were “Applicable to all Microbiology data maintained and all products tested at the Glenmark Monroe site prior to 19Aug2021.” These conclusions contributed to the recall of all commercial products. The investigation was not extended to evaluate how these systemic quality related gaps and concerns impacted data in approved and pending applications that were manufactured and tested prior to August 19, 2021. b. Glenmark was notified by their contract laboratory [redacted] on March 8, 2021, that COAs for sterility testing reviewed by [redacted] were not authentic and did not match samples they had received. The initial investigation was conducted outside of the quality system until Laboratory Investigation LI2021.0119 was initiated April 23, 2021. Drafts of the Laboratory Investigation provided to [redacted] on April 30, 2021 and May 28, 2021 identified a pattern of falsifying COAs to represent sample results when samples were never submitted to [redacted] for multiple products. Impacted products included [redacted] Solution, [redacted] Solution, [redacted] Solution, [redacted] Injection, and [redacted] Solution. The COA falsification was known to the Site Quality Head in March 2021 and to the Senior VP & Cluster Head Formulations - Quality (a member of the corporate quality organization) no later than April of 2021. The laboratory investigation LI2021.0119 was never approved and was kept confidential from other Quality Unit personnel at the site until after the Site Quality Head ended his employment in October 2021. Issue-0522 was initiated February 16, 2022, to document within the findings of LI2021.0119. Issue-0522 did not include the following: i. The Issue-0522 quality investigation did not determine a definitive root cause, but identified a former analyst that was implicated in the manipulation of COAs using Adobe Acrobat software. The investigation did not attempt to interview the former analyst or the analyst’s supervisor or evaluate electronic written communications from either individual. ii. The Issue-0522 quality investigation did not determine the full scope ofwork performed by the implicated analyst to evaluate whether other records may have been falsified. ili. The Issue-0522 quality investigation did not document interviews of other microbiology personnel to determine if other individuals were involved or aware of the COA falsification. iv. The Issue-0522 quality investigation did not include a full evaluation of all data from [redacted] or determine if) had additional information relevant to the investigation. Glenmark provided a partial spreadsheet to [redacted] in April 2021 of sterility testing results purportedly generated from samples sent by Glenmark in support of 4 applications. [redacted] identified suspect data that did not match their laboratory’s internal data. This data included approximately 78 suspect results, 21 suspect results for [redacted], 12 suspect results for [redacted], and 2 suspect results fo [redacted]. v. The Issue-0522 quality investigation did not identify other contract laboratories or service providers used to support the work in the microbiology laboratory or other areas of the facility including the chemistry laboratory, production, engineering, or metrology. Certificates issued by these other contract laboratories or service providers were not evaluated to determine if other third-party documentation had been similarly falsified. c. Issue-0480 was opened to evaluate deficiencies in equipment and utility qualifications following allegations from the hotline complaint investigations that identified the use of unqualified equipment. The investigation found a pattern ofunreliable data and incomplete qualifications. The decision was made to repeat most equipment and utility qualifications throughout the facility. There has been no evaluation of how this site-wide pattern of unreliable or incomplete qualification data impacts the manufacturing of exhibit batches used to support [redacted] applications manufactured during the same time period. Examples of gaps observed in utilities and equipment qualifications include, but are not limited to: i. Wate [redacted] Performance Qualification - no overall summary report was completed and approved. There was missing data including, but not limited to, data to support sampling and testing forR ofth [redacted] in phaseB. ii, [redacted] water system - sampling was not performed for [redacted] and some of the ports were not sampled as required by the protocol. Microbial testing for water quality tests were to be done under performance qualification, however the performance qualification was abandoned two times due to counts that did not meet specifications and no final report was generated. line - no documentation to support performance qualification was available. iv. OM Machine with [redacted] 001 - No documentation to support the performance qualification was available. v. Phase™ [redacted] 1 Solutio [redacted] 1 Compounding Vessel NTNK001 - No documentation to support the performance qualification was available. vi. Air Handling Unit SAHU001 Injectable Plant - multiple pages containing raw data are missing. vii. Air Handling Unit SAHU004 - Calibration verification pages were printed on November 10, 2017, but the execution documented on those pages are dated November 04, 2017. viii. Air Handling Unit SAHU00S - Five copies of attachment-5 in the qualification were printed on November 10, 2016, but the data documented on the pages is dated November 4, 2016. 2. Investigations into any unexplained discrepancy or out of specification results are not thorough and timely. Examples include: a. Deviation-0196 investigated an out of specification result for microbial limits during sampling of point [redacted] on June 21, 2019 with a result of Too Numerous to Count (TNTC). During the investigation, the microorganism was sent for identification and determined to be Burkholderia cepacia. The investigation did not thoroughly evaluate the source and implement corrective and preventive actions for this organism. Additional identification from growth recovered during routine monitoring of the [redacted] water system has identified Burkholderia cepacia 15 times between August 22, 2019 and August 11, 2021. No additional investigation was conducted for these recoveries. Although there have been recoveries fro [redacted] ™—_ water monitoring since August 11, 2021, growth was not submitted for identification because it was below the alert limit tp CFU/ml) and there is no routine identification of recoveries below this alert limit to determine the normal microbial flora ofthe water systems. Additional identifications ofBurkholderia copaicia have been obtained duringA bulk bioburden monitoring o [redacted] lo [redacted] (PV batch), media fill lot [redacted] 4), and media fill lot which supported Phase a production. b. A Detailed Investigation Report (DIR) signed June 23, 2021 referencing LI2021.0060, 0061, 0062, 0179, and 0180 was written to encompass the information from the investigations related to TNTC microbial recoveries i [redacted] bulk product of [redacted] Process Validation batches [redacted] manufactured from February 23, 2021 to March 3, 2021 taken from thepe vessel (tank NTNK002) via a [redacted] sampling port. Issue-0442 was initiated June 24, 2021, to conduct a production investigation, but none was completed as of April 14, 2022. The DIR states that “ [redacted] bioburden testing is conducted for information purposes only in order to allow the site to identify the need for mitigations....” [redacted] bioburden recoveries for the batches ranged from $f to PB CFU/100mL. However, the Root Cause section never addresses the [redacted] system as a potential vector for contamination via the unvalidate [redacted] tank cleaning process. Additionally, the Historical Trend Review only address other “results fo [redacted] bulk solution for [redacted]....” It did not take other products manufactured using the same equipment into account nor did it extend to other batches outside of those in which there were TNTC recoveries. The Impact/Risk Assessment was given as “Low.” The primary reason for this decision is stated as the batches “receiving passing results for finished product bioburden and sterility testing.” The CAPA section of the report states “that Environmental Action Committee (EAC) should take this event up formally as a CAPA....” However, there is no indication that this was ever accomplished. The laboratory investigation found no laboratory error and identified the presence of Gram negative and Gram positive spore forming organisms in these samples. Among the microbes recovered was Stenotrophomonas maltophilia a biofilm-forming, gram-negative, environmental organism found in aqueous habitats. This same organism was identified in youra system on November 23, 2020 and in your [redacted] system April 29 at three different points, May 19 at two different points, and August 12, 2021. At least five recoveries from your water system were documented prior to the signing of this Detailed Investigation Report. All of these batches were released in July 2021 and shipped into commerce. Process validation report RPT-00527 references LI2021.0051, 0052, 0060, and 0061 in Tables 15 and 16: In-process [redacted] Bulk Solution. However, there is no mention of L1I2021.0062, 0179, 0180, or the DIR. RPT-00527 was approved on June 22, 2021, two days before the DIR was signed and despite Issue-0442 being open. In reference to th [redacted] bioburden it states, “Bioburden results came back with multiple inconsistencies but all finished product sterility testing passed.” The only consideration given to bacterial endotoxin is in Table 45: Finished Product Test Results. c. Laboratory Investigation LI2021.0076 was initiated for an OOS result on March 17, 2021 for [redacted] Solution lo [redacted] when the finished product assay did not meet the specification ofA % (4) 0% with a result ofBE %. The laboratory investigation confirmed the result and Issue-0477 was opened for a production investigation on September 13, 2021. No production investigation had been completed as of April 14, 2022. As of May 18, 2022 the lot had a blank status in SAP. d. Laboratory Investigation LI2021.0140 for [redacted] Solution lo [redacted] was opened for a [redacted] bioburden failure with a result ofbas CFU/100ml compared to a specification ofnot more than PB CFU/100ml. The laboratory investigation found no laboratory error and identified Gram negative microorganisms Stenotrophomonas maltophilia and Pantoea septica. No production investigation was conducted. This batch was aborted for fill weight issues, not for contamination issues, but was intended for commercial release. e. Laboratory Investigation LI2021.0175 for Solution lot) was opened for a [redacted] bioburden failure with a result ofB CFU/100ml compared to a specification ofnot more thanB CFU/100ml. The laboratory investigation found no laboratory error. No production investigation was conducted. The lot was commercially released. f. The Laboratory Investigation LI2018.0123 for th [redacted] Solution 4) No.OM — exhibit batch indicates an OOS for a failed BET result after a tr Rinse. According to the investigation, an assignable cause has not been determined through Re-Measurement. According to SOP CM/QC007 Laboratory Investigations for section 5.4.3.4, Laboratory Management must determine if a Phase II Investigation is not warranted, and the determination must be documented witha justification. The investigational plan is crossed out and there is no signature for approval from Lab Management. g. Laboratory Investigation LI2021.0233 for @ 12M Stability lot [redacted] (commercially released) dated July 29, 2021, was opened for a sterility test failure. The investigation was still open with no completed laboratory or production investigations as of April 13, 2022. Laboratory Investigation LI2021.0235 for 12M Stability lot [redacted] (commercially released) dated July 30, 2021, was opened fora sterility test failure. The investigation was still open with no completed laboratory or production investigations as of April 13, 2022. i. Laboratory Investigation LI2021.0195 for [redacted] Injection Long Term 6M stability was OOS for liquid particle count on June 29, 2021, for commercially distributed lots [redacted] and [redacted] @4). The laboratory investigation was still open as of April 13, 2022, and no production investigation was opened. The initial laboratory investigation did not identify an assignable cause. The investigation approved retesting for both lots, which found lot [redacted] was still failing. There was no additional testing approved in the investigation, but a draft investigation report describes how four additional tests were performed for lot [redacted] with passing results and proposes that these will be used to invalidate the first two OOS results. j. Issue-380 was opened for [redacted] Injection lot [redacted], and [redacted] due to observation of particles during filtration and increased filtration times as a result. The investigation identified the presence of insoluble particles attributed to a new lot ofAPI that had not been observed in previous API lots. No further investigation was conducted to identify the particles or further investigate the presence of the particles with the API manufacturer. The production was continued and the lots were commercially released based on routine finished product testing results. k. Laboratory Investigation LI2021.0047 confirmed an OOS for assay of(0) 4) 04, compared to a specification o [redacted] - [redacted] 9% during in-process bulk testing fo [redacted] Solution lot [redacted] on February 24, 2021. The lot received an in-process [redacted] and was released based on finished product testing results. Issue-0383 was opened March 5, 2021 to conduct a production investigation, but no production parece ae investigation had been completed as of April 14, 2022. The impacted lot [redacted] was a process validation batch fo [redacted] The process validation report RPT-00527 was approved on June 22, 2021, even though this investigation was still open. 1. Laboratory Investigation LI2021.0150 was initiated May 22, 2021 fo [redacted] Solution lot that was out of specification with a result ofOM) 0% compared to a specification ofie %{)(4) 0% for assay during in-process bulk testing. The lot was ultimately rejected and Issue-0424 was opened May 28, 2021 to perform a production investigation, but no investigation had been completed as of April 14, 2022. m. Laboratory Investigation LI2021.0138 opened for [redacted] -010 testing on April 29, 2021 with a result ofFe CFU/100ml compared to an action limit ofiB CFU/100ml. The organism was identified as Stenotrophomonas maltophilia, but the investigation was still open with no additional investigation documented as of April 13, 2022. n. The Laboratory Investigation LI2020.0057 for() (4) Solution 4 No. OM — vatc [redacted] indicates an OOS for a failed TOC result after ir Rinse. The root cause classification is specified as not attributed to lab error (result confirmed). The phase I investigation does not appear to have been completed since the investigational plan does not have a signature for approval to proceed by Lab Management. This was an exhibit batch that as of May 19, 2022 had no (blank) status in SAP. o. On March 23, 2019 production weighed two (2) drums of [redacted] Capsules OM No. atc as part of their encapsulation reconciliation record. The nex, (2) 4) batc [redacted] as part ofth psulat 1 d. The next day March 24, 2019, the firm reweighed the second drum referenced on pages 75-76 of the batch record. The reconciliation record on page 77 shows accountable yield calculated with the new weight value as Bt %; however, the accountable yield using the original weight would bebr %, which is outside the yield specification. There was no explanation within the batch record, or investigation by the Quality Unit as to why the drum was reweighed, and hence, the lot was brought into specification then commercially released.

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.

Specifically, 1.During the aseptic filling of [redacted] Injection lot [redacted]: a.The non-sterilized [redacted] glove #4 passes over the sterile stopper bowl and exposed sterile stoppers on th [redacted] machine during stopper addition, when reaching for the sterile forceps, and when clearing stopper jams. The sterilized stoppers are not rejected after the non-steril [redacted] gloves reaches over them as required by SOP-0212 “Aseptic Techniques and Practices”. For example, interventions to add stoppers and clear stopper jams occurred at approximately 8:39am, 9:38am, and 10:42am on March 25, 2021. In engineering drawings for theB ON unit the width of the unit where the stopper bowl resides is measured a [redacted], and the diameter of the stopper bowl is [redacted] leaving only a few inches between the stopper bowl and glove #4. An Assistant Production Manager stated that operators are admonished not to move the glove over the stopper bowl and instead attempt to have the glove as close to the inside a, ofthe™ [redacted] unit. However, with only a few inches of leeway between stopper bowl and (n, and given the bulk ofthe glove, it is highly probable that the operator will either inadvertently disrupt [redacted] air, or touch the inside ofthe™ [redacted] unit multiple times during a production run. SOP-0212 section 5.2.8 does not specifically address touching the inside of the MO) With aM glove, however, it states that if equipment surfaces are contacted, sanitization of both the glove and equipment should occur. There is no evidence in the video that this happened. b.At time stamp 10:53:10 and 11:30:58 an operator places their whole arms and a portion of their upper body into the trash receptacle positioned between ()(4) glove #2 and th [redacted] area used to offload filledEB for the purposes ofcompressing process trash. SOP-0212 does not address compression of the trash specifically, however, section 5.2.12 does state that if an operator “bend[s] below the waist and/or below the working level, [they] must immediately leave the aseptic area and re-gown.” The operator does not leave the area after either time stamp to regown and only sanitizes their hands to their wrists. c.At time stamp 10:11:36 an operator reaches into the Grade A [redacted] area to retrieve a of fe in contradiction of SOP-0212 section 5.2.16.1 which requires sanitization ofthe operators’ gloves “Prior to entering any Grade A area....” An Assistant Production Manager stated, “it was sloppy.” 2.The smoke studies for th [redacted] line do not represent dynamic activities: a.During routine aseptic filling there are stopper bags, empty stopper bags, portable non-viable particle counting equipment,rr wipes, and usedB wipes left in the area around the stopper bowl. The smoke studies did not evaluate whether these materials and the accumulating waste material impacts the airflow out of the RABS. b.The smoke studies do not show the [redacted] line in operation. c.The smoke studies do not evaluate the operations performed by the operator within the Grade A [redacted] such as the addition of empty [redacted] and the removal of filled? [redacted]

Observation 4

Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.

Specifically, 1. The review process for electronic laboratory data does not ensure unreported data, deleted data, or modified data can be detected: a. Empower software is used with the chromatography instruments. The [redacted] electronic data and audit trail review only covers project folders designated for QC testing, raw material testing, and cleaning. All analysts have access to create data in other unlocked folders including, but not limited to, Analytical Research and Development folders, Analytical Method Validation folders, individual product cleaning folders, and training folders. The review would not detect unreported data in folders that were unlocked at the time of the original analysis. Further, an ongoing Data Veracity review for each approved and pending [redacted] application is verifying reported data has corresponding electronic data. The evaluation is not inclusive of all folders in which data could have been created at the time of analysis. b. Electronic data and audit trails for the Liquid Particle Counter with PharmSpec software is not reviewed. The reviewer only reviews the printed result and would not be able to detect unreported data. Review of electronic data for July 16, 2021 observed two results for [redacted] Injection lot) at 4) an [redacted] Only the result was reported and no explanation could be provided for not reporting the result. c. Electronic data and audit trails for the Total Organic Carbon instrument with Data Pro 2 software is not reviewed. The reviewer only reviews the printed result and would not be able to detect unreported data. d. Electronic data and audit trails for FTIR instrument with Perkin Elmer ES software is not reviewed. The reviewer only reviews the printed result and would not be able to detect unreported data. e. Electronic data and event logs for the Titration instrument with Tiamo software is not reviewed. The reviewer only reviews the printed result and would not be able to detect unreported data. f. Electronic data and audit trails for the Atomic Adsorption instrument with Syngistix software is only reviewed to ensure it matches the paper print out. Procedure SOP-0627 “Operation of the Perkin Elmer Atomic Absorption Spectrometer (AAS)” requires electronic data review, but provides no detailed instructions describing what the reviewer needs to evaluate. g. The conductivity and pH meter electronically stores results. These are not reviewed and instead the review relies on printouts and logbooks. On April 11, 2021, when the electronic results were compared to the logbook, it was observed that the) water samples were not entered into the logbook. Additionally, there was a result from 12:52pm that could not be linked to a reported test. 2. The review process for GMP documents including laboratory and batch records does not ensure errors, unreported data, deleted data, or modified data are detected. a. The Batch Production Record fo [redacted] tablets batc [redacted] b. Document No. PRT-00455 Exhibit Batch Sampling Plan for [redacted] Solution PH meof mL for OM No. OM — Batch OM) on page 18 lacks a QA Review signature and date.

Observation 5

Procedures for the preparation of master production and control records are not followed.

Specifically, Documents used for recording raw GMP data are not controlled. Raw data recording forms are attached to SOPs maintained within the Master Control software. According to the System Administrator for Master Control, any employee that has access to Master Control can print any form, and there is no tracking process or reconciliation to ensure all forms for recording GMP data is maintained. Additionally, he stated that the Master Control Audit Trail does not capture the number of forms that are printed. This applies to 665/665 forms used to record GMP data. Examples include: 1. Laboratory Forms: a. FORM-0040 Annexure I, Sterility Method Validation Test Form b. FORM-0909 Process Monitoring Data Sheets for Filling G) c. FORM-0374 Annexure III, Laboratory Investigation Report Form d. FORM-0038 Results of Microbial Analysis: Bioburden 2. Production GMP Forms: a. FORM-0924 Visual Inspector Certificate b. FORM-0923 Qualification /Re-qualification Inspection Record c. FORM-1031 AQL Inspection Form fo [redacted] d. [redacted] Capsules O mg) [redacted] No. 4) Batc [redacted] Annexure I - QA Checklist for Manufacturing BPR Review (FCM/QA023.01.01) ii. FORM-0268: Area And Equipment Line Clearance Checklist For Dispensing Area (Form-0268 Rev.03) iii. Annexure V-Line Clearance Checklist fo [redacted] Encapsulation (FCM/PD097/05.00) e. Annexure I - QA Checklist for Manufacturing BPR Review (FCM/QA023.01.01) f. FORM-0268: Area And Equipment Line Clearance Checklist For Dispensing Area (Form- 0268 Rev.03) g. Annexure V-Line Clearance Checklist fo [redacted] Encapsulation (FCM/PD097/05.00) 3. Metrology Forms: a. FORM-1196 Controlled Temperature unit Calibration Sheet b. FORM-0423 Routine Calibration Evaluation c. FORM-0655 Calibration Extension Form

Observation 6

Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, 1. The [redacted] (asset ID [redacted] 4001) used in the production of exhibit batches o [redacted]) manufactured from [redacted] through [redacted] (1) 4) and OM [redacted]) manufactured [redacted] through [redacted]; did not have documented preventative maintenance (PM) performed after its initial qualification in October 2017. According to a printout from the Blue Mountain Regulatory Asset Manager [redacted] PMs include: A single Work Certificate generated from the Blue Mountain system is available dated October 22, 2018 for the actual start date and October 29, 2018 as the actual end date. This Work Certificate shows no parts, labor, tasks measurements, standards, or assets were used/performed. According to this record of work, the same individual, a Maintenance Supervisor (). requested, supervised, performed, and performed the initial review. However, the signature log indicates that a Sterile Manufacturing Mechanic () opened and then completed the certificate December 17, 2018 atte and [redacted] respectively. is noted in that same signature log as reviewing on January 3, 2019. A Quality Engineer then performed a second review Based upon available records, it is not possible to determine the scope of work performed, who performed the work, when the work was performed, and what was reviewed to approve the work. 2. A piping change was made to the [redacted] Water [redacted] system by an outside contractor on November 1, 2018 that required [redacted] a portion of the a system. During this operation rags used to remove metal particles were left in therr system. [redacted], the contractor used to clean, [redacted], and sanitize the water system was contracted to service the B system on November 8, 2018, one week after the a system was opened. They performed the following services: [redacted] No sanitization of the system occurred. On November 12, 2018, [redacted] the contractor responsible for preventative maintenance of the water system performed work and identified a low flow alert in the [redacted] which is where the rags left in the system were flushed to, jammed, and discovered when the a system was opened again. On November 13, 2018 [redacted] was contracted again to service the B system. They performed the following services: [redacted] No sanitization of the system occurred. No sanitization of the system occurred until July 19, 2019 when the following services were The multiple clean/sanitization cycles could not be explained. On October 27, 2019 [redacted] was called again to perform: [redacted] No explanation was able to be given as to why cleaning, sanitizing, an [redacted] needed to be performed again 100 days later.

Observation 7

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

Specifically, 1. Your visual inspection training related to [redacted] for) [redacted] is deficient the related defect kits for [redacted] is static in that the same defects are found in the same numbered each time and the spacing between defects can be called regular in that the vast majority of spaces fall in the range; b. SOP CM/QA007 Visual Inspector Qualification section 5.3 only denotes {mL [redacted] (>) (4) and indicates that [redacted] would be used to qualify. When asked if the same would apply to a mL [redacted], Eric Cochran, Senior Director Manufacturing Quality Assurance state that it would. Only [redacted] were used in qualifying operators on thefa mL [redacted]; c. Qualification activities, with the exception of the most recent instances (April 4 and 6, 2022) are not noted in the room logbook and do not denote operators taking representative break times; d. On February 11, 15, 16, 17, 22, and March 9-10, 2022, five (5) different operators were trained by two (2) different trainers. A total of 14 attempts to qualify operators on visual inspections were made due to three (3) of the operators requiring three (3) attempts, one (1) operator requiring four (4) attempts, and one only qualifying once. In 14 of 14 qualifications there are either multiple "entry errors", "inadvertently marked", or "defect found after QA review" comments. In 14 of 14 qualifications it is noted that the operators found be ofP defect [redacted] and were given Visual Inspector Certificates valid fo [redacted] ~~” When asked about this process, an operator stated that the trainer goes through the test kit with the operator and they correct their qualification as training. 2. On April 14, 2022, while reviewing the training record for Mr. [redacted] Microbial Limits Training Testing (MLT), FORM-1094, performed on March 5 and 6, 2021, I observed that on the record for the observation portion of the training performed on March 5, 2021, the trainer, Ms. [redacted] and Mr. ()(6) initialed and dated that all a tasks/actions were completed on March 5, 2021. The time frame for this analysis is approximately [redacted], with multiple reads and transfers occurring throughout the analysis. Additionally, on the training record for the Partner portion and the Demonstration portions of the training, performed on March 6, 2021, the trainer, Ms. [redacted] and Mr. 6 again initialed and dated that all EB tasks/actions, for both the Partner and Demonstration portions, were completed on March 6, 2021. The time frame for this analysis is approximately [redacted], with multiple reads and transfers occurring throughout the analysis.

Observation 8

Written production and process control procedures are not followed in the execution ofproduction and process control functions and documented at the time of performance.

Specifically, 1. During the production of process validation batches [redacted] for [redacted] Injection (b) mg/mL (mL [redacted]) a 100% visual inspection was performed on [redacted] respectively. SOP-0428 Visual Inspection of Injectables section 5.2.10.1 "Unit(s) should be inspected for no less than (NLT) [redacted]. a. Batc [redacted], calculations (2 [redacted] +40) inspected) out o [redacted] — /documented instances 13 fell below the required amount of inspection time for a total of approximately PB % of the batch. b. Batch [redacted], calculations out of [redacted] /documented instances 28 fell below the required amount of inspection time for a total of approximatelya % of the batch. c. Batch, calculations out of [redacted] /documented instances 6 fell below the required amount of inspection time for a total of approximately { % of the batch. All three batches passed AQL with a total of two minor defects across rH samples. No documentation of the amount of time was spent inspecting AQL samples, only sample pull times. 2. SOP-0428 Visual Inspection of Injectables section 5.2.10.2 states that "Inspectors should visually inspect for NMT one [redacted] without taking NLT a [redacted] eye break." Logbook 30LB21035 has record of the batches being mspected for over [redacted] respectively. No break times are documented in either the logbook or the batch records. 3. According to standard operating procedure, in the event of a failure of any parameter ofbe rinse cleaning verification testing, the 4, cycle should be rerun and restested. The Batch Production Record for [redacted] Solution (0)4 No. [redacted] batch [redacted]) failed its initial cleaning verification test for TOC in the [redacted] Holding Vessel, NTNKO02 and should have [redacted] rinses, as detailed in Laboratory Investigation 0057.

Observation 9

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, you did not conduct hold time studies for any phase of production at the Monroe site for the following products: Instead, you utilized the hold time study data conducted at the [redacted] site i [redacted] to support the above products all of which were released into commercial distribution.

Observation 10

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

Specifically, on April 25 2022, the firm’s Director of Microbiology indicated that there is no QC microbiological data (such as sterility testing, bioburden testing, and bacterial endotoxin testing) available,for the following batches of) [redacted] Solution [redacted] No..

Observation 11

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

Specifically, 1. Procedure SOP-0522 “Waters Empower Software: System Admunistration” establishes the roles and privileges for users in the Empower chromatography software. However, the roles established within the software did not match the procedure. For example, SOP-0522 does not permit supervisors to acquire samples, edit sample sets, or reinject samples, but they have been given these permissions in the software. Supervisors and Analysts are not permitted to “Access Real Time Review of Run Samples” according to SOP-0522, but both roles are given this permission in the software. 2. Procedure SOP-0485 “Liquid Particle Counter: System Administration” establishes the roles and privileges for users in the HIAC software. However, all analysts were assigned administrator privileges.

Observation 12

The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.

Specifically, There was no raw data to support the suitability of the testing methods used to generate data in support of) [redacted] applications: 1. Liquid Particle Count testing according to SOP-0080 “Operation, Maintenance, and Calibration of the HIAC 9703 Liquid Particle Matter Counter” for [redacted] Injection [redacted] Injection), Injection [redacted]), [redacted] ( [redacted]), and)) 2. Microbial Limits Testing according to SOP-0062 “Microbial Enumeration Test Methods” for [redacted] Capsules (() (4)), [redacted] Tablets [redacted]), and [redacted] Tablets () (4)).

Observation 13

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, product specific test procedures were not established and approved. The analysts must review validation documents or previous analyses to determine sample preparations, dilutions, and other product specific steps when performing analysis to support [redacted] applications. Examples include: 1. SOP-0052 “Procedure for Routine Sterility Testing” is a general testing procedure, but there are no product specific methods for testing [redacted] Injection, [redacted] Injection, [redacted] Injection, [redacted] Injection, [redacted] Solution, or [redacted] Solution. 2. SOP MB016 “Microbial Enumeration Test Methods” is a general testing procedure, but there are noproduct specific methods for testing [redacted] Capsules, [redacted] Tablets, [redacted] Tablets, [redacted] (4) Tablets, and [redacted] Tablets. 3. SOP-0440 “Bacterial Endotoxin Testing-Kinetic Turbidmetric Method” is a general testing procedure, but there are no product specific methods for [redacted] Injection, [redacted] Injection, [redacted] Injection, [redacted] Injection, [redacted] Solution, or [redacted] Solution. In an interview with a Microbiology Analyst whose responsibilities were mainly in the BET area, they questioned that results were reported accurately as the method “felt unofficial” due to the execution requiring “interpretation” as processes were not explicitly stated in a step-by-step fashion. SOP-0080 “Operation, Maintenance, and Calibration of the HIAC 9703 Liquid Particle Matter Counter” is a general testing procedure, but there are no product specific methods for [redacted] Injection, [redacted] Injection, [redacted] Injection, [redacted] Injectio [redacted] Solution, o [redacted] Solution.

Observation 14

An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.

Specifically, ongoing stability studies were discontinued for Arformoterol Tartrate Inhalation 1Smeg/2mL; Chlorzoxazone Tablets USP 375mg and 750mg; Naproxen Sodium Tablets USP 275mg and 550mg; and Zonisamide Capsules USP 100mg following recalls in August of 2021. The recall was not done to the consumer level. No documentation could be provided to justify the corporate decision to discontinue stability testing.

Observation 15

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, 1. During cleaning and disinfection of the asepti [redacted] line following [redacted] Injection lot [redacted]: a. Operators were observed to work from ceiling to walls to “surfaces” to floors. Surfaces are not defined in SOP-0429 Cleaning and Disinfection of the Injectable Classified Areas, however, according to an Assistant Manager for Production surfaces consist of filling equipment, —, gloves, pump kit, [redacted],an [redacted] - and the cleaning methodology (also elucidated in section 5.7.2 of SOP-0429) is to work “top-to- bottom.” There is no determined order for the surfaces to be cleaned. For instance, the filling equipment might be cleaned directly after th [redacted] _, or vice versa. There is also no mention ofthe gloves in SOP-0429. Operators were observed cleaning filling equipment last. b. In cleaning the filling equipment, it was only observed that a cleaning solution, presumably [redacted] was indiscriminately sprayed into the RABS area. However, noce was used after the contact time, and no wipe down of the equipment was observed. As the note in section 5.13.2 of SOP-0429 indicates; should follow [redacted] after being appliedto surfaces... to remove excess cleaning residue.” Additionally, the note in section 5.5.10 of SOP-0429 states that [redacted] must be used to wipe down all surfaces of the fill enclosures....” 2. Studies for disinfectant efficacy have not considered surfaces in the aseptic filling area including [redacted] used for th [redacted] glove [redacted] used a [redacted] on the vial filling line, [redacted] used for th [redacted] separating Grade A and Grade B areas, and) used to cover cables on the PB machine inside the filling? [redacted]

Observation 16

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

Specifically, differential pressure (DP) transmitters INJ026-DP.01 (Vial Filling room [redacted] /corridor [redacted]), INJO29-DP.01 (p Filling room (2) 4) corridor 4), INJO23-DP.01 (Filtration room rH

See all 12 findings in this document
[FDA 483 observation · FDA]Strive Pharmacy LLC — Microbial contamination in sterile compounding
FDA483

Air sample in the critical hood exceeded the action limit with no further investigation

Published 2026-11-13 · Inspection date 09/28/2026 · Producer of Sterile and Non Sterile Drug Products · FEI 3021042485

10 observations
Findings
  1. 1Microbial contamination was present in the ISO 5 area and areas adjacent to production areas.
  2. 2Personnel were observed moving quickly in a critical area or in an area immediately adjacent to a critical area likely causing disruption of unidirectional airflow.
  3. 3Use of non-sterile disinfecting agents and cleaning wipes in the ISO 5 area and classified areas.
  4. 4Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.
  5. 5Smoke studies were inadequately performed under dynamic conditions.
Show 5 more
  1. 6Production areas have difficult to clean or contain porous, particle generating, or visibly dirty equipment or surfaces.
  2. 7Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
  3. 8Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
  4. 9Inadequate routine environmental monitoring in the classified areas.
  5. 10Lack of adequate personnel sampling.
Check points
  • Are extra disinfection and investigation done when mold or spore-formers are found below the action level in critical areas? (Observation 1)
  • Are tools that touch hazardous drugs deactivated, decontaminated and cleaned in order, and checked for residue before storage? (Observation 4)
  • Are media fills designed for the hardest conditions, such as the end of a shift? (Observation 8)
Observation detail · 10 observations · From the source
Observation 1

Microbial contamination was present in the ISO 5 area and areas adjacent to production areas.

Specifically, Peliodic Air and Surface Envfronmental Monitoring A. There was an action level [redacted] active air sample in ISO 5 LFH [redacted] (Hood [redacted] on 11/26/25. Sample ID #BHT112625NHDH1, result 15 cfu, action limit for ISO 5 air samples is [redacted] cfu. Microorganisms were identified as Micrococcus species and coag-negative Staphylococcus species. There was no additional investigation or corrective actions. Technicians do not document what specific activity was occuring in the LHF during sample collection. Technicians made about sterile drug lots inside LFH [redacted] 011 11/26/25. Examples of batches produced and dispensed include Semaglutide 2.5 mg/mL, 1 solution for injection, batches LG364186933 and LG364186939. P ost-Batch [redacted] and Surface Sampling B. About post-batch [redacted] and surface samples collected inside ISO 5 LFH or ISO 5 BSC during the previous year had at least 1 cfo after incubation. Additional disinfection and investigation were not always completed for below action level results, including recovery of mold and spore forming microorganisms. Most batches associated with these below the action level results were released. Examples of batches associated with below action level ISO 5 growih include: Semaglutide/Glycine/B12 injection, 5/5/1 mg/mL, 0.5 mL, batch LG364285563, expiration 10/25/26, post-batch [redacted] sample ID #DJO072726, result 1 CFU Altemaria species. The batch Production Record Checklist inaccurately lists the [redacted] result as <1 CFU, and personnel did not complete the required evaluation for [redacted] growth. The entire lot was dispensed to fill more than [redacted] prescriptions. Semaglutide/Glycine/B12 5/5/1 mg/mL, 2 mL, batch LG364281132, sample ID #GD071926LH, result 3 cfo Bacillus species, coagulase-negative Staphylococcus species, and Micrococcus species. This lot was dispensed. Tirzepatide/Glycine/B12 10mg/5mg/500mcg/mL injection, 4 mL, batch LG364238721, sample ID #OYM032526LH, result 1 cfu Bacillus species. This lot was dispensed.

Observation 2

Personnel were observed moving quickly in a critical area or in an area immediately adjacent to a critical area likely causing disruption of unidirectional airflow.

Specifically, sterile production technicians did not always use slow and deliberate movements in the ISO 5 LHFs and ISO 7 Buffer Rooms. Technicians moved quickly during cleaning, LHF setup, and filling and stoppering of multiple sterile injectable drugs on 09/15/26.

Observation 3

Use of non-sterile disinfecting agents and cleaning wipes in the ISO 5 area and classified areas.

Specifically, sterile [redacted] wipes, bottles of sterile [redacted] solution, and bottles of sterile [redacted] remained open in the ISO 7 Buffer Rooms indefinitely will be technicians actively used these items to disinfect and clean items that entered the ISO 5 LHF and ISO 7 Buffer Rooms on 09/15/26.

Observation 4

Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.

Specifically, A. Nonsterile production technicians in the hazardous room do not always follow the deactivate, decontaminate, and clean process. Technicians did not adequately deactivate or decontaminate mixing blades, spatulas, glass beakers, and various [redacted] removable parts that directly contact hazardous drugs. I watched multiple technicians wipe equipment and utensils with a single-use wipe [redacted] with [redacted] in [redacted] immediately rinse the items with tap water, wash the items w-ith tap water and [redacted], and then place them on a drying rack. B. Red spatula with unknown white residue and powder, black spatula with unknown white residue and powder, [redacted] with unknown white residue and a brownish particulate, scraper with unknown white residue and powder. All these items were observed to be comingled with other utensils and were designated clean and ready for use. C. The mouse, keyboard, [redacted] scammer, and [redacted] at the workstation for each of the [redacted] in the hazardous production room were not deactivated, decontaminated, and cleaned adequately. I watched a technician use the mouse at the workstation next to Hood [redacted] on multiple days. The mouse contained visible white residue in the seams every time I examined it. I watched multiple technicians remove their hands from the [redacted] during active production and then use items at the workstation without decontaminating or changing gloves. p r o ducer o f sterile and nonsterile drugs D. [redacted] Hood [redacted] had a hole and an about two-inch-long open crack on the back wall of the unit. There was also a buildup of residue on the left side panel above the hinge for the front panel. E. The work surfaces in [redacted] Hood [redacted] Hood [redacted] Hood and Hood Contained excessive scratches, pits, and other wear that made the surfaces not smooth and easily deactivated, decontaminated, and cleaned.

Observation 5

Smoke studies were inadequately performed under dynamic conditions.

Specifically, smoke studies did not introduce smoke into the entire ISO 5 LFH to confirm unidirectional airflow throughout the aseptic processing area. Additional technicians in the ISO 7 Buffer Rooms during the smoke studies were stationary which was not representative of routine production. I reviewed the most recent smoke studies completed in April 2026 for Hood [redacted] and Hood [redacted] in Lane [redacted] and completed in May 2026 for Hood [redacted] and Hood [redacted] in Lane [redacted] Technicians produced all sterile injectable drugs in these LFH which includes more than [redacted] sterile drug vials in the previous three months.

Observation 6

Production areas have difficult to clean or contain porous, particle generating, or visibly dirty equipment or surfaces.

Specifically, A. There was visible adhesive facing upward on the partially unsecured tape attempting to secure the damaged height adjustment control panel underneath the worksurface of ISO 5 Hood [redacted]. The exposed adhesive was within six inches of the seated technician filling multiple lots of Semaglutide 2.5 mg/mL on 09/15/26. B. There is a large glassware washing sink and a small hand washing sink in the ISO 8 Anteroom. Technicians wash and dry all glassware used during sterile compounding drug formulation in the ISO 8 Anteroom before it is traits fell to another room for [redacted] preparation. Sterile production technicians gown within a few feet of these sinks. The ISO 8 Anteroom is connected to both ISO 7 Prep Rooms used to formulate drugs. Both ISO 7 Pre Rooms are connected to ISO 7 Buffer Rooms that contain ISO 5 LFHs used to sterile [redacted] and fill finished drugs. producer of s terile and nonsterile drugs C. There was apparent corrosion and damage to the bottom of multiple [redacted] all door frames where they met the floor in the cleanroom.

Observation 7

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically, I watched a sterile production technician don sterile garb inside the ISO 8 Anteroom about two to form feet away from a laboratory support technician who was manually washing about 15 soiled glassware items in the approximately four-foot-wide sink. The production technician entered the Lane ' [redacted] 7 Prep Room. Flow of materials and personnel: ISO 8 anteroom ➔ ISO 7 Prep Rooms ➔ ISO 7 Buffer Rooms.

Observation 8

Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

Specifically, media fills are not always conducted llllder the most challenging and stressful conditions. Technicians work [redacted] shifts, but there is no requirement for media fills to occur at the end of a technician's shift when they are presumably most fatigued. The end of the shift ensures the technician would have interacted with the most materials, performed, environment, and other items that could contribute to particulates, microorganisms, or other contaminants in the media fill.

Observation 9

Inadequate routine environmental monitoring in the classified areas.

Specifically, stools positioned at all [redacted] ISO 5 LFH are not included in the EM surface sample program. I observed technicians in the Lane ISO 7 buffer room and the Lane ISO 7 buffer room directly contact a stool with their gloved hands during filling operations for sterile injectable drugs. Technicians sit on the stools while filling. Technicians sit on a bench in the ISO 8 anteroom while donning sterile gowning. The anteroom bench is approximately than one-foot-away from the hand washing sink and four-foot-away from the glassware washing sink.

Observation 10

Lack of adequate personnel sampling.

Specifically, a pharmacist, who was performing [redacted] assessment on 09/16/26 cracked both [redacted] plates all the way across and through the depth of the [redacted]. Also, an approximately 1 inch piece broke off the side of their plate lid and fell onto this surface. The QA Technician administering assessment did not invalidate the assessment and incubated the damaged plates. Damage [redacted] surface can inhibit growth of microorganisms. p r oducer of sterile and nonsterile drugs

See all 3 findings in this document
[FDA 483 observation · FDA]Hybrid Pharma LLC — Aseptic facility and quality oversight gaps
FDA483

Lots compounded after cleanroom floor painting with no record of wall and ceiling cleaning

Published 2026-11-13 · Inspection date 08/27/2026 · Outsourcing Facility · FEI 3011319445

17 observations
Findings
  1. 1Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
  2. 2Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
  3. 3Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
  4. 4Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
  5. 5There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Show 12 more
  1. 6Laboratory controls, do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.
  2. 7Aseptic processing areas are deficient in that floors are not smooth and/or hard smfaces that are easily cleanable.
  3. 8There is no quality control unit.
  4. 9Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purpolied or represented to possess.
  5. 10Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
  6. 11Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.
  7. 12Employees engaged in the manufacture, processing, packing and holding of a drug product lack the education, training and experience required to perform their assigned functions.
  8. 13Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet each appropriate specification as a condition for their approval and release.
  9. 14The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
  10. 15Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
  11. 16Your outsourcing facility compounds drug products using bulk drug substances that cannot be used in compounding under section 503B of the Federal Food, Drng, and Cosmetic Act (FD&C Act) because they (a) are not used to compound drug products that appear on the diug shortage list in effect under section 506E of the Act and (b) do not appear on a list developed by FDA of bulk drug substances for which there is a clinical need.
  12. 17Laboratory records do not include complete records of the periodic calibration of laboratory instruments.
Check points
  • After facility work such as cleanroom flooring, are wall and ceiling cleaning and cleanroom recertification completed before compounding resumes? (Observation 1)
  • Is the pressure differential between adjacent classified rooms checked daily in electronic monitoring records to confirm flow from higher to lower grade rooms? (Observation 4)
  • Are access restrictions and an audit trail configured in the HPLC data acquisition software? (Observation 8)
Observation detail · 17 observations · From the source

Inspectors: Compliance Officer Veronica Fuentes · Andrew O Ejiofor

Observation 1

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, A. Your [redacted] laminar flow cabinet serial number [redacted] used for all your sterile batches has a HEPA filter that provides first air to your ISO-5 filling environment. This HEPA filter at the time of the inspection was observed with stains of unknown origin in the cabinet right side. This is a repeat observation from the inspection that ended on 11/9/2023. B. The design of your [redacted] flow hood cabinet serial number [redacted] used for all your sterile filled batches, has perforations of approximately the width of one inch throughout the rear-lower side. These perforations do not appear to have strong positive pressure which would prevent air from the ISO 7 to enter the cabinet which could impact the ISO-5 environment and the compounded sterile drug product. These perforations were not assessed during your 2024, 2025, and 2026 airflow studies. C. You failed to clean your ISO 7 buffer room completely after the performing maintenance work in your controlled area before compounding sterile drug product. These were the instances where the room was not cleaned: 1. On 2/27/2026, you paid for the painting of the cleanroom's floor. According to the owner, these paint jobs were on Friday evening, Saturday or Sunday. According to the owner, the floor was prepared by sanding, and then it was painted. After painting, the cleaning maintenance log does not document cleaning of walls and ceiling until 3/21/2026. Between these dates [redacted] lots were compounded in the ISO 7 cleanroom. 2. On 3/7/2026, you paid for the painting of the Buffer room [redacted] floor. The floor was prepared by sanding, and then it was painted. After painting, the cleaning maintenance log does not document cleaning of walls and ceiling until 3/21/2026. Between these dates [redacted] lots were compounded in the ISO 7 cleanroom. 3. The last work performed on the floors was paid on 3/30/2026 for the second coat of the cleanroom. According to the owner, this work was done on the weekend and paid that Monday. The ISO 7 cleanroom wall., walls and ceiling were cleaned on 4/8/2026, 4/13/2026, and 4/17/2026. Between 3/30/2026.and 4/8/2026, batches were compounded m the ISO 7 cleanroom. The firm did not have a documented change control or CAP A for these floors. The room was certified on 3/20/2026 and not repeated after the conclusion of the floor project. D. Your firm routinely cleans and disinfects the ISO Class 5 laminar flow cabinet solely using [redacted]. A sporicidal agent is not routinely utilized to sanitize the critical ISO 5 direct compounding area. Additionally, a deactivating agent is not used after sterile compounding of hazardous drug. CMP Testosterone Cypionate Injection to prevent cross-contamination. compounding area. Additionally, a deactivating agent is not used after sterile compounding of hazardous diu g, CMP Testosterone Cypionate Injection to prevent cross-contamination. E. Your ISO 7 cleamoom whr.ere your laminIar flow hood is located contain [redacted] HEPA filters that have [redacted] cleamoom. [redacted] tape attached to the border of these filters. You provided no justification for the reason for using this tape. Additionally, HEPA filters in ISO 7 cleanroom were observed with unsmooth caulking in its comers. F. The [redacted] laminar flow cabinet ISO 5 used for all sterile compounded drugs had surfaces that could collect dust and may be difficult to keep clean to include the [redacted] work bench appeared scratched, had three exposed bolts with oversized [redacted] retention clip, and an electric outlet cover located approximately two inches above the ISO 5 work surface and directly in the path of where aseptic production occurs. The smoke studies provided are inadequate in assessing the air flow patterns. The placement of the electrical outlet could cause eddies/turbulence that could impact the direct compounding area. The cabinet was observed with some residue, later confnmed to be leftover glue from a tape in the top, front sash. According to your pharmacy technician, the residue is on the outer side of the cabinet. This is a repeat observation from the inspection that ended on 11/9/2023. G. The buffer room ( cleanroom) ISO-7 used for all the sterile compounded drugs had surfaces that could collect dust and may be difficult to keep clean including beams with exposed bolts running along the top of the room walls, poles supporting beams in each comer, and protruding metal beams on the ceiling near the HEPA filters, wall baseboard with bolts, and ledges above the windows and doors. This is a repeat observation from the inspection that ended on 11/9/2023. Dee rfiel d Beach, FL 3344 2- 7707 Out sour cing Facility The buffer room ( cleanroom) ISO-7 used for all the sterile compounded drugs had surfaces that could collect dust and may be difficult to keep clean including beams with exposed bolts running along the top of the room walls, poles supporting beams in each comer, and protruding metal beams on the ceiling near the HEPA filters, wall baseboard with bolts, and ledges above the windows and doors. This is a repeat observation from the inspection that ended on 11/9/2023. H. The ante room used for gowning and used to enter the ISO-7 buffer rooms had [redacted] doors which contained [redacted] at the opened [redacted] on each [redacted] doors [redacted] the ante room leading to the ISO-8 drug preparation room, buffer room [redacted] and buffer room On 8/17 2026, visible particulates were observed in the [redacted] of these [redacted] doors. This is a repeat observation from the inspection that ended on 11/9/2023. I. The ISO-8 diug preparation room has base boards that are [redacted]. The ISO-8 painted door frame (towards the anteroom) appeared damaged at the bottom. This is a repeat observation from the inspection that ended on 11/9/2023.

Observation 2

Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.

Specifically, your firm reuses sterile vials supplied by an external vendor. The process to clean and [redacted] Ithese vials is deficient in that: 1. Vials are [redacted] with [redacted] and left to dry in the ISO-8 environment. After drying these [redacted] vials are stored in an uncontrolled environment, exposing them to unknown bioburden and endotoxin limits prior to [redacted] 2. Following the <Re dacted B4> vials are wrapped in [redacted] and stored in an ISO 8 storage cabinet without an assigned expiration date. These vials can be stored in the ISO 8 cabinet up to [redacted] Since these vials are added from different batches, the fom only captures the [redacted] and not the independent supplier's lot number. When these [redacted] vials are used, there is no traceability to the original supplier's lot number.

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Specifically, A. The initial media fills simulations conducted by your new Pharmacy Technician [redacted] between 3/31-6/1/2026 consisted of one configuration or size per media fill simulations. These included [redacted] units of 1 mL in 3mL syringes,units of IOmL vials, [redacted] units of 6 mL vials, [redacted] units of 30 mL vials, lb) [redacted] units of 30 unit mL lvials. Only one media fill was performed for the worst-case condition of [redacted] solution [redacted] units of 30mL vials). This was not a recertification.This is a repeat observation.from the FDA inspection ending on 7/28/2016, 6/24/2019, and 11/9/2023. B. The LFH smoke flow studies (videos) [redacted] performed on March 2026 of the [redacted] laminar flow cabinet serial number [redacted] did not demonstrate the lammar air flow room the HEPA located above the tray of the open [redacted] glass vials. Additionally, it did not demonstrate if the electrical outlet cover in the back of the cabinet created turbulence near the direct compounding area. The smoke study did not include all aseptic operations, including interventions. Static conditions were not demonstrated. Additionally, you do not have a report for this smoke airflow studies. You only have videos for the smoke simulation. This is a repeat observation from the FDA inspection ending on 6/24/2019, and 11/9/2023. 1015 W Newport Center Dr Ste 106a CITY. STATE. ZIP CODE. COUITTRY TYPE ESTABU SHMENT INSPECTED Deerfield Beach, FL 3344 2- 77 07 Outsourcing Facility smoke simulation. This is a repeat observation from the FDA inspection ending on 6/24/2019, and 11/9/2023. C. The acceptance criteria for the post fill surface sampling listed under Section Clean Room Testing: Viable and Non-Viable Action Levels and Corrective Action of SOP Environmental Viable Airborne Particle Testing Program, Rev. 3, Effective 10/1/2021 is [redacted] contact plate and this is not adequate for monitoring ISO-5 surfaces. This is a repeat observation from the FDA inspection ending on 11/9/2023. D. On 8/18/2026, I observed the post fill environmental monitoring performed by your Pharmacy Technician, and the sleeve sample plate contacted the sleeve for less than one (I) second. Your written procedure, Document No. 6.01, Environmental Monitoring During Aseptic Processing, Effective Date: 09/01/2023, does not specify the sampling technique, including duration of contact and/or pressure to ensure gown sleeve samples are collected in a consistent and reproducible manner.

Observation 4

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically, A. Your facility's cleanroom suite is not designed, maintained, or operated to prevent microbiological containination of your sterile drug products. These data demonstrate a [redacted] pressure cascade where the ISO 7 Anteroom is at a significantly higher pressure than the ISO 7 Buffer Room [redacted] creating a pathway for lower-quality air to flow into the primary sterile compounding area. Additionally on 8/18/2026, we observed the container with bulk CMP PROCAINE Hydrochloride (2%) lot 260818A in the ISO 7 area with one of the sides of the container opened to permit the filling tube to exit to [redacted] and fill vials. This container was in proximity to this exhaust vent. 1. Your cleanroom suite does not maintain a proper cascading [redacted] pressure differential. Your ISO 7 Buffer Roont 1 is maintained under [redacted] pressure relative to the adjacent ISO 7 Ante Room. This [redacted] is documented in your firm's [redacted] certification reports, including: Dee rfiel d Beach, FL 33 44 2- 7707 Out sour cing Facility Certification Report, Control ID [redacted], dated 20 MAR 2026, which documents a pressure of -0.029 inches of water column. 2. Your firm's electronic pressure monitoring system provided direct evidence that the facility fails to maintain a proper cascading pressure differential between its classified rooms. On August 17, 2026, the monitor displayed the following pressure relationships: ISO 7 Buffer Room [redacted] +0.03174 in. W.C. ISO 7 Anteroom: +0.07794 in. W.C. ISO 7 Buffer Room [redacted] +0.00450 in. W.C. These data demonstrate a~) (4) pressure cascade where the ISO 7 Anteroom is at a significantly higher pressure than the ISO 7 Buffer Room ri creating a pathway for lower-quality air to flow into the primaiy sterile compounding area. Addition~iy, on 8/18/2026, we observed the container with bulk CMP PROCAINE Hydrochloride (2%) lot 260818A in the ISO 7 area with one of the sides of the container opened to pe1mit the filling tube to exit to 4 (b) l and fill vials. This container was in proximity to this exhaust vent. 3. Your HV AC system is not appropriately designed to ensure proper air circulation and removal of contaminants. Specifically: This is a repeat observation from the FDA inspection ending on 7/28/2016 and 11/09/2023. i. Your ISO 7 Buffer Room [redacted] and your ISO 7 Ante Room have no designed mechanical air return vents. The absence of an engineered pathway for air to exit these rooms has resulted in significant over-pressurization, preventing proper top-to-bottom airflow. a. To compensate for a lack of mechanical air returns, your firm has [redacted] and continues to use in the solid doors separating classified cleanrooms. This practice destroys the physical barrier of the cleanrooms and prevents the maintenance of a verifiable pressure cascade. L_j ii. The air returns for your ISO 7 Buffer Room [redacted] (in close proximity to ISO 5 [redacted] and ISO 8 Prep Room consist of open, unsealed cutouts in the walls that vent directly into a non-controlled space and are not equipped with backdraft dampers._Moreover [redacted] worktables block the airflow to the vents inside both the ISO 7 Buffer Room and ISO 8 Prep Room. The unclassified side of the ISO 8 Prep Room vent is obstructed by a [redacted] storage rack containing cluttered materials. Your HV AC system is not appropriately designed to ensure proper air circulation and removal of contaminants. Specifically: This is a repeat observation from the FDA inspection ending on 7/28/2016 and 11/09/2023. 4. Your firm failed to conduct and document dynamic airflow visualization studies (i.e., smoke studies) in the ISO 7 and ISO 8 classified cleanrooms to demonstrate clean-to-dry air directionality at critical boundaries, such as doorways and other physical openings between the ISO 7, ISO 8, and unclassified areas. The fnm's ISO 8 preparation has [redacted], where the firm stores the [redacted] used for covering containers, vials, trays used for the [redacted] B. You completed your ISO 7, ISO 8 and ISO 5 (cabinet) room certification on 3/20/2026. On 3/30/2026, the work for your new floor was completed, after the completion of the cleanroom (Buffer room [redacted] second coat. After completion of the floor, you failed to repeat the room certification to assess HEPAs, differential pressures, or environmental monitoring. This has not been completed by the time of our inspection.

Observation 5

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, you failed to complete an adequate investigation or open an investigation for the following discrepancies: Dee rfiel d Beach, FL 33 44 2- 7707 Out sour cing Facility A. Unexplained discrepancies in laboratory test results are not thoroughly investigated. Specifically, an unexplained, significant extraneous peak was observed in the Ascorbic Acid HPLC assay for Lot [redacted], and there is no record of an investigation into this discrepancy by the quality control unit prior to assigning a passing result. 1. The chromatogram for the analysis of Lot [redacted] acquired on 07/28/2026 at 3:26:48 PM, displays a significant, unidentified peak at a retention time of approximately [redacted]. [J 2. The corresponding "DEFAULT REPORT" calculates this extraneous peak as representing 0.11 % of the total peak area. This peak is entirely absent from the corresponding USP Reference Standard injection. 3. Despite the presence of this unknown peak, the "Ascorbic acid assay HPLC" summa1y report documents the result for Lot # [redacted] as "Pass" with no documented investigation, impurity evaluation, or assessment regardmg tlie nature of the contaminant. B. You did not have a completed cleaning maintenance log of the Buffer [redacted] ISO 7 (where the LFH ISO 5 is located) for the month of August. You completed a logbook that contains check marks, comment, and initials, but this log page contains no month. It is lmknown if this log is for the month of August. By 8/24/26, you had not opened an investigation for this discrepancy. C. You completed [redacted] cleaning maintenance logs for ISO 8 Preparation room. It is lmknown if cleaning was performed [redacted], or if the information was copied. By 8/24/26, you had not opened an investigation for this discrepancy. D. On 8/19/2026, during the post fill of CMP Buprenorphine HCl (PF) lot 260819A, your Pharmacy Technician sampled [redacted] environmental monitoring plates, [redacted] of these were labeled the same, [redacted] (as in [redacted]. There was a sample location missing, which was the surface flow hood sample since it appears there was a mistake that was made during the labeling. Your Pharmacy Technician said that he knows which one is the surface flow hood and which one was the correct [redacted]. Upon discovery, the Quality Assurance director instructed him to write the explanation on the sheet of paper with the plates. By 8/24/26, you had not opened an investigation for this discrepancy. Dee rfield Beach, FL 3344 2- 7707 Out sour cing Facility Quality Assurance director instructed him to write the explanation on the sheet of paper with the plates. By 8/24/26, you had not opened an investigation for this discrepancy. E. You failed to adequately investigate a "burst" in the tube while [redacted] Sodium Chloride into Ascorbic Acid for lots 250605A and 250605B. This was captured in an incident report and a blank sheet of paper which was only included in Ascorbic Acid lot 250605B batch report. The investigation does not reference how much was [redacted] when the burst happened, and if the replacement [redacted] was the same as the original [redacted] (since an additional lot was not added to the batch record). You used the maintenance of the [redacted], of this batch as the basis for the product quality determination without adequate justification. Additionally, Ascorbic Acid lot 240605A had 11 vials with defects detected in the visual inspection from a total of the vials [redacted] 15.88%). According to your [redacted] written procedure, Module 8-68.2 QC-OJ, Visual Inspection, Revision 1, "based upon the yield up to [redacted] (ball of a batch can be rejected for cracks, defects, particulates, or precipitates before an entire batch is rejected". However, this batch was not rejected or the 5.88% of defects were not investigated. F. You failed to investigate entries for your July 2026 Log Sheet for Temperature Records in Pharmacy, Refrigerator and Freezer, multiple entries were concealed with white-out, and the original data recorded under these entries are unknown.

Observation 6

Laboratory controls, do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, 2. You do not routinely test your Ascorbic Acid for Injection, 500 mg/mL, for the "Limit of Oxalate", a known compendial impurity, and have not scientifically established the omission of this impurity testing. 1. From January 2024 to May 2026, you released over [redacted] batches ( approximately over [redacted] vials) of Ascorbic Acid for Injection without performing routine release testrg for oxalate. While you performed a qualitative limit test on [redacted] selected batches on a [redacted] as documented in "Absence of oxalate-Ascorbic acid Injection" (dated October 30, 2023), you failed to test the other batches released over this two-year period. 2. Your fir m di d not use a compendia! reference standard for assay testing. The non­compendial standard your firm used has not been characterized and qualified as a reference standard. As documented in "Ascorbic acid Assay Method Validation", dated 8/29/2021, your method validation for Ascorbic Acid used a standard purchased from [redacted] lot [redacted] which was not a USP reference standard. This is a repeat observation from the inspection ending on 11/9/2023. B. You failed to properly incubate settle plates during your [redacted] environmental monitoring erformed in June 2026. Your settle plates were incubated at [redacted] from [redacted], and at [redacted] from [redacted]. The 1 incubation period at [redacted] should have been for [redacted] however, the plates were incubated for only 4 days. C. You failed to properly incubate environmental monitoring plates taken during the production of sterile drug product, Ascorbic Acid lot 260602A. Your settle plates were incubated at [redacted] from [redacted]. The incubation period at oul have been for [redacted], however, the plates were incubated or only 4 days. D. During your [redacted] environmental monitoring performed June 2026, you documented your verification and review 6 of the [redacted] incubation of [redacted] on [redacted]. The [redacted] incubation [redacted] from [redacted] was not performed or documented. It is unknown if the settle plates were read after the [redacted] incubation. incubation [redacted] from (6) 4 was not performed or documented. It is unknown if the settle plates were read after the 6 4 incubation. E. You "calibrate" your scales used to measure materials for the compounding of sterile and non-sterile drug product in house. This is done [redacted] using your certified weights from [redacted] to [redacted]. These certified weights have not been re-certified since they were acquired. Additionally, the check weigh is not verified [redacted] the scales are [redacted]

Observation 7

Aseptic processing areas are deficient in that floors are not smooth and/or hard smfaces that are easily cleanable.

Specifically, the ISO-7 buffer room [redacted] has cracks on the new [redacted] floor which was completed between February and March 2026. These cracks were observed in the floor adjacent where the laminar flow hood ISO-5 is kept, and close to door towards the anteroom ISO-7. These cracks are not easily cleanable. Additionally, peeling of this new [redacted] floor was observed in the anteroom ISO-7 exposing the old [redacted] floor beneath. This is a repeat observation.from the inspections that ended on 6/24/2019, and 11/9/2023.

Observation 8

There is no quality control unit.

Specifically, your firm has a lack of Quality oversight. The lack of Quality oversight was observed in the following: A. Quality does not issue the batch record to be compounded. Batch records can be printed by any personnel. B. You do not perform acceptance quality limit (AQL) sampling and visual inspection on finished injectable drug product batches following 100% manual visual inspection, to verify the effectiveness of the 100% visual inspection process and ensure units are free of visible particulate matter and container-closure defects prior to release and distribution. C. The HPLC data acquisition software [redacted] lacks security controls to prevent the deletion of system and error logs. On 8/24/2026, facility personnel inadvertently deleted system error logs within the software while attempting to export electronic data files during the inspection. Additionally, the software was configured without access restrictions, administrative privileges, or an audit trail to record the deletion, user ID, and timestamp of erased logs. Your firm lacks written procedures for data export, routine audit trail review, and archival controls for the [redacted] system to prevent loss of critical system event records. D.Logbooks are in loose sheets of paper. There are no bounded notebooks for equipment logbook (except [redacted]), temperature and humidity logbooks, cleaning logbook and laboratory notebooks. There are no controls for these log pages, as there could be two of the same log pages at a time. These log pages are not issued by quality. E. There is a lack of control in analytical sheets. Analytical sheets are not numbers and are not provided by Quality. F. Quality failed to approve several written procedures. Some of the written procedures that were observed without approval included but was not limited to: I. Document No. 6.01, Environmental Monitoring During Aseptic Processing, Effective Date: 09/01/2023. 2. SOP No. 3.017 -Safe Handling of Hazardous Drugs. 3. SOP No. 200 -Policy and Procedures for USP 800 Hazardous Drugs. 4. SOP No. 3.028 -Storage and Transport of Hazardous Drugs 5. SOP No. 3.030-Hazardous Drug Spill Kit 6. SOP No. 3.032 -Disposing of Cytotoxic or Hazardous Drug Waste 7. Doc No. Module 6-EM-65A, Surface sampling in all ISO classified areas, Rev 2. 8. Doc No. Module 6-EM-64B, Environmental Viable Airborne Particle Testing Program, Rev 3. 9. Doc No. Module 6-EM-60, Clean Room Suite Environmental Monitoring (EM), Rev 3. G. Quality Unit does not perform oversight of Personnel Monitoring post-fill. Personnel perform self­sampling and self-label the plates after sampling. H. Quality Unit does not perform Environmental Monitoring on compounding days in the ISO 8 preparation room. This is not done for active air, nonviable particles, and surface sampling. I. Quality Unit does not approve the results of Environmental Monitoring as observed in the following: 1 [redacted] Environmental Monitoring performed in June 2026. 2l 4): £ d h h l'b d d C l'b J. Your Quality Assurance <Re dacted B4> perfor me d the in- ho use calibratio n and appr oved it. Ca libr ations must be performed by one person and approved by quality. Dee rfiel d Beach, FL 33 44 2- 7707 Out sour cing Facility must be perfo1med by one person and approved by quality. K. You have not completed Annual Product Reviews (APR) since an unknown date. During our inspection, no APRs were provided.

Observation 9

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purpolied or represented to possess.

Specifically, A. Your non-viable [redacted] Particle Counter Asset ID: [redacted] used in your ISO-5 Laminar Flow Cabinet is calibrated every [redacted]. This equipment was last calibrated on May 22 2026 and the time recorded in the print-out of tliis equipment is incorrect by [redacted] and [redacted]. The equipment calibration is due on [redacted] Calibration of every [redacted] is not adequately justified for particle counters in ISO-5 as it may give a false negative result of the ISO-5 environment. B. Your non-viable [redacted] Particle Counter Asset ID [redacted] used injectables on ISO-7 Buffer room where your laminar flow cabinet is located, is calibrated every [redacted]. This equipment was last calibrated on October 21, 2024, and it is due on [redacted] Calibration of every [redacted] is not adequately justified for particle counters in ISO-7 as it may give a false negative result of the ISO-7 environment. C. You calibrate your ISO-7 Buffer room ID# [redacted] and Anteroom (ID# [redacted] in house. You place all devices at the same location alon with a standard (NIST) device at the same temperature C/F and humidity (%) for about [redacted]. Your acceptance criteria are temperature within [redacted] and humidity [redacted] meet the specifications. You do not perform multi-point calibration with different environments, including low point (operational minimum), midpoint, and highpoint ( operational maximum) temperature and humidity. This calibration is not acceptable since you cannot prove linearity, and there is no evidence the temperature and humidity sensors can drift evenly if the temperature is different from the temperature calibrated at. Dee rfiel d Beach, FL 33 44 2- 7707 Out sour cing Facility minimum), midpoint, and highpoint ( operational maximum) temperature and humidity. This calibration is not acceptable since you cannot prove linearity, and there is no evidence the temperature and humidity sensors can drift evenly if the temperature is different from the temperature calibrated at. D. You failed to keep the [redacted] ID# [redacted] in a location to assess the correct temperature of the area where the compounded sterile product is dispensed. This [redacted] reports kept in [redacted] of the table in ISO-7 Buffer room [redacted]. The sterile product is filled at approximately more than six feet where the [redacted] is kept at. The temperature and humidity could be different closer to the laminar flow component due to additional generation of heat. On 8/18/2026, during our observation of dispensed batch CMP PROCAINE Hydrochloride (2%) lot 260818A, the temperature was recorded at 71.2°F and humidity of 55.1%. E. You failed to document your change and/or verification of the [redacted] containment receptacle in ISO-8 preparation room. According to your Quality Assurance [redacted], the [redacted] is verified and/or changed every [redacted] and they know it must be changed when the transparent [redacted] can be seen with) ( containment is used to [redacted] when it is weighed in the [redacted] containment hood. The lack of documentation for this [redacted] containment receptacle creates the concern that there could be a possible backflow and/or not appropriate [redacted]. F. You failed to perform an adequate hold time study for your [redacted] of glass vials used as primarily containers for finished [redacted] product. This study does not contam raw data, sample size, [redacted] lot numbers, [redacted] date and [redacted], when it was tested, report number or approvals.

Observation 10

Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

Specifically, The firm uses a [redacted] for the compounding of both hazardous and non-hazardous drug substances. Progesterone ( classified as a Group 2 hazardous [redacted] a drug Testosterone ( classified as a Group 3 hazardous drug) were stated to be handled in the same [redacted] hood as non-hazardous drug substances, as confnmermb the firm's own Pharmacy Hazardous Drug List, which identifies progesterone [redacted] testosterone cypionate [redacted] and testosterone USP [redacted] among the hazardous compounding [redacted] handled at the facility. A review of the following fnm' s written procedures and documents provided to investigators revealed no written procedures addressing the shared use of the [redacted] hood between hazardous and non­hazardous drug products: SOP No. 3.017 -Safe Handling of Hazardous Drugs*: This SOP does not establish any cleaning or decontamination requirements specific to transitioning between hazardous and non­hazardous drug operations in a shared hood. No procedures were identified requiring verification of the absence of hazardous drug residue prior to non-hazardous drug compounding in the same equipment. SOP -Handling Hazardous Drugs, Effective Date: 8/25/2023: This SOP does not mention the scenario in which the same [redacted] is used for non-hazardous drug compounding. No procedures were identified that: (1) differentiate cleaning or decontamination requirements when transitioning between hazardous and non-hazardous drug operations; or (2) require analytical or visual testing to confirm the absence of hazardous drug residue or canyover prior to non­hazardous drug compounding. SOP No. 200-Policy and Procedures for USP 800 Hazardous Drugs*: This SOP does not address shared hood use between hazardous and non-hazardous drug products, nor does it establish any residue monitoring or canyover verification requirements. SOP No. 3.028-Storage and Transport of Hazardous Drugs*: Addresses storage and transport of hazardous drugs only. No procedures relevant to shared hood use, equipment cleaning between drug categories, or canyover prevention were identified in this SOP. Dee rfield Beach, FL 33 44 2- 7707 Out sour cing Facility cleaning between drng categories, or canyover prevention were identified in this SOP. SOP No. 3.030 -Hazardous Drug Spill Kit*: Addresses spill response procedures and spill kit contents only. No procedures relevant to shared hood use or cleaning between hazardous and non-hazardous operations were identified in this SOP. SOP No. 3.032-Disposing of Cytotoxic or Hazardous Drug Waste*: Addresses disposal of cytotoxic and hazardous drug waste only. No procedures relevant to shared hood use, equipment cleaning between drug categories, or carryover prevention were identified in this SOP. (*None of these SOPs have effective date or revision number) No residue monitoring program, canyover verification protocol, or cleaning validation specific to the shared use of the [redacted] hood between hazardous and non-hazardous drug products was identified in any SOP or document provided to investigators. The absence of adequate written procedures and controls for the shared [redacted] hood presents a risk that non-hazardous drug products may be contaminated with hazardous drug residues, which could have a harmful effect on product quality and patient safety. Additionally, SOP -Handling Hazardous Drugs, Effective Date: 8/25/2023, under the cleaning section, requires the use of [redacted] RTU. On 8/17/2026, during our interview with your Pharmacist Intern, she explained that she only uses [redacted]. On 8/19/2026, the Pharmacist Intern explained that the Quality Assurance is [redacted] explained to her that she was performing the cleaning of the non-sterile hood at [redacted] with [redacted] RTU, but she was unaware of this. However, this cleaning performed by Quality Assurance L [redacted]: is not documented in the Form 78NS-Cleaning Maintenance Log: Prescription room/ Non-sterile compounding room (Rev 1) log from January -August 2026. This is a rep eat observation from FDA inspection ending on 11/9/2023.

Observation 11

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.

Specifically, A. The scale used during compounding operations generates printouts that do not capture the date and time of the weighing activity. The absence of date and time information on scale printouts limits the ability to establish traceability of weighing data to specific batch production events and undermines the completeness of batch production records. This is a repeat observation from FDA inspection ending on 11/9/2023. B. The ISO-8 diug preparation room had a tile and grout floor located under the firm's [redacted] containment hood that houses [redacted] scales that are used for weighing non-sterile drug substances, excipients, and [redacted]. This tile and grout floor could be a surface that if contaminated by various bulk drug substance would be hard to clean and may be a resource for facility wide cross contamination through employee movement and cleaning implements such as mops. Additionally, on 8/17/2026, we observed a wooden paint brush in this [redacted] containment hood. This wooden paint brush was used to dust off residual [redacted] from scales in thls hood. The [redacted] which is porous, and fibers of the brush make it difficult to clean and dry and could be a potential source of cross contamination. This is a repeat observation from FDA inspection ending on 11/9/2023.

Observation 12

Employees engaged in the manufacture, processing, packing and holding of a drug product lack the education, training and experience required to perform their assigned functions.

Specifically, A. On 8/18/2026, your Pharmacy Technician [redacted] was observed performing manufacturing operations, specifically weighing and mixing, during compounding activities. During the observation, the Quality Control of [redacted] provided direct, ongoing supervision and instruction throughout the operations. The level of direction and guidance provided raised concerns as to whether the personnel can independently perform this critical compounding operation in accordance with established procedures. B. On 8/18/2026, the licensed pharmacist was present at the facility, however, direct supervision of compounding operation was performed by your Quality Control [redacted] who does not hold the requisite. It was confirmed and verified during the inspection that she is not a registered pharmacist. The supervision of compounding operations by an individual who does not hold the requisite professional licensure and qualifications raises significant concerns regarding the adequacy of oversight of drug manufacturing activities at this facility. Personnel responsible for supervising manufacturing operations must possess the education, training, experience, and where applicable, professional licensure necessary to ensure that compounding operations are performed in accordance with CGMP requirements and applicable regulations. Additionally, supervision of the sterile dispensing operations held in the ISO-5 is performed from the ISO-8 environment (by viewing the process from a [redacted]. On 8/18/2026, during the filling of CMP PROCAINE Hydrochloride (2%) lot 260818A, supervision of sterile filling operations was conducted from outside the ISO-7 cleanroom environment, through [redacted] into the ISO-5 area (inside Buffer room [redacted]. This did not provide adequate oversight to ensure that aseptic techniques were being followed, as the supervisor was unable to verify if first are was being blocked during the filling of vials, if environmental monitoring was being conducted appropriately, or if environmental monitoring samples were being labeled correctly.

Observation 13

Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet each appropriate specification as a condition for their approval and release.

Specifically, you have not established written procedures defining the testing requirements for drug products placed in quarantine due to a temperature out-of-specification (OOS) condition. As a result, there is no assurance that affected drug products are adequately tested to confirm they meet established specifications for identity, strength, quality, and purity prior to release or disposition. Fi rm personnel were asked to describe the testing procedure for product quarantined following a temperature OOS event. The personnel were unable to provide the procedure and deferred to the Quality Control [redacted]. She stated verbally that potency testing is performed on quarantined product; however, this practice was not documented in any written procedure reviewed. Additionally, no written procedures were identified addressing: (1) whether microbiological testing is required for quarantined product; (2) the testing and disposition requirements for finished product that had already been released and distributed prior to identification of the temperature excursion; and (3) the acceptance criteria applied to any testing performed on quarantined product prior to a release or rejection.

Observation 14

The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.

Specifically, your test method validations for drug products are inadequate in that they fail to demonstrate the methods are stability-indicating, specific, accurate, and reproducible for their intended use. A. Your test method validation for the [redacted] used to determine the assay/potency of Ascorbic Acid for Injection, 500 mg/mL, did not demonstrate the specificity of the test method for the finished drug product. i. Your validation study, documented in "Validation studies -Hybrid Ascorbic Acid 500 mg-ml Validation Studies" (executed for batch TR210829, dated 08/29/2021), concludes that [redacted] did not interfere with the [redacted] reaction. You have not performed testing to show the [redacted] method can distinguish the active ingredient from known impurities or degradation products. Y our internal study, titled "Absence of oxalate-Ascorbic acid injection" (dated October 30, 2023), shows lack of specificity of the [redacted] test method. In an attempt to prove [redacted] did not interfere, the study concludes that [redacted] of a [redacted] did not alter the [redacted] result (remaining at [redacted] confirming the method does not detect this known degradant/impurity. ii. Your validation for accuracy and repeatability in "Validation studies -Hybrid Ascorbic Acid 500 mg-ml Validation Studies" (executed for batch TR210829, dated 08/29/2021) was inadequate. You tested only one concentration of Ascorbic Acid [redacted] if times and failed to generate statistical data across multiple varying concentration levels. Therefore, you have no documented assurance that your method can accurately detect sub-potent or super-potent batches outside of that single tested target. B. Your in-house Ascorbic Acid injection HPLC method, as outlined in "Test Method for Ascorbic Acid for injection HPLC test method and testing forms, ", has not been adequately validated for its intended use. " i. No documentation was provided to demonstrate that a forced degradation study was conducted to evaluate whether impurities and/or degradants interfere with the analysis. Therefore, the method has not been demonstrated to be stability-indicating. to evaluate whether impurities and/or degradants interfere with the analysis. Therefore, the method has not been demonstrated to be stability-indicating. C. Your firm's practice of utilizing a non-specific [redacted] method as the primary mechanism for batch release, supplemented only by the [redacted] or [redacted] appilcation of an unvalidated in-house HPLC method, is scientifically unjustified and fails to resolve established laboratory control deficiencies. Neither analytical method has been subjected to adequate validation to demonstrate accuracy, precision, and specificity for the finished dosage form. The intermittent use of a secondary, unvalidated method does not compensate for the inherent lack of specificity in your primary release assay, nor does it provide the necessary scientific assurance that all distributed batches conform to safety and purity standards. This is a repeated observation from FDA inspections ending on 7/28/2016, 6/20/2019, 9/3/2021, and 11/09/2023. i. Your firm uses a non-specific, unvalidated test [redacted] for routine batch release, and only triggers the HPLC method reactively if the [redacted] result falls outside an "action limit" [redacted]. Your firm's practice of utilizing a non-specific [redacted] method as the primary mechanism for batch release, supplemented only by the [redacted] or [redacted] appilcation of an unvalidated in-house HPLC method, is scientifically unjustified and fails to resolve established laboratory control deficiencies. Neither analytical method has been subjected to adequate validation to demonstrate accuracy, precision, and specificity for the finished dosage form. The intermittent use of a secondary, unvalidated method does not compensate for the inherent lack of specificity in your primary release assay, nor does it provide the necessary scientific assurance that all distributed batches conform to safety and purity standards. This is a repeated observation from FDA inspections ending on 7/28/2016, 6/20/2019, 9/3/2021, and 11/09/2023. D. Your firm's test methods for sterility are not established and documented to ensure they are accurate and sensitive. Specifically, your procedure "Sterility Method Suitability" fails to conform to the requirements of USP <71> for demonstrating method suitability (bacteriostasis and fungistasis). The procedure does not include the challenge organism Clostridium sporogenes, an anaerobic bacterium required by the USP. The procedure lacks a defined, scientifically sound, and validated method for neutralizing antimicrobial properties of drug products. It vaguely states to "Modify the conditions" without specifying how these modifications should be developed and validated.

Observation 15

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your facility's [redacted] cleanroom certification reports are deficient and fail to demonstrate a state of control. A) Your firm failed to perform concurrent viable environmental monitoring (microbial air and surface sampling) during the [redacted] cleanroom physical certifications. This data is absent from your certification reports dated [redacted] 2025 (Control ID: [redacted] and [redacted] 2026 (Control ID [redacted]. B) Your firm failed to establish formal specifications for critical cleanroom parameters. In the Certification Report dated 27 SEP 2025 (Control ID: [redacted] key performance data, including HEPA filter airflow velocities and Air Changes per Hour (ACPH) for the ISO 8 Prep Room, are marked as "For Reference Only" and are not formally passed or failed against established criteria. C) The documentation for HEPA filter integrity testing is inadequate. Your certification reports provide only a summary "Pass" status and lack detailed, filter-by-filter raw data, such as aerosol challenge concentrations and individual leak percentages. This is a repeat observation from the FDA inspections ending on 06/20/2019, 09/03/2021, and 11/09/2023.

Observation 16

Your outsourcing facility compounds drug products using bulk drug substances that cannot be used in compounding under section 503B of the Federal Food, Drng, and Cosmetic Act (FD&C Act) because they (a) are not used to compound drug products that appear on the diug shortage list in effect under section 506E of the Act and (b) do not appear on a list developed by FDA of bulk drug substances for which there is a clinical need.

section 506E of the Act and (b) do not appear on a list developed by FDA ofbulk drng substances for which there is a clinical need. Specifically, your facility compounded human drug products using semaglutide and tirzepatide bulk drug substances.

Observation 17

Laboratory records do not include complete records of the periodic calibration of laboratory instruments.

Specifically, the documentation and chromatographic raw data provided for the "Calibration and Performance Maintenance of HPLC, [redacted] are incomplete, contradictory, and fail to demonstrate that the instrument is operating in a verified state of control as detailed below: A. The firm maintains multiple, conflicting records for the same performance qualification event. For example, one "Reproducibility Test" report sheet documents an [redacted] injection sequence with a calculated %RSD of 0.15%. This sheet is unsigned and undated, referencing raw chromatograms acquired on 09/19/2025. A separate, conflicting "Reproducibility Test" report sheet documents a [redacted] injection sequence with a calculated %RSD of 0.2142%. This sheet is also unsigned and undated, referencing raw chromatograms acquired on 09/19/2025. B. Test records, such as the "Flow Rate Accuracy Test" report sheet, remain completely unexecuted and undated. For example, the fields for "WEIGHT OF SAMPLE, g" contain only placeholder values [redacted] for the solvent sample weights, leaving the flow rate accuracy of the pump completely unverified. C. Chromatogram raw data acquired on 09/19/2025 (and printed on 01/25/2026) was generated using [redacted] Standard " (Lot# [redacted]) that had expired prior to use. According to the accompanying handwritten, undated "Test Materials and Test Equipment Certification form, this standard carried an expiration date of October 31, 2023. Consequently, the reference standard used to qualify the system was expired by nearly two years at the time of testing. Dee rfiel d Beach, FL 33 44 2- 7707 Out sour cing Facility standard used to qualify the system was expired by nearly two years at the time oftesting. D. A review of the raw chromatogram printouts from the 09/1 9/2025 sequence reveals active system suitability and contamination issues that were neither investigated nor resolved: 1. The chromatogram designated as a "blank/solvent" injection (found within Result File: blank/00l.rst) shows significant baseline noise and a distinct, unexpected peak at approximately 0.310 minutes, indicating carryover from previous runs or contamination of the mobile phase/autosampler system. 2. Chromatograms representing test injections (found under Result File: rsd-001.rst) display noticeable peak tailing for the main [redacted] peak (Retention Time ~0.206 minutes) and erractic baseline drift, indicating potential column degradation or detector lamp instability. E. Records for executed tests fail to document the calibration status of the measuring equipment used to qualify the HPLC system: 1. The "Oven Temperature Accuracy" report sheet (referencing recorded test measurements of [redacted] has no entry in the "Next Calibration Date" field for the [redacted] or [redacted] " used to verify the column oven. 2. The "Test Report" sheet for the certification of test equipment fails to document the "Last Cal. Date" and "Next Cal. Due" columns for the [redacted] balance (Serial Number: [redacted] used for gravimetric verification. F. There is a total absence of Quality Unit oversight and analyst verification across all calibration record packages,. Specifically, the executed test reports or summary sheets, including the handwritten, undated "Performance Certification of an HPLC Autosampler" form and the corresponding printed test summaries, did not contain the required signatures or dates in the "Qualifying Engineer" or "Reviewed By" signature fields. This complete lack of documented review and authorization leaves the operational suitability and calibration status of the system completely unverified by the quality unit. completely unverified by the quality unit.

See all 9 findings in this document
[Warning Letter · FDA]Nanjing Hanxin Pharmaceutical Technology Co. Ltd. — Failed supplier oversight for API materials
FDACGMP

The quality unit did not adequately qualify suppliers of critical raw materials

After reviewing records submitted under a 704(a)(4) request, FDA issued a warning letter to Nanjing Hanxin Pharmaceutical Technology Co. Ltd., an API manufacturer in Nanjing, China. FDA placed all drugs offered for import from the firm on Import Alert 66-40 on 2026-06-22.

Published 2026-11-10 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 11/03/2026

Key facts · Basis: official index plus supporting sources
  • Violation 1: quality unit failed its CGMP responsibilities (501(a)(2)(B)) — suppliers of critical raw materials for APIs used in sterile products and compounding were not adequately qualified
  • Violation 2: importation of unapproved drugs (503A/503B) — registered APIs left out of the records response included one not permissible for compounding under 503A or 503B
  • Response and FDA's assessment: the firm said production moved to a subsidiary after November 2025; FDA found its supplier oversight deficient
  • Agency action: placed on Import Alert 66-40 on 2026-06-22; written response required within 15 business days
Response and FDA's assessment · as stated in the source

The supplier the firm qualified for a critical starting material was a site whose drugs FDA found adulterated after inspection and placed on Import Alert 66-40. FDA stated that presenting the firm rather than the actual manufacturer may have been an attempt to circumvent safeguards. The letter requested a list of all drugs distributed in the last three years with their original suppliers, and copies of written customer notifications for lots made from non-compliant suppliers' materials.

Check points
  • Is the import alert status of critical starting material suppliers checked at approval and at periodic requalification? (Violation 1)
  • When production moves to another site or subsidiary, is the actual manufacturing site reflected in supplier management and regulatory filings? (Violation 1)
  • Does each API for the U.S. market have stability data supporting its retest date? (Violation 1)
[Warning Letter · FDA]Chongqing Qiancan Technology Co., Ltd. — Refusal to provide records
FDACGMP

The firm de-registered and delisted one day before replying to the records request

FDA issued a warning letter to Chongqing Qiancan Technology Co., Ltd., an API manufacturer in Chongqing, China, that did not provide records requested under 704(a)(4). FDA placed all drugs offered for import from the firm on Import Alert 66-79 on 2026-08-26.

Published 2026-11-10 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 10/29/2026

Key facts · Basis: official index plus supporting sources
  • Violation 1: refusal to provide records (301(e)) — records requested electronically on 2026-06-17 via the registration contact email were never provided
  • Response and FDA's assessment: the firm de-registered and discontinued its drug listing on 2026-06-29, replied on 2026-06-30 that it could not meet FDA requirements, and re-registered on 2026-07-13
  • Agency action: placed on Import Alert 66-79 on 2026-08-26; written response required within 15 business days
Response and FDA's assessment · as stated in the source

A review of import records found multiple shipments of API for prescription compounding that declared this firm as the manufacturer. FDA stated that without the records it has no indication of the level of quality assurance, although APIs made by the firm were imported and remain within expiry. The letter noted that the firm may request an FDA inspection in its response.

Check points
  • Is the registration contact email monitored continuously with an assigned owner for regulator records requests? (Violation 1)
  • Does supplier evaluation check whether an imported API site is on an import alert for refusing FDA records requests? (Violation 1)
[Warning Letter · FDA]USV Private Limited — Aseptic design flaws and weak visual inspection
FDACGMP

Published 2026-11-10 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 11/02/2026

3 violations
Findings
  1. 1Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)). 21 CFR 211.113(b)
  2. 2Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance. (21 CFR 211.42(c) and 21 CFR 211.63). 21 CFR 211.42(c) · 21 CFR 211.63
  3. 3Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)). 21 CFR 211.160(b)
  • Agency action: written response required within 15 business days; FDA warned of withheld approval of new applications and refusal of admission under 801(a)(3) until violations are resolved
Response and FDA's assessment · as stated in the source

The firm hired an independent consultant and concluded in a retrospective risk assessment that the process was in control, citing passing sterility, endotoxin and media fill results. FDA found the response inadequate, stating that fundamental design flaws in airflow, ergonomics and aseptic practice cannot be validated and require redesign. On visual inspection, FDA said retrospective destructive testing of in-date batches cannot substitute for characterization and control that were missing at the time of production.

Check points
  • Do smoke studies on aseptic filling lines evaluate airflow under dynamic conditions, including ISO 5 to ISO 7 transition interfaces? (Violation 1)
  • Has it been verified that conveyors and equipment along open-container transfer paths do not block ISO 5 unidirectional airflow? (Violation 2)
  • Does the injectable visual inspection program set both alert and action limits for visible particulates and classify particles as extrinsic or intrinsic? (Violation 3)
Violation detail · 3 items · From the source
Violation 121 CFR 211.113(b)

Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).

Violation 221 CFR 211.42(c) · 21 CFR 211.63

Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance. (21 CFR 211.42(c) and 21 CFR 211.63).

Violation 321 CFR 211.160(b)

Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).

[Warning Letter · FDA]Tianjin Healthcare Medical Technology Co., Ltd. — Refusal of access to and copying of records
FDACGMP

The firm refused to provide requested records, citing an end to U.S. production

FDA issued a warning letter to Tianjin Healthcare Medical Technology Co., Ltd., an API manufacturer in Tianjin, China, that refused a 704(a)(4) records request. FDA placed all drugs offered for import from the firm on Import Alert 66-79 on 2026-08-25.

Published 2026-11-10 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 10/29/2026

Key facts · Basis: official index plus supporting sources
  • Violation 1: refusal to permit access to or copying of records (301(e)) — on 2026-06-24 the firm answered the 2026-06-17 request by saying it would discontinue production for the U.S. market and refused to provide documents
  • Response and FDA's assessment: after a 2026-06-25 follow-up noting in-date APIs on the U.S. market, the firm again refused; FDA stated that ceasing distribution or intending to stop production does not retroactively relieve regulatory obligations
  • Agency action: placed on Import Alert 66-79 on 2026-08-25; written response required within 15 business days
Response and FDA's assessment · as stated in the source

A review of import records found multiple shipments of APIs for pharmacy compounding that declared this firm as the manufacturer. FDA stated that a firm no longer making or distributing drugs for the U.S. market must formally update its registration and drug listings within 30 calendar days of ceasing operations under 21 CFR 207.29(a)(3).

Check points
  • After a product withdrawal or production stop, are records for in-date product still on the market retained so they can be provided on regulator request? (Violation 1)
  • Is there a procedure to update registration and drug listings within 30 days when production for a foreign market stops? (Violation 1)
[FDA 483 observation · FDA]Qingdao Kangyuan Pharmaceutical Co., LTD — Unmet impurity study commitment
FDA483

Balance for incoming materials and its reference weight sat on the warehouse floor

Published 2026-11-13 · Inspection date 04/22/2016 · API Manufacturer · FEI 3006512854

6 observations
Findings
  1. 5Th of the ater system is not monitored and now® are installed throughout the system.
  2. 6The firm has conducted bulk hold-time studies for th peratio e firm, however, did not produce bulk hold-time data for the@@ crude stages ofthe roduction.
  3. 7The scale, ID # SC-DZC-17-06, which is used in the oom, is@@ calibrated using amo standard weight weighing range is between 0) In addition the vendor calibration certificate dated id not indicate that the scale had been calibrated within the scale weighing range.
  4. 8On 4/18/16, we observed an electrical balance, 1D # SC- -|7-04, and a container housing a®® reference weight, 1D # SC-DZC-17-04, sitting on the floor ofthe arehouse@@ which may be subject to contamination and instability.
  5. 9On 4/18/16, we observed an attachment form, titled “ Balance using records 03-103-A1 02”, which was used to record the weight of materials.@ lL) EE) Crude, on 4/2/16.
Show 1 more
  1. 10The written procedure, Gauge and Calibration Management, SOP 03-103, version 02, effective date 7/20/15, did not include adequate instructions regarding where a balance should be placed for weighing and measuring operations.
Check points
  • Are commitments and deadlines from prior inspection responses tracked and met? (Observation 1)
  • Is there qualification data for HVAC shut down during non-operation? (Observation 3)
  • Does balance calibration cover the working range, with re-calibration after moves? (Observation 7)
Observation detail · 6 observations · From the source
Observation 5

Th of the ater system is not monitored and now® are installed throughout the system.

There is no indication ofth [redacted] water distribution tank and the loop system to the building workshop.

Observation 6

The firm has conducted bulk hold-time studies for th peratio e firm, however, did not produce bulk hold-time data for the@@ crude stages ofthe roduction.

Observation 7

The scale, ID # SC-DZC-17-06, which is used in the oom, is@@ calibrated using amo standard weight weighing range is between 0) In addition the vendor calibration certificate dated id not indicate that the scale had been calibrated within the scale weighing range.

The scale alibration does not cover the stated scale weighing range.

Observation 8

On 4/18/16, we observed an electrical balance, 1D # SC- -|7-04, and a container housing a®® reference weight, 1D # SC-DZC-17-04, sitting on the floor ofthe arehouse@@ which may be subject to contamination and instability.

The balance is used to check the weight of incomin [redacted] raw materials after receipt by the warehouse.

Observation 9

On 4/18/16, we observed an attachment form, titled “ Balance using records 03-103-A1 02”, which was used to record the weight of materials.@ lL) EE) Crude, on 4/2/16.

The actual weight of each material is not recorded on the form. This form was found sitting on the floor ofhe Varese to the electrical balance, |D # SC-DZC-17-04, and a container housing [redacted] reference weight, ID # SC-DZC-17-04.

Observation 10

The written procedure, Gauge and Calibration Management, SOP 03-103, version 02, effective date 7/20/15, did not include adequate instructions regarding where a balance should be placed for weighing and measuring operations.

This procedure only states to place the instrument in a clean and dry environment. The procedure also does not have instructions regarding re-calibration ofa balance after it is moved. Observation 1. On 4/20/16, during the walkthrough ofthe buildin [redacted] Workshop, we observe [redacted] stations situated on the exterior of the building which contained no [redacted]

See all 5 findings in this document
[FDA 483 observation · FDA]Qingdao Kangyuan Pharmaceutical Co., LTD — Process water and equipment upkeep gaps
FDA483

Water used to make the API was not tested for objectionable organisms like E. coli

Published 2026-11-13 · Inspection date 08/16/2024 · API Manufacturer · FEI 3006512854

4 observations
Findings
  1. 1Laboratory controls do not include scientifically sound and appropriate specifications, sampling plans and test procedures designed to assure that raw materials conform to established standards of quality and/or purity.
  2. 2The master batch production record lacks an established time limit and detailed production instructions to ensure the quality of intermediates and APIs are met for individual processing steps and/or total process.
  3. 3Failure to validate and verify the suitability of analytical methods.
  4. 4Equipment used in the manufacture of intermediates and API’s should be maintained in a good state ofrepair to prevent contamination that would alter the safety, identity, strength, quality and purity ofthe drug product.
Check points
  • Does microbial testing of process water include methods for objectionable organisms? (Observation 1)
  • Do batch records set step time limits and record time for each individual load? (Observation 2)
  • When another pharmacopeia's ID method is used, is equivalence to the USP shown? (Observation 3)
Observation detail · 4 observations · From the source

Inspectors: Alan A. Rivera · Chad Rice

Observation 1

Laboratory controls do not include scientifically sound and appropriate specifications, sampling plans and test procedures designed to assure that raw materials conform to established standards of quality and/or purity.

: Specifically, Your firm failed to monitor the water system, so it consistently produces pharmaceutical grade water that, at a minimum, meets the USP monograph for[a and appropriate microbial limits. Your firm’s current test methods used to detect objectionable microbiological contamination in water used to manufacture APIs do not — include microbial testing methods to detect the presence of objectionable organisms such as Burkholderia cepacia complex, Escherichia coli or Staphylococcus aureus. Furthermore, your firmbaw sampling Standard Operating Procedure titled “Water for Production Use Operational Procedures ersion No:10, Effective Date: 08/02/2024, SOP Number: 09-224 specifies in section 5.1.4.2.2.4 that aeet be performed the GA personnel collecting the water sample. Your firm Standard Operating Pr ure tl r System Operating, Maintenance and Cleaning”, Version No:11, Effective Date: 08/02/2024, S umber: 02-104 used to instruct operators on the use of(water in the manufacturing areas does not establish a ese. Jiaozhou City Qingdao Shandong 266300 China API Drug Manufacturer Your sampling methods are not representative of the actual water use practices at your firm production areas. ater is used as a raw material in the manufacturing process of your API. PRODUCTION SYSTEM

Observation 2

The master batch production record lacks an established time limit and detailed production instructions to ensure the quality of intermediates and APIs are met for individual processing steps and/or total process.

Specifically, Your firm failed to establish and document a specific time limit in the Batch Manufacturing Record (BMR) for the step in the crude manufacturing process of MA dditionally, there is Moccurrin during the process that is not being recorded in the manufacturing record. Your firm operates with different capacitiesENSEachhas different capabilities, causing the ime to vary from batch to batch. Similarly, your firm did not record the duration ofth rocess following the steps. The current Batch Manufacturing Record (B ogs the total time taken to complete ai loads but fails to document the time for each individual load. Although your firm has set a minimum a: of 004, it did not document whether this time requirement was met for each oad. LABORATORY SYSTEM Jigozhou City Qingdao Shandong 266300 China API Drug Manufacturer

Observation 3

Failure to validate and verify the suitability of analytical methods.

Specifically, Your firm is using the Chinese Pharmacopeia for identity testinga: raw material used in the production of ou have not validated or verified that the Chinese Pharmacopeia identity test method for is equivalent to, or better than, the U.S. Pharmacopeia (USP) identity test method for the same substance. FACILITIES AND EQUIPMENT SYSTEM

Observation 4

Equipment used in the manufacture of intermediates and API’s should be maintained in a good state ofrepair to prevent contamination that would alter the safety, identity, strength, quality and purity ofthe drug product.

Specifically, During the inspectional walkthrough, on 08/12/2024 it was observed that your firm failed to maintain equipment Haozhou City Qingdao Shandong 266300 China APT Drug Manufacturer used in the manufacturing ofAPI and intermediates in a good state of repair. Your located in building used in the manufacture o had aterial flaking into the our firm’s equipment preventive maintenance records show that a preventive maintenance check was performed on 08/01/2024, but this deficiency was not addressed. Furthermore, andie in building MMused in the manufacture of ere marked as cleaned, but had what appeared to be rust flakes at the otiom of the pon further mspection, it was determined that the rust flakes originated from theff [redacted] ocated on top each [redacted]

See all 3 findings in this document
[FDA 483 observation · FDA]Biosafety Testing Laboratory in Agricultural Technology Rese… — Unsupported frozen storage of mycoplasma samples
FDA483

Quality unit does not review original microscopy images on analysts' personal SD cards

Biosafety Testing Laboratory in Agricultural Technology Research Institute (ATRI) · Published 2026-11-13 · Inspection date 04/27/2026 · Testing Facility · FEI 3020688999

3 observations
Findings
  1. 1Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to ensure that test materials conform to appropriate standards of identity, strength, quality and purity.
  2. 2Not all laboratory records include accurate and complete data derived from all tests and examinations necessary to assure compliance with established specifications and standards.
  3. 3Analytical assay invalidation and reanalysis are not always scientifically justified and documented under an appropriate system for quality review and trending.
Check points
  • For mycoplasma samples tested after frozen storage, is there viability data covering the storage period? (Observation 1)
  • Does the quality unit directly review original images generated on analysts' personal storage media? (Observation 2)
  • Is prior quality unit approval and a deviation record required when reanalyzing for reasons outside system suitability criteria? (Observation 3)
Observation detail · 3 observations · From the source
Observation 1

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to ensure that test materials conform to appropriate standards of identity, strength, quality and purity.

Specifically, Your test procedure WT-01-03, Mycoplasma Testing — [redacted], Version 2.4, Effective 07/23/2023 allows for long-term storage of the [redacted] unprocessed bulk (UPB) under frozen condition (Step [redacted] for up to [redacted] However, you were unable to provide supporting data to demonstrate that viability ofMycoplasma spp. in they can be maintained after™ [redacted] of frozen storage. Mycoplasma spp. does not have cell walls and is prone to cell destruction during freezing and thawing absent the protection of its host cell. Long-term storage ofthe [redacted] (4) as permitted in WT-01-03 can potentially lead to false negative results and impact the safety of commercial [redacted] product distributed to the United States market.

Observation 2

Not all laboratory records include accurate and complete data derived from all tests and examinations necessary to assure compliance with established specifications and standards.

Specifically, Your firm lacks an adequate audit procedure for digital microscopy images captured on each analyst’s personal SD card, transferred to their work laptops, and uploaded to server for archival. On 04/23/2026, your Quality Director verbally confirmed that the quality unit does not review the original raw data stored on the SD cards to ensure all data reported is reliable and no data is omitted. Instead, the quality unit reviews images on the final report against archived images that do not represent the true copy of the original data. Microscopic images are used to support the final reportable result ofUSP <63> mycoplasma Jhunan Township, Miaoli County 350401, Taiwan Testing Facility and USP <1237> in vitro virus testing ofmw UPB.

Observation 3

Analytical assay invalidation and reanalysis are not always scientifically justified and documented under an appropriate system for quality review and trending.

For example, [redacted] UPB sample of [redacted] lot mw, was tested on 12/11/2025 for mw 0) by [redacted] and the results were reanalyzed on 12/15/2025 because standard deviation (SD) for [redacted] was [redacted] Variation ofmw is not among the system suitability criteria specified in WT-04-62, oe Assay, Version 1.3, Effective 06/23/2020 or the sample test record [redacted] _—srepresents the method limit of detection (LOD) at [redacted] 4) and the results are expected to have high variability. Nevertheless, you proceeded to re-analyze the data without obtaining prior approval from the quality unit and failed to initiate a deviation or laboratory investigation to document this event for future trending and continued improvement. SEE

[FDA 483 observation · FDA]MSN Life Sciences Private Limited, Unit II — Insufficient basis for invalidating OOS results
FDA483

Analyst used a different sample solution in retesting, not investigated as a deviation

Published 2026-11-13 · Inspection date 09/13/2024 · API Manufacturer · FEI 3011543392

4 observations
Findings
  1. 1Your firm failed to thoroughly investigate critical deviations and/or the failure(s) of a batch to meet specifications.
  2. 2Your quality unit failed to review all critical deviations or non-conformances and related investigations for all API products.
  3. 3Your quality unit failed to perform one of it's core responsibilities to ensure that critical deviations are investigated and resolved.
  4. 4Your production areas fail to provide adequate washing facilities for personnel.
Check points
  • Are retest errors and system suitability failures during OOS investigations logged as separate deviations or lab incidents? (Observation 1)
  • Are quality events grouped in one investigation split out for trending? (Observation 2)
  • Are out-of-trend criteria defined for products with few batches? (Observation 3)
Observation detail · 4 observations · From the source
Observation 1

Your firm failed to thoroughly investigate critical deviations and/or the failure(s) of a batch to meet specifications.

Specifically, Al. Out-of-Specification (OOS)=23064 Investigation was inadequately completed to justify the invalidation of the initial OOS result for Assay by HPLC (Preparation-2) for [redacted] 2 [redacted] Lot ow for stability testing (long term 36 months). A2. During the investigation for OOS-23064, an analyst was identified to conduct a remeasurement of the sample solutions to determine a probable root cause for OOS=23064. However, per the investigation report (07- 00S823064-R-01), the analyst inadvertently utilized a different sample solution to complete the re-vial testing. Even though the investigation acknowledges the human error, the investigation does not appear to include a new re-vial testing conducted for the true sample solution utilized in the original OOS, and the human error for the re- vial test was not identified and investigated as a separate quality-related event such as a Deviation. B1. OOS-24006 Investigation was inadequately completed to justify the invalidation of the initial OOS result for Assay by HPLC (Preparation-1) foro Lo [redacted] for stability testing (long term 24 month). B2. During the investigation for OOS-24006, there was a system suitability failure during the remeasurement testing (re-injection; re-vial; and re-dilution) analysis. Even though the system suitability failure was documented in the investigation, the investigation did not conduct a new remeasurement analysis to determine a root cause and support a re-analysis of the stability sample. Additionally, the quality unit failed to separately investigate the system suitability failure under a Laboratory Incident Form per the firm's SOP CQC-0052-000 titled "GOOD LABORATORY PRACTICES" with an effective date of 01/03/2022 (March Ist, 2022). C. There were a pattern ofOOS Investigations where the quality unit failed to initiate and complete a separate investigation (Laboratory Incident Form) for each suitability failure identified during each investigation including the one specified under B2: -OOS-24032 --Missing at least one (1) laboratory incident form -OOS-23093 --Missing at least two (2) laboratory incident forms

Observation 2

Your quality unit failed to review all critical deviations or non-conformances and related investigations for all API products.

Specifically, There were quality-related events (OOS, deviations, system suitability failures [invalid and incident]) that were not separately identified for the purposes of review and/or trending purposes to identify quality-related deficiencies. Multiple quality-related events were identified within one (1) quality event investigation which can dilute the total number of quality-related events to review within a given time period.

Observation 3

Your quality unit failed to perform one of it's core responsibilities to ensure that critical deviations are investigated and resolved.

Specifically, Out-of-Trend (OOT) ranges were not calculated and evaluated for a number of specification tests for some of your API products that were: 1) manufactured with less than [redacted] batches and 2) were not updated within the firm's recently implemented LIMS system. According to your firm's SOP CQC-0003-002 titled "HANDLING OUT-OF-TREND RESULTS" with an effective date of 05/06/2023 (June 5th 2023), sectio [redacted] describes a way for handling OOT during API release testing for APIs without trend limits calculated from the [redacted] batches. FACILITIES AND EQUIPMENT SYSTEM

Observation 4

Your production areas fail to provide adequate washing facilities for personnel.

Specifically, The washing area(s) prior to entry into the cleanroom area(s) of production did not have access to hot water for hand washing.

[FDA 483 observation · FDA]Wasserburg Arneimittelwek GmbH — Inadequate aseptic area SOPs
FDA483

Gloves used ambidextrously were sampled on only one side during environmental monitoring

Published 2026-11-13 · Inspection date 02/11/2022 · Drug Product Manufacturer · FEI 3002806849

1 observation
Findings
  1. 1Standard Operating Procedures are not followed or are not adequate in the description of operations.
Check points
  • Do environmental monitoring procedures require sampling both sides of gloves used ambidextrously? (Observation 1)
  • Do procedures require folding sanitizing wipes after each stroke so the soiled side is not reused? (Observation 1)
  • Is there a procedure to segregate non-GMP development material from GMP API storage? (Observation 1)
Observation detail · 1 observation · From the source

Inspectors: Michael Shanks · Unnee Ranjan

Observation 1

Standard Operating Procedures are not followed or are not adequate in the description of operations.

Specifically, A. On Tuesday, February 8, 2022, during filling activities in Bldg. Production Ared [redacted] Filling Line(Rm. yr the"be gloves in front ofthe were used ambidextrously. Following the fill, during environmental monitoring activities, these gloves were only monitored on one side of the gloves. The SOP's do not direct the sampling of th gloves for both sides when the glove is used in production activities ambidextrously. SOP A-008814, ver. 14.0, effective date April 23, 2021, Monitoring/Mikrobiologie: Bemusterung von Oberflachen, and SOP A-008921, ver. 21, Attachment 7.1.3, effective date January 19, 2018, Monitoring/Mikrobioligie: Oberflachenkeimzahl-Geréate, Maschinen und Raéume, describes the procedure and locations for environmental monitoring in Grade A area, that includes the monitoring of* gloves, do not describe ambidextrous monitoringof 8gloves. B. On Tuesday, February 8, 2022, in Bldg.ro Production Ared Filling Line‘QRm.ie during the set up activities for filling,[| *s wipes were used to wipe down materials prior to placing them in the-_— (e.g. P| During the sanitization ofthese[Ts the/ 7% wipes were never folded after each wipe stroke and the soiled side of the wipe was further used. The Senior Manager of Compliance stated that folding o wipes is not described in any of SOPs regarding sanitizing objects prior to placing them into th C. On Tuesday, February 8, 2022, in Bldg. ‘Production Area‘GFilling Line(Rm. during set up activities ofthe filling line, EM plates were placed in the transfer area that feeds the vials to the When the operator opening the Nee into Grade B, the Grade A side ofthe was not sanitized prior to closing. SOP A 064805, ver. 05, November 24, 2021, Vorbereitung und Durchftihrung von mikrobiologischen Umgebungskontrollen bei Abfiillung auf) does not describe sanitization of the prior to closing back into Grade A after it has been opened into Grade B. Drug Product Manufacturer D. On Monday, February 7, 2022, in Bldg.Room an area used to store quarantine and released API, development bottles of— which were not quarantine or release GMP API, were noted in one ofthe Quarantine/Released freezers. The Sr. Manager Regulatory Affairs stated that an SOP for handling ofnon-GMP material is not currently available. E. On Tuesday, February 8, 2022, in Bldg! Production Area [redacted] Filling Line(Rm. during fill operations, two process waste bottles used during filling, one inside the and one outside ofthe were noted as "not labeled." Additionally, on Thursday February 10, 2022, a cart with multiple on it was noted in the Production Area Grade D corridor. Neitherthe or the cart were labeled for status. SOP A 0096, ver. 12, September 1, 2020, Reinung, Geriate fiir Ansatz und Abfiillung, is deficient in describing the labeling of these items. F. On Thursday, February 8, 2022, a Grade D operator was observed in ee (Rm.a and was standing on the Grade C (Compounding Rm.) side ofthe| 74 This room has no demarcation line or way to separate Grade D and Grade C operators. SOP 022403, ver. 3.0, effective date April 5, 2017, Umwandlung von Geraten, Behaltern und Rohstoffgebinden: Zonenwechsel von D (Produktionsbereich) nach C (Ansatzraum) is deficient in describing the segregation ofGrade C and Grade D operators in this area.

[FDA 483 observation · FDA]Phoenix Innovative Healthcare Manufactures Private Limited — Audit trail disabling, uninvestigated deviations
FDA483

The QC manager could disable parts of the audit trail in lab software

Published 2026-11-13 · Inspection date 09/27/2024 · Drug Manufacturer · FEI 3010408344

6 observations
Findings
  1. 1Laboratory controls do not include the establishment of scientifically sound and appropriate standards, sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
  2. 2There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
  3. 3Reserve drug product samples are not retained and stored under conditions consistent with product labeling.
  4. 4Deviations from written production and process control procedures are not recorded and justified.
  5. 5Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of holding of the drug product.
Show 1 more
  1. 6Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and suitably located to facilitate operations for its intended use.
Check points
  • Are audit trail settings in lab software protected from change by lab managers? (Observation 1)
  • Are all alert and action limit excursions logged and investigated per procedure? (Observation 2)
  • Do trial batches receive batch numbers and manufacturing records? (Observation 4)
Observation detail · 6 observations · From the source

Inspectors: Steven A Brettler

Observation 1

Laboratory controls do not include the establishment of scientifically sound and appropriate standards, sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Electronic records are used, but they do not meet requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records. Specifically, A. Your Quality Unit failed to scientifically justify the lack of stability batch testing for batches manufactured unde [redacted] completed process validations, and [redacted] of those process validations have no stability testing conducted at all. B. Your Quality Unit failed to initiate, review, and complete a process validation for a change control (CC-PHX-24-113) that required a new pipe to be installed for the transfer of bulk solution from multiple [redacted] tanks ta [redacted] machine solution tank. There are approximately up to [redacted] batches of released and distributed drug product within the U.S. Market manufactured under this change. Additionally, your Quality Unit failed to scientifically justify why none of those batches were placed on Stability. C. Your Quality Unit did not scientifically justify why the QC Manager has full admunistration privileges for the Gas Chromatography (GC) software, Clarity. During the inspection, I observed that the QC Manager was able to disable elements of the audit trail where a number of changes were not tracked and documented. Additionally, the QC Manager appeared to have full administrative privileges for Chromeleon 7 software for GC as well.

Observation 2

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, A. Your Quality Unit failed to document, track, and investigate alert and action limits foi [redacted] testing per your SOP/QC/003 titled "Sampling of [redacted] ". Per your SOP, [redacted] excursions would require an investigation and each alert and action limit would be documented within the Out of Alert/Action Limit Log. Upon retrospective review o [redacted] sampling results from 2022 to present, there were approximately 138 identified alert/action limit excursions not documented with approximately six (6) instances of [redacted] alert/action limit excursions that should have been investigated. B. Your Quality Unit failed to investigate the Out-of-Specification (OOS) for the reconciliation yield for [redacted] caps within [redacted] lot [redacted] despite documenting [redacted] as Out-of- Specification within the manufacturing batch record. C. Your Quality Unit failed to thoroughly investigate complaints without attempting to collect any physical samples. Your SOP, QSP/QA/013 titled "Customer Complaints" fails to require an attempt or multiple attempts to collect the complaint sample for the investigation. D. Your Quality Unit failed to document, track, and investigate each instance of damaged and repackaged outer boxes when drug products are returned from terminal sterilization via [redacted] Even though there appears to be a damage report, each event is not documented as a non- conformance for rework (repackaging) and appropriately investigated and/or tracked for trends. Upon a retrospective analysis during the inspection, there are approximately 234 instances where a non- conformance should have been investigated.

Observation 3

Reserve drug product samples are not retained and stored under conditions consistent with product labeling.

Specifically, During the facility walkthrough on 09/25/2024, I observed the reserve sample area within an uncontrolled environment where there was no temperature mapping completed for the designated area, and the temperature being recorded [redacted] does not include the highest and lowest temperatures for (4) There is no data available to provide assurance that the retains were stored within an environment as specified per the drug products' labeling. PRODUCTION SYSTEM

Observation 4

Deviations from written production and process control procedures are not recorded and justified.

Specifically, During document review on 09/23/2024, I observed Out-of-Specification (OOS) OOS/22/002 for a stability sample failure for [redacted] lot [redacted] Upon closer inspection, there was not adequate documentation available to determine if any of the batch was distributed within the US. Market. Upon investigation by your Quality Unit during the inspection, multiple deviations were -The batch that failed was not part of the commercial batch [redacted], but rather, it wasa trial batch for [redacted] without the appropriate batch identification numbering for trial batches. -No records were kept at any stage during [redacted] production. -No records were kept of destruction of both the rejected [redacted] and trial me -Batch Manufacturing Records (BMRs) were not prepared for the trial of» [redacted]

Observation 5

Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of holding of the drug product.

Specifically, There is no yield reconciliation calculated and assessed when each drug product that undergoes terminal sterilization via [redacted] is returned to the facility, and the outer boxes are found to be damaged and replaced by repackaging (rework) as documented within the production batch record for each impacted drug product batch. FACILITIES AND EQUIPMENT SYSTEM

Observation 6

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and suitably located to facilitate operations for its intended use.

Specifically, During the facility walkthrough on 09/25/2024, I observed droplets of unidentified liquid on both the floor and corners of the viewing window of the [redacted] stability chamber for accelerated studies (Equipment ID: QA-299). The unidentified liquid appears to have originated from an external tubing connected outside the unit that may have allowed liquid to flow back into the stability chamber instead of outside the unit; however, there is/are no probable root cause(s) identified and provided by your Quality Unit during the time of inspection.

See all 4 findings in this document
[FDA 483 observation · FDA]Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. — API residue on cleaned equipment, weak OOS probe
FDA483

Glove contamination blamed without evidence; batches released after passing retest

Published 2026-11-13 · Inspection date 03/07/2025 · Drug Manufacturer · FEI 3007498452

3 observations
Findings
  1. 1Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
  2. 2There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
  3. 3The responsibilities and procedures applicable to the quality control unit are not fully followed.
Check points
  • Does cleaning validation for shared equipment cover hard-to-reach areas such as ducts? (Observation 1)
  • Is supporting data required before concluding analyst error as the OOS root cause? (Observation 2)
  • Does the quality unit control and record GMP documents discarded in the laboratory? (Observation 3)
Observation detail · 3 observations · From the source

Inspectors: Khoa Nathan V Tran · Lillian S Wu

Observation 1

Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, during the inspection, we observed residue 4a in the wa duct of YOUrga wa (equipment ID # gy which was labeled "cleaned", Afier analysis, your firm identified the residue to contain active pharmaceutical ingredient 4)4: is non dedicated and is used to manufacture multiple drug products, including 4,4 Be Tablets for the U.S. Additionally, your firm failed to assess the [redacted] duct of your oe during your cleaning validation study.

Observation 2

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, your out-of-specification (OOS) investigation is not thorough and complete. For example, OOS investigation # 20240601 was initiated when 44» residue tests yielded OOS results for three (3) batches oe Tablets: Batch # by a3/or/eors- ee Result)(4). (specification: NMT..... 0pm) OXC) The investigation determined that the most likely root cause was glove contamination caused by analyst error. This root cause was not adequately supported with evidence or data. Instead, 4 fresh sample solutions were prepared for each affected batch for retesting. The retest yielded passing results, and the batches were released.

Observation 3

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, during the inspection, we observed torn and discarded GMP documents in the trash bin located in the QC laboratory. Your firm was unaware that these GMP documents were altered and discarded. GMP documents are not managed according to your procedures, document # 02-QA-2-001 and 02-QA-2-004. Lillian S, pital sionedby x Wu-s roicispened

See all 3 findings in this document
[FDA 483 observation · FDA]Anhui Poly Pharm Co., Ltd — Inadequate bulk intermediate hold time studies
FDA483

Bulk hold time studies did not include stability of the finished API

Published 2026-11-13 · Inspection date 02/27/2025 · API Manufacturer · FEI 3020871572

1 observation
Findings
  1. 1In-process materials are not tested for quality by the quality control unit after storage for long periods.
Check points
  • When setting intermediate hold times, is stability data obtained for finished product made from maximally held intermediates? (Observation 1)
  • Are in-process materials retested before use after extended storage? (Observation 1)
Observation detail · 1 observation · From the source

Inspectors: Josh Renzo Ramilo

Observation 1

In-process materials are not tested for quality by the quality control unit after storage for long periods.

Specifically, In the bulk hold time studies that your firm performed for the following API products, you did not include a study that assessed the bulk intermediate APl [redacted] study samples and then placement of the finished API on stability: OX).; wo The allowable bulk hold time for [redacted] API intermediates [redacted] 1I [redacted]

[FDA 483 observation · FDA]Nippon Kayaku Co., Ltd — Weak oversight of lab electronic systems and data
FDA483

Chromatography data generated between batch release tests is not reviewed

Published 2026-11-13 · Inspection date 05/29/2026 · API and Finished Dosage Manufacturer · FEI 3002807722

1 observation
Findings
  1. 1Supervisory oversight over the laboratory electronic systems and data is deficient.
Check points
  • Are issued and returned counts reconciled for official GMP forms printed from electronic systems? (Observation 1)
  • Do data and audit trail reviews cover chromatography data generated outside release testing? (Observation 1)
Observation detail · 1 observation · From the source
Observation 1

Supervisory oversight over the laboratory electronic systems and data is deficient.

Specifically, A. Your firm does not reconcile official GMP documents issued from your ArcSuite Engineering document management system. Your firm uses ArcSuite Engineering to issue test records used for GMP testing and to issue manufacturing batch records. You stated the documents are approved by QA in the electronic system prior to printing out, but your firm does not have an audit trail or document history tracing each document that has been printed out. In addition, your firm does not reconcile all of the official GMP documents printed from ArcSuite Engineering. Your firm implemented ArcSuite engineering in April 2020 and uses it to issue official GMP records for manufacturing and testing of [redacted] API. B. Your firm does not review 100% of the audit trails and electronic data in your Lab Solutions chromatography software. Your firm reviews the audit trails related to batch release testing, but your firm does not review all of the data generated between batch release testing. You are unable to confirm the presence or the absence of trial injections or other illegitimate testing due to the lack of 100% review. Your firm uses Lab Solutions for performing finished product testing on [redacted] API.

[FDA 483 observation · FDA]Zhejiang Guobang Pharmaceutical Co., Ltd — Unjustified water microbial limits
FDA483

Microbial recoveries from process water tests were not identified to species

Published 2026-11-13 · Inspection date 03/03/2025 · Active Pharmaceutical Ingredient Manufacturer · FEI 3008617115

1 observation
Findings
  1. 1Laboratory controls lack scientifically justified and appropriate specifications and test procedures necessary to ensure that components meet established standards for identity, quality, and purity.
Check points
  • Is there documented justification that the water sample volume tested gives statistically valid colony counts? (Observation 1)
  • Are microbial recoveries from process water routinely identified to maintain a house isolate list? (Observation 1)
  • Does validation of the water microbial test method include house isolates? (Observation 1)
Observation detail · 1 observation · From the source

Inspectors: Monica E. Murie · Victoria Spivak

Observation 1

Laboratory controls lack scientifically justified and appropriate specifications and test procedures necessary to ensure that components meet established standards for identity, quality, and purity.

Specifically. [redacted] water is utilized in the critical cleaning of equipment in classified rooms during the manufacturing processes ofyour drug substances. [redacted] water was also used as a component in the manufacturing of drug substances including, but not limited to. Batch co)) released and shipped to the US market. A. USP compendial methods recognize that scientific standards for culturing [redacted] water samples include sample sizes of up t [redacted] mL for [redacted] Your firm has not justified that the» [redacted] mL sample of &) (4) water currently tested for microbial monitoring o [redacted] sampling locations 1s anpropriate to derive staustically valid colony counts at your site. Additionally, your firm has not validated that [redacted] mL sample taken forme adequately captures all microbial colonies present in the large [redacted] mL sample collected at each [redacted] water [redacted] B. Your firm has failed to detect and enumerate microorganisms that have been released by potential biofilms within you [redacted] water system to evaluate the overall state of control of the [redacted] water system. Current method validation studies do not include additional organisms typically isolated from th [redacted] water system (house isolates) since your firm does not identify the normal microbiome. C. Your firm’s [redacted] water specification is not scientifically justified to exclude objectionable microorganisms from th [redacted] water samples cultured during the tests for Total Aerobic Microbial Count (TAMC)and ain Bacteria, Molds and Yeasts Count (TYMC). The microbial specifications forme water include "Total Viable Count [redacted]:fu/mL", "Total Aerobic Microbial Count [redacted] cfu/mL", “Total Bacteria, Molds and Yeasts Shaoxing, Zhejiang Province, 312300, P.R. China Active Pharmaceutical Ingredient Manufacturer Count [redacted] cfu/mL", and "Specified Microorganisms: Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus should be [redacted] per [redacted] mL of water sample". Your firm has failed to speciate recoveries found on TAMC and TYMC [redacted] to determine if the specified objectionable microorganisms or other pathogenic bacteria are present in your [redacted] water system below alert and action limits.

[FDA 483 observation · FDA]Cdymax (India) Pharma Private Limited — Microbial method suitability and isolate ID gaps
FDA483

Only 1 colony morphology record for 2024 production-area environmental monitoring

Published 2026-11-13 · Inspection date 02/28/2025 · Drug Manufacturer · FEI 3030133758

1 observation
Findings
  1. 1Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.
Check points
  • Does microbial enumeration method suitability include data starting from the lowest dilution? (Observation 1)
  • Is colony morphology and identification recorded for each environmental monitoring isolate? (Observation 1)
Observation detail · 1 observation · From the source

Inspectors: Eileen A. Liu

Observation 1

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

A. [redacted] Microbial Enumeration Test (a release test) method suitability did not include scientifically supported conclusion that the method is most suitable a [redacted] product dilution. Per pharmacopeia requirement, the lowest possible dilution factor of the drug product must be used. Your method suitability did not include sample preparation such as at [redacted] dilutions to justify the use of a higher dilution at [redacted] B. The we is a raw material used for the manufacturing of [redacted] Your firm’s [redacted] monitoring is deficient in that the isolate identification is not appropriately performed. SOP-MBGN-023-04 requires to record and compare representative isolate colony morphology to the in-house isolate library for further species identification. In 2024, a total of [redacted] samples were collected for monitoring. You have only 4 documented records that show isolate morphology observation were performed. You do not have records for the other [redacted] observations you supposedly performed. C. The viable environmental monitoring (EM) for your production area is deficient in that the EM isolate identification is not appropriately performed. Specifically, SOP-MBGN-023-04 requires to record and compare representative EM isolate colony morphology to the in-house isolate library for further species identification. In 2024, a total o [redacted] viable EM samples were collected from the production locatio [redacted] where [redacted] room are located. You have only 1 documented record to show that colony morphology observation was performed. You do not have records for the other [redacted] observations you supposedly performed.

[FDA 483 observation · FDA]Lyophilization Services of New England, Inc. — Inadequate sterile contamination controls
FDA483

Sporicidal disinfection was stopped without a risk assessment

Lyophilization Services of New England, Inc. dba PCI Pharma Services · Published 2026-11-13 · Inspection date 06/10/2026 · Manufacturer · FEI 3008546445

6 observations
Findings
  1. 1Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
  2. 2There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
  3. 3Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
  4. 4Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.
  5. 5Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
Show 1 more
  1. 6Buildings used in the manufacturing and processing of a drug product are not maintained in a good state of repair.
Check points
  • Are Grade A personnel monitoring action-level excursions investigated for aseptic gowning breaches as a root cause? (Observation 2)
  • Is a microbiological risk assessment done before changing disinfectants in aseptic areas? (Observation 1)
  • Do dynamic smoke studies demonstrate first air over open vials? (Observation 1)
Observation detail · 6 observations · From the source

Inspectors: Daniel L Zheng · Armen H Youssoufian · Ogechi C Nna · Talia A Faison · Wayne E Seifert

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, I. Your firm failed to enact adequate production process controls for manufacturing of commercial sterile drug product. For example: a. Your firm failed to provide documented evidence to demonstrate the use of [redacted] goggles in the Grade A and B cleanroom spaces and its potential impact in the environment from skin flora and subsequent microbial contamination risk to sterile drug products. On 06/02/2026 we observed multiple operators in room [redacted],) performing the setup for the for sterile drug product Lot # Goggles ID# 70071542560 which includes of the goggles. b. A change to stop applying a sporicidal as part of the disinfection regimen for [redacted] in the aseptic manufacturing area at the was implemented 2/5/25 without a risk assessment to evaluate the microbiological impact of the change. As part of CAPA-2024-1332, the firm stopped applying the sporicidal agent onto the [redacted] during installation and cleaning. The firm continues to use, anon-sporicidal agent, to sanitize the during these steps. However, the firm does not apply any sporicidal agent to the Since 2/5/25, approximately lots of th drug product have been manufactured on this [redacted] line, ofwhich approximately lots have been released. c. On June 02, 2026 at approximately 7:34AM, in room at the/ [redacted] an operator was observed leaning into the [redacted] during pre-production setup. During this intervention, the operator's gown made contact with interior surfaces of the [redacted] Although the operator performeda partial surface disinfection following the intervention, not all [redacted] interior surfaces contacted by the operator's gown were wiped down prior to the resumption of setup activities. d. During setup of the assembly for of sterile drug product [redacted] tot! [redacted] in iSO-5/6 Room [redacted] Building on 6/2/2026, operators were observed forming the aseptic connections between Assembly [redacted] and Assembly™as well as between Assembly™and the! [redacted] on the line of demarcation between ISO-5 and ISO-6. Your firm’s procedures require these connections to be made within unidirectional GradeA first air from HEPA units within the Grade A area, and your firm was unable to provide evidence that Grade A first air could be maintained on the line of demarcation. e. Your firm failed to perform environmental monitoring to evaluate the risk to ISO-5 environments during critical process interventions. Specifically, during filling of drug pr i 6) SNE NNN NNN HN our firm's process involves opening a [redacted] door in ISO-5/6 Room™™to load| [redacted] into the filling line hopper, exposing the Grade A [redacted] interior to the surrounding room. Your firm does not perform environmental monitoring in the vicinity of this intervention to evaluate potential exposure of [redacted] to contaminants and has provided no scientific justification for the absence of environmental monitoring at this location. f. Your firm failed to perform personnel monitoring in accordance with firm procedures and good manufacturing practices. For example, during setup activities for filling of sterile drug product lot [redacted] in ISO-5/6 Room 107, Building on 6/2/2026, production operators were observed rolling only half of each finger for. Your firm’s procedures for personnel monitoring, including SOP-07509 Environmental Monitoring of the 29H Aseptic Area During Processing, require operators to complete a— [redacted] for personnel monitoring. 6 026-2OC nrerobielesistiwas-_observed sanitizing thet swith: -and stewinstheasenttedry-beferetmmediate perfermines bop persctitiel g. Your firm’s dynamic airflow pattern analysis studies (smoke studies) conducted for the 25 Commerce Drive Facility conducted on 7 February 2025 (VAL-0025011) and 1 May 2025 (VAL-0026208) are inadequate. Your firm lacks smoke studies to demonstrate unidirectional first pass airflow over exposed vials during dynamic operating conditions for the sterile filling line. Il. Additionally, failure to adhere to or establish process controls, an equipment design that ensures the ( [redacted] drug product manufactured at/) 7) [redacted] 7) by(OA) fitt tine has the identity, strength, quality, and purity it purports or is represented to possess. Specifically: a. On27 May 2026, observed was the fill line unde decontamination, with — [redacted] extended into the by. At two locations, [redacted] from alternate sides of the [redacted] were in contact with each other, potentially inhibiting the [redacted] sanitization process. At another location, was touching the [redacted] side wall. According to SOP-07627, “Operation of the Fill Revision 7, Effective date 14 April 2026, Section 7.6.9 states to ensure the [redacted] surface is not in contact with any load item or component within the [redacted] You failed to follow the procedure. b. Observed during fill line(yA) decontamination were unwrapped sterile forceps in tool holders inside the Multiple forceps were positioned with tips in contact with the tool holder mounting bar which is nota sterile surface. SOP-07637, “Aseptic Technique for Filling [redacted] Revision 3, Effective date 14 June 2024, Section 7.4.12 states to position sterilized parts, such as forceps, to ensure maximum air flow and to ensure that first air is present. You failed to follow the procedure. c. On 28 May 2026, observed was the filling process for [redacted] drug product Batch — [redacted] — At the time of fill line stoppage, the %™) fill needles used in the filling process were observed with prominent drug product droplet formation at the fill needle tips, a sterility assurance concern. d. The fill needle holder and| [redacted] system transfer arm located directly above open and filled vials are sanitized surfaces, not sterile. e. The drug product fluid pathway located in Grade C space next to the fill line includes sterilizing,a drug product bag and drug product, with th assembly including many connections and clean connects. During the sterile process, there is no instruction for visual verification and documentation for absence of leaks. f. Observed during the drug product filling process for Batch| [redacted] multiple QC operators performed interventions at various— [redacted]. environmental monitoring settling plate exchange. Aseptic technique during interventions were inconsistent or absent per the following: i. No visual check of the external surfaces of— [redacted] at time of insertion. SOP-07637, Section 7.3.3 states to visually inspect the for installation and proper seating prior to use. Additionally, SOP-07642, “Fill-Line Set-up and Aseptic Interventions for— [redacted] Revision 4, Effective date 10 September 2025, Section 7.2.3 states to visually inspect the [redacted] used for holes or tears prior to use. You failed to follow the procedures. ii. No visual checks of the front and back surfaces of~ [redacted] for obvious defects upon entry. SOP-07637, Section 7.3.5 states to visually inspect the [redacted] for holes or tears prior to any manipulations within the [redacted] You failed to follow the procedure. ii. No visual checks of the front and back surfaces of— [redacted] after completing interventions. SOP-07637, Section 7.3.6 states to visually inspect the for holes or tears after any use that could have potentially damaged the You failed to follow the procedure. iv. Reaching straight into— [redacted] over critical surfaces and blocking first air when entering. SOP-07642, Section 7.2.2 states aseptic technique should be followed when using the(4) [redacted] minimizing the entry ofthe [redacted] into first air. You failed to follow the procedure. v. Rapidly entering and exiting— [redacted] to— [redacted] — when accessing items inside the during interventions. SOP-07637, Section 7.3.4 states to insert into the— [redacted] to reduce impact to the [redacted] internal pressure avoiding disturbance of first air. Additionally, SOP-07642, Section 7.2.5 states when - [redacted] operators [sic] movements should be to ensure that the [redacted] pressure is not disturbed. You failed to follow the procedures. g. Observed during the drug product environmental monitoring settling plate exchange for Batch a sterile forceps was used and returned to the tool holder with the tip facing down and the handle over the sterile tip blocking first air. SOP-07637, Section 7.4.12 states to position sterilized parts, such as forceps, to ensure maximum air flow and to ensure that first air is present. You failed to follow the procedure. h. On 1 June 2026, observed was the simulated fill line setup process for the [redacted] system that included mounting the [redacted] sterilized to the transfer arm by [redacted] open door intervention. Mounting included tightening the with a sanitized wrench, with the use of the sanitized wrench failing to maintain the quality of those surfaces intended to remain sterile. Furthermore, assembly ofthe- [redacted] system included the operator’s upper torso and head within the [redacted] with exposed face skin. Post — [redacted] system installation, you failed to sanitize the [redacted] doors prior to closure back into Grade A air supply from Grade C space. 1. The [redacted] fill line! [redacted] ” asset JO007 includes a fixed recipe for CIP, with the CIP process validated based on [redacted] TOC swab testing. Although the cleaning process is validated, the recipe does not control to a final rinse conductivity value that would provide a robust cleaning process to account for variability in the batch manufacturing process. j. According to Document: POL-05158,! [redacted] and [redacted] Rev 02, Effective date 14 November 2023, Section 7.1 General Requirements, Subsection 7.1.1 specifies| [redacted] 7 and/or [redacted] intervals is based on visual inspection ofeach system for discoloration during preventative maintenance activities as performed at a minimum every 4) years. You fail to follow the procedure with routine preventative maintenance failing to visually inspect stainless steel surfaces for absence of [redacted] k. On 28 May 2026, observed were- [redacted] sterilized rotary pumps assembled to the [redacted] fill line where blue surgical wrap was secured by to the drug product fluid pathway ports, with the application of at the critical pump interface ports potentially presenting a [redacted] penetration, sterilization challenge. 1. The smoke study for the [redacted] dispense process does not represent the manufacturing process procedurally for appropriate use of— [redacted] A hanging forceps obstructed the use of an and hanging packaged media plates were located above the [redacted] hopper. The hatch mechanism and [redacted] chute and hopper design fails to allow for the dispensing of [redacted] in a manner that maintains those surfaces and component intended to remain sterile, which includes first air broken by sanitized — [redacted] You fail to have a smoke study for the [redacted] open door! [redacted] system installation.

Observation 2

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, your firm’s investigations into personnel monitoring (PM) action level excursions at A ae to assess aseptic gowning practices such as the use of(ex4) goggles as a potential root cause. Data for the facility shows action level recoveries of skin flora at the chest and/or forehead of 1 CFU/mL or more in your Grade A cleanroom spaces for approximately 90 instances from December 2024 to March 2026. Despite these action level recoveries at the chest and/or forehead in your Grade A cleanroom space, your firm reported the root causes as inconclusive and isolated incidents with no investigation into the breach in aseptic gowning. CAPA-2025-0563 was initiated on 05/05/2025 to address the increased PM recoveries at the Bedford, NH facility, however, the CAPA remains open with no documented investigation into the probable aseptic breach in gowning, nor implementation of corrective actions to address the recoveries.

Observation 3

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, procedures in support of [redacted] drug product manufacture at (bY(4) are deficient or not available. For example: a. On 28 May 2026, observed during the [redacted] drug product Batch filling process was a forceps used to remove debris froma vial— [redacted] with an used in the process extending over open vials, breaking first air. SOP-07637, “Aseptic Procedurefor ‘ [redacted] Aseptic Techniquefor F:illing\ [redacted] v3.0, Effective date 14 June 2024, Section 7.4.7 indicates personnel should avoid reaching over any open or partially [redacted] vials during aseptic production operations as much as possible, to avoid interruption of first air. The procedure fails to restrict reaching over open or partially [redacted] vials by sanitized [redacted] b. You indicate that the fill line_ [redacted] system is [redacted] rinsed with(04) in preparation for sterilization. There is no procedure or training performed for the equipment rinse process. You further fail to have a procedure for the validated [redacted] rinse of the filling pumps nor is there visual confirmation and documentation that the pumps are clean. c. SOP-07617, “Routine Environmental Monitoring ofNon-Aseptic Area at! [redacted] y - Revision 2, Effective date 06 November 2024 specifies for Grade C space surrounding the [redacted] fill line (roomf [redacted] Section 7.2.3: Rooms associated with non-aseptic areas will be routinely monitored as found, Note: per SOP-07618. You fail to conduct environmental monitoring within Grade D and C space during manufacture, under dynamic conditions in assurance the manufacturing space is in a state of control. d. On27 May 2026, [redacted] personnel were gowning in Room 120-C. In a prior gowning [redacted] personnel were gowning as one individual was ungowning. PQ-J0001-001, Environmental Monitoring Performance Qualification (EMPQ) ofClean Rooms at the LSNE [redacted] ae. issue date 28 August 2023 identifies a limit ofm>ersonnel to be present in gowning)) 120-C at any given time. SOP 07593, “Gowning Procedure andPersonnel Flows”, Revision 6, Effective date 20 February 2026 fails to prevent the potential for contamination in personnel gowning [redacted] 120-C by not restricting access based on the EMPQ. You failed to implement procedural controls and area signage for established room maximum occupancy limits. You further failed to implement restrictions to prevent simultaneous gowning and degowning activities. e. SOP-07593, “Gowning Procedures and Personnel Flows”, Revision 6, Effective date 20 February 2026, Section 7.1.12.3 indicates to wash hands in provided sink and soap for a minimum of— [redacted] ensuring that all exposed skin on the hands is washed, followed by dry hands prior to entry into the cleanroom. The washing of hands for entry into GMP space is not conducted according to a specific process consistent with good industry practice nor is there an illustration of the hand washing process at the washing station.

Observation 4

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, utilities in support of [redacted] drug product are not monitored in assurance the qualified validated state is maintained. Equipment and facilities used in the manufacture of [redacted] drug product at (bY(4) are not adequately maintained. For example: a. The [redacted] water system used as(ox) water for the multiple effect still and clean [redacted] generator fails to have water environmental monitoring testing conducted at any frequency to a specification. b. The distribution system used in back fill of the— [redacted] and a point ofuse drop at the fill line fails to have environmental monitoring testing conducted at any frequency to a specification. c. Observed in Grade C space surrounding the [redacted] fill line were two wheeled carts, with the cart caster assemblies in a deteriorated state, rusty. Other carts in manufacturing space were observed with a similar attribute but to a lesser extent. d. Observed in personnel [redacted] 165-C was a [redacted] mounted to the wall in a deteriorated state, broken with cracks in multiple locations.

Observation 5

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Specifically, your firm is unable to use some (64) without breaking first air to open vials. For example,— [redacted] — on the— [redacted] which your firm uses for routine interventions during the filling process for sterile drug product a. cannot be introduced into the [redacted] environment without breaking first air to open vials, post-wash and [redacted] on the vial— [redacted] and vial [redacted] Your firm’s procedures for aseptic technique prohibit operators from breaking first air.

Observation 6

Buildings used in the manufacturing and processing of a drug product are not maintained in a good state of repair.

Specifically, on 6/1/2026, a divot approximately two to four inches long was observed approximately one foot off the ground on the comer of a wall pillar in ISO-5 Room 149A Sterile Staging, Building 25 Commerce, immediately next to the exit door of thebo) oven. Similarly, on 6/2/2026, a floor divot approximately one inch in diameter was observed in ISO-6 Room 108, Building! / [redacted] ". approximately five feet from the closed [redacted] exposing what appeared to be concrete subsurface under the cleanroom floor lining. 5/27/2026(Wed), 5/28/2026(Thu), 5/29/2026(Fri), 6/01/2026(Mon), 6/02/2026(Tue), 6/03/2026(Wed), 6/04/2026(Thu), 6/10/2026(Wed) Armen H Youssoufian Ogechi C Nna xX Seo SREY HLICUSEN s xX Boe Sigved 06102026 16:50:34

See all 5 findings in this document
[FDA 483 observation · FDA]Vetter Pharma-Fertigung GmbH & Co. KG — Aseptic contamination control and inspection gaps
FDA483

Operator touched a sterile product-contact gasket on the filling line with a glove

Published 2026-11-13 · Inspection date 04/24/2024 · Sterile Drug Manufacturer · FEI 3002808846

3 observations
Findings
  1. 1Procedures designed to prevent microbiological contamination of drug product (DP) purporting to be sterile are not established and followed.
  2. 2The visual inspection program forDp is deficient and was not able to remove defects, resulting in multiple 100% visual inspections failing the major defect acceptance criterion.
  3. 3Environmental monitoring of aseptic processing areas following critical GradeA filling operations is deficient.
Check points
  • Is there a procedure detailing each step where gloves contact product-contact parts during aseptic filling? (Observation 1)
  • When 100% visual inspection exceeds acceptance criteria, is the defect cause investigated before re-inspection? (Observation 2)
  • Do surface EM sites include cleanroom door handles touched by operators? (Observation 3)
Observation detail · 3 observations · From the source
Observation 1

Procedures designed to prevent microbiological contamination of drug product (DP) purporting to be sterile are not established and followed.

Specifically, A. There is no assurance that OI bp re maintained sterile after nd prior to aseptic filling. Specifically, th re temporarily stored ona non-sterilized rack in clean room™/ [redacted] Rags afte The rack is wiped w isinfectant after each batch and disinfected wit B. Multiple deviations have been initiated from December 2020 to 2024 due to not conforming the manufacturer specification(s) before recalibration. For example, for cleanroom Pe ecalibration results for i and 2024 respectively, did not conform to the specifications fo size calibration, or size resolution (deviations 757638, 828507, 905985, respectively). Among these [redacted] bserved during the 2022, 2023, and 2024 recalibrations, respectively, belong to cleanroom where DP is aseptically filled. In addition, there is no assurance that deviation 757638) and PO deviation 828507) have no product impact because the count rate efficiency at(yum could not be determined for both during recalibration. C. The dynamic smoke study videos (Documents “Room and process overview for flow visualization for Clean room) and Clean room or filling tine PO and)where) [redacted] pp is aseptically filled, showed that RABS reviously touching non-sterile surfaces of the filling line came in contact with direct and indirdct product-contact equipment. For example, 88085 Langenargen, Germany Sterile Drug Product Manufacturer 1. During the etween theMO and the [redacted] on the filling line using a n operator was observed touching the sterile-product contact gasket inside th ith a RAB There is no SOP describing details of this extensive aseptic manipulatio f th According to Vetter management, operators are allowed to touch the asket with RAB uring the MO assembly process. 2. An operator was observed stretching rab) and blocking Grade A laminar air over the on the filling line when putting on RABOar th 3. During replacement, the RAB 4 ouched the end of the that is used to connect th with theQAI on the filling line. 4. During eplacement, an operator was observed holding thpe near the with RABSO)(4) 5 D. During aseptic filling operations for Ove patch in filling room OnPpa PHA Rass previously touching non-sterile surfaces of the filling line was observed coming in ct with direct and indirect product-contact equipment: 1. During installation of the for th an operator was observed holding ene TT Inca th th the RABS 2. During environmental monitoring operations, an operator was observed stretching RaBs| over the ontaining steric Warts and blocking Grade A laminar air over the arts. E. TheVO er the requires extensive manipulation, and therefore is unsuitable for the aseptic filling operations of P manufacturing.

Observation 2

The visual inspection program forDp is deficient and was not able to remove defects, resulting in multiple 100% visual inspections failing the major defect acceptance criterion.

Specifically, linical batch!) ‘deviation PR 745461) failed 100% visual inspection and AQL due to the p irt/abrasion and foreign particle at The 100% visual inspection was repeated two additional times. The cumulative stopper defect rates for the 00% visual inspections were 88085 Langenargen, Germany Sterile Drug Product Manufacturer respectively, which exceeded the acceptance criterion for the major defects. A 100% visual inspection focusing onPi efects was subsequently conducted and resulted in ania) % defect rate, which is above the acceptance n of<9.

Observation 3

Environmental monitoring of aseptic processing areas following critical GradeA filling operations is deficient.

Specifically, A. [redacted] monitoring is deficient. For example, on April 16, 2024 and April 17, 2024, during filling line setup and filli ivities in clean roo RAB a wereol eethe same used with f the operators). During environmental monitoring ofthe~ the note that were used were not monitoredPS B. The environmental surface monitoring program does not include the door handles of DO pe] which are used by the operator to open and closethe)

[FDA 483 observation · FDA]BSP Pharmaceuticals S.p.A. — Weak computer system checks, no retraining
FDA483

No retraining after gowning failure was named the root cause

Published 2026-11-13 · Inspection date 12/16/2016 · Drug Manufacturer · FEI 3007255826

1 observation
Findings
  1. 4removedfollowing a discussion ofthe conditions surrounding the incident describes in the original FDA-483.
Check points
  • Does the master validation plan assign responsibility for validation done by outside firms? (Observation 1)
  • Are new LIMS functions tested and users trained before use? (Observation 2)
  • Do deviations attributed to human error lead to retraining or other preventive action? (Observation 5)
Observation detail · 1 observation · From the source
Observation 4

removedfollowing a discussion ofthe conditions surrounding the incident describes in the original FDA-483.

5. Employees engaged in the manufacture of a drug product lack the training required to perform their assigned functions. Specifically, on October 20, 2016, an environmental surface sample yielded\g) >fu/25 cm? in a Grade C area, which was out of the action limit of cfu/25 cm? for a Grade C area. After investigation, the root cause was determined as a human error, not properly following the gowning procedure. However, no re-training or any other actions were taken to prevent the reoccurrence of this kind of error.

[FDA 483 observation · FDA]BSP Pharmaceuticals S.p.A. — Filed information vs. contract site operations
FDA483

Procedure does not define disposition of a batch with a confirmed release failure

Published 2026-11-13 · Inspection date 09/21/2018 · Drug Substance Manufacturer · FEI 3007255826

3 observations
Findings
  1. 1There are discrepancies between the information included in the and the operations at the contract manufacturing facility.
  2. 2Pressure monitored during routine of the drug product is not representative of the pressure validated duringthe microbial retention studies.
  3. 3Procedure QC-001 for Management ofOut of Specification and Out-of-Alert limits is inadequate.
Check points
  • Are batch rejection criteria in filed documents reflected in site test and deviation procedures? (Observation 1)
  • Does routine pressure monitoring location represent microbial retention study conditions? (Observation 2)
  • Does the procedure define disposition of a batch with a confirmed release OOS? (Observation 3)
Observation detail · 3 observations · From the source
Observation 1

There are discrepancies between the information included in the and the operations at the contract manufacturing facility.

Specifically, —_ a. Section 3.2.P.3.3 of the states that in case of a post-use integrity failure of the the::, 4)»... batch will be rejected. However, neither the integrity test procedure OP-002, section 5.10 nor the deviation procedure DQA-013 indicates whether a confirmed failure ofthe ntegrity test will result in batch rejection. we) we b. Information provided in section 3.2.P.3.5 of the -o supportStopper ST3-032 corresponds to validation studies conducted to support ofseals for a different 4) product not related to pS:: + (oa) [redacted]:.

Observation 2

Pressure monitored during routine of the drug product is not representative of the pressure validated duringthe microbial retention studies.

Specifically, pressure is monitored in the holding tank of the but is not monitored immediately of the [redacted].: [redacted] and 1s not continuously monitored of the

Observation 3

Procedure QC-001 for Management ofOut of Specification and Out-of-Alert limits is inadequate.

Specifically, the procedure does not specify the disposition of a batch with a confirmed release out-of- specification, yp. \ \y “a

See all 3 findings in this document
[FDA 483 observation · FDA]BSP Pharmaceuticals S.p.A. — No yield criterion for media fills
FDA483

Rejected vials were left out of reconciliation as having a very low fill volume

Published 2026-11-13 · Inspection date 03/31/2022 · Drug Product Manufacturer · FEI 3007255826

4 observations
Findings
  1. 1Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
  2. 2Complaint handling procedures describing the handling of written and oral complaint related to drug products are deficient.
  3. 3Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
  4. 4Input to and output from the computer, related systems of formulas, and records or data are not checked for accuracy.
Check points
  • Are acceptance criteria set for media fill yield and the number of rejected vials? (Observation 1)
  • Are all rejected media fill vials included in batch record reconciliation regardless of reason? (Observation 1)
  • Are audit trails and electronic raw data of standalone lab instruments reviewed on the system? (Observation 4)
Observation detail · 4 observations · From the source

Inspectors: Yasamin Ameri

Observation 1

Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

Specifically, the media fill program is deficient in that: a) acceptance criterion for yield (total units incubated/total number of units filled) has not been established for media fills. For example, during the review ofmedia fills report for OM ejected vials were discarded out of a total of8) ited vials. Rejected vials were included in the report but no acceptance criterion was established for the number of rejected vials. b) media fill batch record) demonstrated that there were ™)vials rejected for out ofIPC weigh range on the batch report printout. You recorded onlyON out ofOY vials rejected on the batch record reconciliation form. You failed to include() rejected vials for low fill volume, and used "very low fill volume" as justification for excluding them from the reconciliation form.

Observation 2

Complaint handling procedures describing the handling of written and oral complaint related to drug products are deficient.

Specifically, complaint investigation process is deficient. For example, complaint No. M-RR-21-055 received from a customer on 04/09/2 ber 4, 2021) for observing foreign particles inOo vial of MO drug product lot # Your investigation report demonstrated that you repeated visual inspection on the retain samples ofthe ials but failed to14H the retain sample vials before visually inspect vials for foreign particles. Drug Product Manufacturer

Observation 3

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Specifically, qualification ofequipment used in production of Oydrug product are deficient in that you failed to properly qualify equipment for their intended use. for example: a) Qualification ofOM in in Sterile{{) and Sterilefajproduction area, failed to study the ability ofthe for remov. foreign particles that might be adh inside ofal b) Qualification of s) [redacted] integrity tester in Sterile(4y production area failed to validate equipment’s software program which operates the integrity tester unit in Sterilei)

Observation 4

Input to and output from the computer, related systems of formulas, and records or data are not checked for accuracy.

Specifically, control over electronic data generated from computerized systems in production and QC laboratory is deficient in that you failed to: a) implement control measures on all systems to prevent change in data/parameters or result of analysis in validate standalone systems, e.g. HPLC, UPLC, GC b) review electronic raw data generated by these systems on the system c) review audit trails for all systems.

See all 3 findings in this document
[FDA 483 observation · FDA]BSP Pharmaceuticals S.p.A. — Non-sterile indirect surfaces in aseptic filling
FDA483

Sterile stoppers loaded into sterile bags via a merely sanitized transfer chute

Published 2026-11-13 · Inspection date 02/29/2024 · Manufacturer · FEI 3007255826

1 observation
Findings
  1. 2Indirect product contact surfaces used in aseptic drug productdiljing operations are not always sterile.
Check points
  • Are operators monitored with finger dab plates right after Grade A critical setup operations? (Observation 1)
  • Are indirect contact surfaces such as transfer chutes for sterile components sterilized rather than sanitized? (Observation 2)
Observation detail · 1 observation · From the source
Observation 2

Indirect product contact surfaces used in aseptic drug productdiljing operations are not always sterile.

Specifically, the loading of sterile stoppers into sterile Bagsuses a sanitized transfer chute within the. [redacted],.: Grade A transfer [redacted] \ocated in Bldg [redacted] Sterile Suite Room

[FDA 483 observation · FDA]STAQ Pharma Inc — Leak above sterile rooms and aseptic practice gaps
FDA483

Standing water observed on the mezzanine floor directly above a sterile injectable room

Published 2026-11-13 · Inspection date 09/08/2026 · Producer of Sterile Drug Products · FEI 3015144909

3 observations
Findings
  1. 1Buildings used in the manufacturing, processing, packing and holding of a drug product are not maintained in a good state of repair.
  2. 2Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not.
  3. 3Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Check points
  • Is the space above cleanrooms routinely checked for leaks and standing water? (Observation 1)
  • Are EM plates placed so operators need not reach deep into the aseptic workstation to change them? (Observation 2)
  • Is there a procedure to assess environmental and product risk when discoloration is found on cleanroom equipment? (Observation 3)
Observation detail · 3 observations · From the source

Inspectors: John P Mistler

Observation 1

Buildings used in the manufacturing, processing, packing and holding of a drug product are not maintained in a good state of repair.

Specifically, your firm does not maintain your facility adequately to prevent water intrusion into the mezzanine space directly above ISO-7 spaces utilized to produce injectable drug products purported to be sterile. On August 27, 2026, I observed standing water on top of non ­impervious [redacted] flooring within the mezzanine immediately above ISO-7 Production Room [redacted], Room [redacted], which contains an ISO-5 [redacted] Laminar Airflow Workstation, [redacted] Series. Subsequent inspection revealed notable staining on the back side of five (5) cleanroom tiles. This condition was present during the production of Fentanyl Hydrochloride 160 mcg/ml 50 ml Syringes, Lot 26166677A.

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not.

Specifically, on September 1, 2026, Sterile Filling Technician [redacted] was observed in ISO-7 Production Room [redacted] (Room [redacted] producing Fentanyl 10 mcg ml 100ml IV Bags, Lot 26102671A, at an ISO-5 [redacted] Laminar Air Flow Workstation. While exchanging an environmental monitoring (Efv1} active air sample plate, [redacted] was observed extending her arms fully into the hood, up to her shoulders. The EM active air sample plate is positioned on a stand located above the [redacted] IV Bag Filling and Closing Machine, greater than 12 inches from the deck of the hood, posing a risk of microbiological contamination. Additionally, the firm's personnel monitoring program includes [redacted] sampling; however, at an action level of Colony Forming Units (CFUs), posing a nsk o environmental assurance and potentially missing sources of microbial contamination. EM PLOYEE(S) Produc er of Steri l e Drug Product s stand located above the (15 (21- IV Bag Filling and Closing Machine, greater than 12 inches from the deck of the hood, posing a risk of microbiological contamination. Additionally, the firm's personnel monitoring program includes (6) (~) sampling; however, at an action level of Colony Forming Units (CFUs), posing a nsk o environmental assurance and potentially missing sources of microbial contamination.

Observation 3

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, [redacted] located in IS0-7 Production Room (Room Production [redacted] exhibited visible discoloration, appearin browrns to blackish in color, on [redacted] in Room [redacted], [redacted] is utilized to hold a [redacted] bin for in-process product to be placed in prior to exiting the room. In Room [redacted] environmental monitoring equipment used duing the production of drug products is placed [redacted] of [redacted]. Cleaning of [redacted] of [redacted] occurs [redacted] however, your firm has not assessed the discolorations for potential risk to cleanroom environment and product.

[FDA 483 observation · FDA]JOINN Laboratories (Suzhou) Co. Ltd — Nonclinical specimen archiving and labeling errors
FDA483

Archive software listed 63 wet tissue bags but 62 were found on the shelves

Published 2026-11-12 · Inspection date 05/15/2026 · Nonclinical Laboratory · FEI 3012611386

2 observations
Findings
  1. 1Testing facility management failed to assure that all personnel clearly understood the functions they were to perform.
  2. 2The testing facility is not of suitable size and construction to facilitate the proper conduct of nonclinical laboratory studies.
Check points
  • Are system-recorded specimen quantities reconciled against physical archive counts? (Observation 1)
  • Are block codes verified and recorded against slide labels at microtomy? (Observation 1)
  • Are hygrometer corrected values applied to temperature and humidity records? (Observation 1)
Observation detail · 2 observations · From the source

Inspectors: Julian C. Hanson

Observation 1

Testing facility management failed to assure that all personnel clearly understood the functions they were to perform.

Specifically, a. Section 4.3.1 of SOP ADM-027 Version 16, “Archive Administration,” effective July 5, 2023, states, “The study number, archive date, specimen type, storage location, amount and other relevant information shall be documented in database (the Ziguang Archive management software).” For study (IBNA), the Ziguang archive management software entry listed 63 wet tissue bags on May 11, 2026; however, 62 wet tissue bags were physically verified as archived on shelves 52-1-7 and 51-3-7 in Building 8, room 8103. b. Section 4.3.1 (Specimen Storage) of SOP ADM-027 Version 23.0, “Archive Administration,” effective March 23, 2026, states, “When Document Management System (DMS) is adopted, the archive administrator shall enter the information such as the specific placement position and quantity of the samples.” Thirty-four trays of ((B)NAY blocks (e.g. IINBII4}) were temporarily stored in the Building 27 document archives (room 27104) due to space limitations in the Building 27 specimen archives (room 27102); however, DMS was not updated to reflect this temporary storage location when observed on May 11, 2026. — Section 4.2.5 of SOP PATH-020 Version 3, “Microtomy offf{6)M4) Sections,” effective February 2, 2023, states, “Verify the block code and record the block code on the glass slide (or verify the block code if the glass slide is printed with a block code).” For study (0K5)%4), upon comparing the (§M5)M4) blocks to the corresponding slides, the slide generated from NBA) block IHNEN) code 3 (brain section 3, dorsal) was erroneously labeled as (MB)I4) code 38 (brain section 3, ventral), and the slide generated from [IMB)(4) blocKNB) code 3B (brain section 3, ventral) was erroneously labeled as (§MB)N4) code 3 (brain section 3, dorsal). d. 21 CFR 58.83 states, “All reagents and solutions in the laboratory areas shall be labeled to indicate identity, titer or concentration, stora iration date.” Mobile phase for GLP study und in room 8232 was not labeled with an expiration date or e. Section 4.5.1.2 of SOP ADM-029 Version 15.0, “Use and Management of Equipment,” effective April 2, 2026, states, “When using the following externally calibrated/verified equipment, their corrected values or error values should be introduced ***. Hygrometers used for monitoring environmental temperature and humidity (excluding EB! system monitoring probes).” The Room Temperature and Humidity Record (Form BA-041-F03) for Room 8237 recorded temperature and humidity readings twice daily without applying the corrected values from April 2, 2026, through May 12, 2026.

Observation 2

The testing facility is not of suitable size and construction to facilitate the proper conduct of nonclinical laboratory studies.

Specifically —— <i ——=Z2 In Building 7, where reserve animals were being held, the floor in one area of animal room 7176 did not slope toward the drain. We observed discoloration and pooling liquid in one part of this area. b. In Building 7, in the corridor near room 7178, we observed bubbling and cracking in the surface of the PVC floor. c. In Building 5, near animal room 5264, the vertical locking mechanism for the door separating the silent area corridor would not stay in place. We observed non-human primates pushing this door open while undergoing observations. az _—

[FDA 483 observation · FDA]Raptim Research Private Limited — Biosample control and record discrepancies
FDA483

Samples were reanalyzed before the quality assurance unit finalized the run

Published 2026-11-12 · Inspection date 07/25/2025 · Contract Drug Manufacturer · FEI 3007267856

6 observations
Findings
  1. 1The firm did not follow practices and procedures established in standard operating procedures (SOPs) or standard test procedures (STPs).
  2. 2The firm did not have adequate information in their source documents for complete reconstruction of study activities.
  3. 11The in vitro sample disposal record dated 14/May/2025 documents that the samples were retrieved for disposal from freezer number INS/ANA/269.
  4. 3The firm did not demonstrate consistent practices and procedures.
  5. 4The firm did not consistently follow good documentation practices in their raw data management during conduct ofmethod validation ofes(RRL-ANA-MVR1409).
Show 1 more
  1. 5The firm did not consistently follow the standard operating procedure eSOP/IT/006 v 01 for back up for computer system.
Check points
  • Is reanalysis blocked until the quality assurance unit approves the analytical run? (Observation 1)
  • Do storage locations and disposal counts of biosamples match between the sample system and freezer logbooks? (Observation 2)
  • Were any backup verifications signed on dates when the backup failed? (Observation 5)
Observation detail · 6 observations · From the source

Inspectors: Courtney N. Long

Observation 1

The firm did not follow practices and procedures established in standard operating procedures (SOPs) or standard test procedures (STPs).

Specifically: a. eSOP/ANA/006 (version 05, Amendment 01) states that analytical runs should not be considered final until QA has reviewed and approved the status of the run. In study, Tun 251024) was finalized as rejected by QA on 29/Oct/2024. However, samples from subject ere reanalyzed on 28/Oct/2024 (run 281024REPO01[), which was prior to final QA approval ofrun 251024 0 b. eSOP/ANA/001 states that biological sample disposal details should be recorded on the biological sample disposal record form, ANA-eFM-179. However, for multiple studies including 7),Oe, oS complete disposal details. c. The STP/ANA/946 for quantitation ofWM [redacted] and requires that samples should be discarded after completion of an analytical batch. However, in project, samples from a repeat run completed on 03/Jul/2025, were retained in the autosampler until at least 14/Tul/2025, despite batch processing records indicating sample disposal on 04/Tuly/2025. d. eSOP/ANA/021 states that QC audit findings reported in the QC report will be reviewed and addressed by the respective departments, including any corrections as needed. The corrections will be subsequently verified by QC. However, QC review reports found in a binder labeled “Miscellaneous data” in instrument room 02 were incomplete because they did not contain departmental responses, required corrective actions and subsequent QC verification. Impacted projects includePn and RRL-ANA-MV-896. e. eSOP/ANA/001 states that biological matrix (e.g., plasma) should be used within one year after collection. The firm had multiple lots ofpooled plasma samples exceeding the one-year expiration date that were not discarded. Examples include plasma lots: 1. 210324 stored on 21/Mar/2024: 46 mL not discarded u1. 210324 stored on 21/Mar/2024: 135 mL not discarded ii. 180324 stored on 18/Mar/2024: 144 mL not discarded iv. 080523 stored on 05/Aug/2023; 169 mL not discarded

Observation 2

The firm did not have adequate information in their source documents for complete reconstruction of study activities.

a. Analytical staff could not locate the current storage location of lot 012024004103 ofplasma. The plasma was transferred from the clinical department to the analytical department on 8/Nov/2024 for use as blank biological matrix for method development/validation. The Biological Matrix Consumption Record documented that the plasma was stored in Freezer INS/ANA/505 on 8/Nov/2024. Freezer INS/ANA/S05 is no longer present at the facility. b. Disposal of samples from study (Analytical aliquot) was documented on 07/Aug/2023 in the sample disposal record. However, the samples were documented as disposed on 17/Oct/2024 in CREDBio. c. The unique identifier of a lot of whole blood used as blank biological matrix for method development RRL- ANA-MD-1336 was documented incorrectly. Lot No. 012025000575 of whole blood (300 ml) was transferred from the clinical department to the analytical department on 2/Mar/2025. The volunteer consent form for blank biological matrix donation lists the unique identifier as 012025000575. However, the Biological Matrix Consumption Record and the documentation for RRL-ANA-MD-1336 document the lot No. as 012025000515. d. CredBio and the logbook for freezer INS/ANA/507 documented that period 1, period 2, and period 3 samples from study JO were stored on shelfA4 of the freezer. However, when sample custodians attempted to retrieve the samples, period 2 samples were not located on shelf A4, but were instead on shelf AS. e. The Sample Disposal Records from in vitro study ee contained multiple discrepancies. i. Samples from Donor [ [redacted] } cell 10, aliquot 1 were documented as disposed of on a Biological Sample Disposal Record dated 14/May/2025. However, an additional form for in vitro sample disposal dated 18/Jun/2025 documents the disposal of samples from Donors), aliquot 1, including Donor [redacted] cell 10, aliquot 1. The freezer logbook for INS/ANA/259 also documented disposal of samples from Donor |} cells 1-22, aliquot 1 on 18/Jun/2025.

Observation 11

The in vitro sample disposal record dated 14/May/2025 documents that the samples were retrieved for disposal from freezer number INS/ANA/269.

The samples are also documented as being retrieved and discarded of from freezer INS/ANA/259 on 14/May/2025. INS/ANA/269 is not a valid Raptim Research freezer identification number. ili. There were 308 samples collected per donor (14 samples per cell, 22 cells) in study Te. The Biological Sample Disposal Record dated 14/May/2025 documents that 14 samples were discarded for Donor 3} cell 10, aliquot 1. The INS/ANA/259 freezer log documents that the total number of samples discarded for Donor [redacted] } is 292 which indicates that 16 samples were previously discarded instead of 14 samples. Contract Research Organization iv. The In vitro Sample Disposal Record dated 17/Jun/2025 documents that 2380 samples were discarded for Donors0). aliquot 1. The logbook for freezer INS/ANA/259 documents that 2378 samples were discarded for Donors— [redacted], aliquot 1. f. There was a discrepancy in the biological matrix consumption record for the pooled plasma from study Oe (lot 120324, [redacted]. Pooled plasma was prepared on 12/Mar/2024, but the lot ID, matrix type, anticoagulant, number of containers, and freezer ID for that lot were documented on 12/Mar/2023. g. The biological matrix consumption record and CREDBio entry for pooled plasma lot 120324 from studyDyes documented the presence of 3 vials (vial 01 containing 100 mL; vial 02, containing 35 mL; and vial 03 containing 35 mL) in freezer INS/ANA/835 on shelf A3. However, vial 01 could not be located in the freezer. h. There was a discrepancy in the pooled plasma lot 100124 4 retrieval information between the biological matrix consumption record and CREDBio. Consumption records document storage of 6 pooled plasma containers in freezer ANA/INS/506, and retrieval of 3 containers on 22/Jan/2024. However, CREDBio documents transfer of the containers to freezer ANA/INS/512 on 20/Jan/2024. This information was never updated in the biological matrix consumption record. i. Sample discard records were not stored or archived adequately. For example, for multiple studies conducted in 2022, 2023 and 2024, sample discard records were not archived in the respective archive binder for that year. Instead, they were found in a binder with records for 2025.

Observation 3

The firm did not demonstrate consistent practices and procedures.

Specifically: a. In studyDyess segregation activity for ISR experiment 02 (samples from subjectsPes andeS) was documented in CREDBio. However, this was not done for ISR experiment 01 (samples from subjects a). Contract Research Organization b. Replicate aliquot samples were not consistently documented in CREDBio for all studies. For example, in study [redacted] information from replicate aliquot samples was entered in CREDBio on the date the samples were received (24/Feb/2024). However, in study), samples were received on 27/Sep/2024, but sample information was not entered in CREDBio until 13/Apr/2025. Similarly, in study yes samples were received on 03/Apr/2024, but sample information was not entered in CREDBio until 26/Feb/20235. c. Sample transfer records were not consistently uploaded into CREDBio. For example, for studiesOe and ye. sample transfer records for both analytical and replicate aliquots were uploaded into CREDBio. However, for studiesyyy and [redacted]. only the analytical sample transfer records were uploaded to CREDBio.

Observation 4

The firm did not consistently follow good documentation practices in their raw data management during conduct ofmethod validation ofes(RRL-ANA-MVR1409).

For example, in raw data forms (17242, 7215, 0597) several corrections were made to address QC findings. However, the changes were made without documenting when the change was made and who made the change.

Observation 5

The firm did not consistently follow the standard operating procedure eSOP/IT/006 v 01 for back up for computer system.

For example, for a 90-day period (22/April-20/July/2025) that was reviewed for instrument ID API2000-01, the backup plan failed on July 14, June 27, June 26, June 16, June 03, June 1, May 1, and April 30, 2025. The eSOP/IT/006 v 01 required a full and incremental back up of the computer systems. Although the backup activity failed, backup activity was indicated to have been verified by the IT administrator and QA in verification of backup logbook (RRL-IT-LG-007-001/25).

See all 6 findings in this document
[FDA 483 observation · FDA]KDC/ONE Socal Laboratories, LLC — Per-drum testing and cleaning gaps
FDA483

Mixing tanks labeled as cleaned held white powder and pinkish residue clumps

Published 2026-11-12 · Inspection date 04/14/2026 · Contract Manufacturer · FEI 3021082665

5 observations
Findings
  1. 1Each lot of components, drug product containers and closures is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.
  2. 2The written stability program for drug products does not include test intervals based on statistical criteria for each attribute examined to assure valid estimates of stability.
  3. 3Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least (b)(4) for evidence of deterioration.
  4. 4Records are not kept for the cleaning and sanitizing of equipment.
  5. 5Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Check points
  • Is every container of a multi-drum component lot identity-tested? (Observation 1)
  • Are post-validation production batches placed on ongoing stability each year? (Observation 2)
  • Do cleaning records for shared equipment state the method used each time? (Observation 4)
Observation detail · 5 observations · From the source

Inspectors: Thuy Tram L Nguyen · Navneet Kaur

Observation 1

Each lot of components, drug product containers and closures is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.

Specifically, A. Your firm received multiple drums of — [redacted] but conducted identity and [redacted] testing on only [redacted] instead of testing each drum individually. The following [redacted] lots were used in OTC drug manufacturing: 1) Approximately lots of OTC drug products manufactured using untested from Lot. 2) Firm has used_ batch of OTC drug products manufacturing by using untested from Lot [redacted]. 3) Firm has used of OTC drug products manufacturing by using untested from Lot [redacted] B. Your firm received) drums of (Item #19539, Control #25- 1230-1, Lot) but only conducted identity and testing on| [redacted] rather than testing each drum. This [redacted] was used in approximatelyOM lots ofOTC In addition, your firm has no written procedure that describes the sampling requirements for high-risk components for identity testing and testing for impurities in each container you have received. QUALITY SYSTEM

Observation 2

The written stability program for drug products does not include test intervals based on statistical criteria for each attribute examined to assure valid estimates of stability.

Specifically, Your firm failed to conduct ongoing stability studies for OTC drug products beyond the initial studies performed during process validation. Examples include: [redacted] (4)_ First manufactured in 2016. All4 process validation batches were placed on [redacted] and real-time stability studies, with no subsequent batches tested. [redacted] - First manufactured in 2016. During process validation, al [redacted] ™batches underwent! [redacted] stability testing and [redacted] batches underwent real-time studies, with no subsequent batches tested.

Observation 3

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least (b)(4) for evidence of deterioration.

Specifically, Although your firm maintains reserve samples for a period ofup toes years, the annual product review process includes visual examination of only lots ofreserve samples during thexe year. Your firm has not conducted the required annual visual examinations of reserve samples in subsequent years to assess for signs of deterioration. For example, in OTC batches were manufactured and their retain samples were examined 1 but not in or in [redacted] 4)_ while the products are still within expiry date. Similarly, OTC batches manufactured in (4) had retain samples examined in()(4) but not in FACILITIES AND EQUIPMENT

Observation 4

Records are not kept for the cleaning and sanitizing of equipment.

Specifically, Your firm failed to document and maintain cleaning records for non-dedicated equipment used in Over- the-Counter drug product manufacturing, includinga mixing tanks,(oa) fillers homogenizers, anc [redacted] pumps. Specifically, records did not identify which cleaning method ( or) was employed during each cleaning process. [This is a repeat observation]

Observation 5

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, During the walk-through on 4/8/26, we observed mixing tanks (Equipment ID aa) in the compounding room displayed a sign indicating the equipment was in a cleaned status, waiting for sanitization. However, upon visual inspection of the equipment interior, unidentified white powder on the side and large pinkish clumps of residue were observed near the rim of the equipment.

See all 5 findings in this document
[FDA 483 observation · FDA]Similasan AG — Untested components and PV batch size gaps
FDA483

Operators can change the filling speed but the actual speed is not recorded

Published 2026-11-12 · Inspection date 04/27/2026 · Homeopathic Drug Manufacturer · FEI 1000110034

3 observations
Findings
  1. 1Determinations of conformance to appropriate written specifications for acceptance are deficient in that they are not made for each lot within each shipment of components used in the manufacture, processing, packing or holding of drug products.
  2. 2Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
  3. 3Routine checking of mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.
Check points
  • Is every incoming component lot tested for suitability for intended use? (Observation 1)
  • Do process validation batch sizes cover the upper commercial batch size allowed in master batch records? (Observation 2)
  • If a filling machine's speed is changed, is the value recorded in the batch record? (Observation 3)
Observation detail · 3 observations · From the source

Inspectors: Matthew B Casale · Saleem A Akhtar

Observation 1

Determinations of conformance to appropriate written specifications for acceptance are deficient in that they are not made for each lot within each shipment of components used in the manufacture, processing, packing or holding of drug products.

Specifically, [redacted] used in homeopathic formulations are not tested at raw material stage and/or at finished product stage for [redacted] test to demonstrate their suitability for intended use. The site manufactures numerous homeopathic formulations (including but not limited to [redacted] (XC) using oe On 4/23/2026, the QA Manager stated these mw are not tested for mw test when received at the site. The QA Manager confirmed the firm does not test [redacted] (Finished Products) fo [redacted] test as well.

Observation 2

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, process validation performed as per Validation Report QUAL VAL 124124 (effective date Homeopathic Pharmaceutical Manufacturer;;) (4) 6/27/2023) for w [redacted] products including [redacted] is deficient as the batch size of the validation batches is not representative of the commercial batch size. For example: The process validation was performed by manufacturing [redacted] batches using [redacted] material code [redacted] 4):;. and by manufacturing [redacted] other batches using [redacted] material code [redacted] The batch size of all [redacted] validation batches was w [redacted] each. However, the review of the Master Batch Records of [redacted] products indicated the commercial batch size ranges from [redacted] to [redacted]. For example, in June 2025, the firm manufactured [redacted] batch [redacted] batch size [redacted]. The firm’s Master Batch records allow the commercial batch size up to [redacted]. The firm failed to perform process validation studies covering the upper batch size Tange 1.€., [redacted] to demonstrate process robustness. Additionally, following deficiencies were observed in Room [redacted] that was being used for [redacted] we for oe batch [redacted] A. Some of the [redacted] were not [redacted] step that is performed in the oe were observed (indicating [redacted] material inside) at the [redacted] step. B. After [redacted], the [redacted] are transferred into the [redacted] bags for [redacted]. (4) (approximately for [redacted] It was observed the 4) were not [redacted] After [redacted], theme are filled and packed for commercial distribution.

Observation 3

Routine checking of mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically, adequate controls are not exercised over filling machine (equipment ID: [redacted] that is used to fill numerous homeopathic formulated drugs including but not limited to [redacted] XC) oe for the US market. The filling machine [redacted] was qualified at the filling speed of [redacted] units me The filling speed can be modified by the manufacturing personnel. The machine does not retain any batch data, and the actual filling speed is not documented on the batch records. Under these circumstances, if the filling speed is modified, it can go undetected. Similar deficiencies were also observed in Filling Machine (equipment ID: me used to fill homeopathic [redacted] Additionally, in-process fill weight checks for filling line [redacted] are deficient as it does not include statistically sound sampling plans. For example, weight verification is performed for [redacted] OC). [redacted] samples sample is checked for fill weight [redacted] units filled oe Homeopathic Pharmaceutical Manufacturer SaleemA Akhtar xX Bae Sitea: 04-27-2026 10:41:22

See all 3 findings in this document
[FDA 483 observation · FDA]Swati Spentose Private Limited — Untrained data reviewers, recurring human error
FDA483

Over one hundred out-of-specification and incident probes closed as human error since 2021

Published 2026-11-12 · Inspection date 05/31/2024 · API Non-Sterile Drug Substance Manufacturer · FEI 3009765202

2 observations
Findings
  1. 1Employees are not given role specific training to perform their function.
  2. 2The responsibilities and procedures applicable to the quality control unit are not fully followed.
Check points
  • Are data reviewers trained and qualified for each test they review? (Observation 1)
  • How many OOS investigations per year are closed as human error? (Observation 2)
  • When the same analyst repeats the same error, are actions beyond retraining considered? (Observation 2)
Observation detail · 2 observations · From the source

Inspectors: Ankur Patel

Observation 1

Employees are not given role specific training to perform their function.

Specifically, As per SOP # QCD/0117/000, “Procedure for Review ofAnalytical Documents and Reviewer Qualification”, the QC laboratory reviewer who reviewed the testing data needs to be trained and qualified to perform the review of the analyzed test however your firm failed to ensure that all Quality Control (QC) laboratory reviewers are adequately trained to review laboratory data for product release. For example, A) Residual Solvents test by Gas Chromatography (GC) was performed on 02/14/2024 for [redacted] 0) USP, batch # [redacted] The QC laboratory reviewer who reviewed the testing data was not properly trained and qualified to perform the review of the analyzed test. B) Residual Solvents test by Gas Chromatography (GC) was performed on 09/26/2023 for [redacted] USP, bate #w [redacted]. The QC laboratory reviewer who reviewed the testing data was not properly tramed and qualified to perform the review of the analyzed test.

Observation 2

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, API Non-Sterile Drug Substance Manufacturer Your firm failed to ensure that all Quality Control (QC) laboratory personnel perform product testing according to approved testing procedures. Over one hundred OOS/Incidents investigations have been concluded as human errors since Jan 2021 despite ongoing retraiming and requalification of analysts. Human errors in the QC lab such as incorrect entry of the sample details into LIMS system, dilution error, preparation error, wrong weight error, weight transfer error etc. have occurred repeatedly since January 2021 (as shown in the table below) despite of corrective actions including awareness training, retraiming and requalification of analysts. Year Of. Number of Human errors Total evaluation 2021 Incorrect entry Ps Preparation error/Dilution error Error due to overlook BP Weighing error/weight transfer error Incorrect data path 2022 Error due to overlook Preparationerror Incorreet entry thereon 2023 Error due to overlook Preparationerror oT Transeriptioneor Po theremor API Non-Sterile Drug Substance Manufacturer 1. INC-01-23-0342was opened on 09/15/2023 to investigate OOS results for Water Content by KF for [redacted]. Lot #aw. It was determined that the transfer ofg) [redacted] -—SWeight (a human error) was not properly performed by the QC Analyst. A similar incident was opened about 6 months ago on 03/30/2023 under INC-01-23-0145 to investigate OOS results for Water Content by KF for [redacted]. Lot # [redacted] 4) performed by the same QC Analyst. The corrective actions, including awareness training, implemented had proven to be ineffective.

[FDA 483 observation · FDA]Bora Pharmaceutical Laboratories Inc Zhongli Plant — Cleaning validation and repeat dissolution OOS
FDA483

APIs from prior products found in ducts of equipment recorded as cleaned

Published 2026-11-12 · Inspection date 03/27/2026 · Drug Manufacturer · FEI 3005674517

1 observation
Findings
  1. 4e responsibilities and procedures applicable to the quality control unit are not fully followed.
Check points
  • Do cleaning validation and procedures for non-dedicated equipment cover ducts and hard-to-reach areas? (Observation 1)
  • Is prior CAPA effectiveness evaluated when OOS results recur at the same test and time point? (Observation 2)
  • Are recipe edit and delete rights on inspection equipment restricted, with per-batch audit trail review? (Observation 3)
Observation detail · 1 observation · From the source

Inspectors: Khoa Nathan V. Tran · Anney Lin

Observation 4

e responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, your firm’s management ofmanufacturing materials is inadequate. On March 17, 2026, in the Manufacturing Department Holding Area for Disposal, an unlabeled bag containing approximately [redacted] of tablets was observed. There was no information to identify the product, associated batch number, or reason for disposal. Additionally, a separate bag containing tablets was observed with a partially completed label; however, the label did not identify the individual who disposed of the material or the individual who approved the disposal. Both bags were staged for disposal in a drum; however, the associated rejection record for the drum did not include any documentation accounting for these materials. “our procedure governing disposal of manufacturing materials (1SOP-0301) requires that rejected materials be appropriately labeled with the item name, batch number, process step, weight, disposing personnel, and verifying personnel. The procedure further requires that materials designated for destruction be labeled and documented on he rejection record.

[FDA 483 observation · FDA]Genzyme Ireland Limited — Sterility not maintained in aseptic setup
FDA483

An operator assembled sterilized parts using a glove that was only sanitized

Published 2026-11-12 · Inspection date 01/17/2025 · Drug Product Manufacturer · FEI 3003809840

4 observations
Findings
  1. 1Procedures, process and testing designed to prevent microbial contamination of the drug product purporting to be sterile are not established.
  2. 2The “systems in support of ®®drug product manufacture are not adequately maintained.
  3. 3A standard operating procedure was not followed.
  4. 4Equipment used in the QC Microbiological Lab is not adequately maintained.
Check points
  • Have smoke studies been performed for assembly interventions on product-contact parts such as the stoppering system? (Observation 1)
  • Do procedures require sanitizing sterile parts each time they move from Grade C into Grade A? (Observation 1)
  • Are HEPA filter screens on laminar flow hoods routinely inspected and recorded? (Observation 4)
Observation detail · 4 observations · From the source
Observation 1

Procedures, process and testing designed to prevent microbial contamination of the drug product purporting to be sterile are not established.

Specifically,: (OC a. a. As observed on 16 January 2025 for assembly of the stoppering system to the Fill Line [redacted] 6) [redacted]. [redacted] for drug product manufacture Batch you did not perform the setup of the [redacted] nan aseptic manner. Specifically, you did not maintain sterility of the stoppering equipment a [redacted]. [redacted]. ee. [redacted] |sterilized by during and instead you rely on sanitization of the [redacted]: [redacted] component contact equipment (e.g., stopper bowl and with b) (4... [redacted] to render it ready for aseptic fill-finish. c [redacted] - [redacted] You further failed to sanitize the upon into Grade A space from Grade C space for each [redacted] “a:::: ‘ ‘ b)(4) J event. Additionally. you failed to conduct smoke studies for the stoppering system installation “ interventions. a - [redacted] b. As observed on 13 January 2025 for the setup of the for drug product [redacted] i... batch the following deficiencies were noted:; 1.) 4). [redacted] oar [redacted] An operator was observed using a sanitized glove during assembly of the sterilized me [redacted] to the sanitized.: [redacted] ¢ During assembly of each of the sterile to the drug product [redacted] an operator was observed touching the connection interface, blocking first air (unidirectional laminar air ma. ole [redacted]: [redacted] (b): [redacted] flow) over the with the sanitized glove, with and [redacted] touching the glove. (b) 4): [redacted]: ‘ The located directly over the oper during manufacture is a sanitized surface, not sterile. Waterford, [reland X91 TP27 Drug Product Manufacturer You failed to maintain or provide manufacturing surfaces intended to be sterile in assurance ofproduct sterility.

Observation 2

The “systems in support of ®®drug product manufacture are not adequately maintained.

Specifically, On 09 January 2025, the following was observed: a. aot the floor at the [redacted] skid, below the OOsystem. ba. leak at the [redacted] supply to the “ analyzer. od,. ‘. [redacted],..: (b) C. dripping from the multiple distribution tank (Tank [redacted] from the manway. b) (4 d.. on the floor below the 0 [redacted] below “

Observation 3

A standard operating procedure was not followed.

Specifically, a. According to QU-SOP-0056623, “Monitoring of [redacted] in the Facilities and the Aseptic Processing Workshop”, v4.0, Section 5.6, Tracking Out of Trends (OOT) for the instruction is to record the OOT details in logbook 000426. There wasno logbook available for documenting the OOTs and for trending. b. According to QU-WIN-0034155, “Data Integrity”, v13.0. Section 5.4, Logbook Reviews, upon completion of the final activity on the page, the page review must be conducted by an independent person. You failed to complete the page review for the following logbooks: + Internal Sample Request Logbook ENV24000691 + Inspection Hood Measurement Logbook ENV240000545 Cold Room Entry/Exit Logbook ENV240000825

Observation 4

Equipment used in the QC Microbiological Lab is not adequately maintained.

Specifically, EMPEOMEE(S) Waterford, Ireland X91 TP27 Drug Product Manufacturer: [redacted] a.. On 15 January 2025, Laminar Flow Hood LAF used in in-process control bioburden testing was observed with the!) “HEPA filter screen discolored, with the same observed for many other LAF units. You indicated the discoloration was rust. You failed to maintain the qualified state. \ \ q\:\ \, \, 7 14° pepe ‘ / cies

See all 4 findings in this document
[FDA 483 observation · FDA]Huons Co., Ltd — Falsified micro data and aseptic process gaps
FDA483

Micro lab lead changed photo dates of plates and had worksheets backdated

Published 2026-11-12 · Inspection date 11/21/2025 · Sterile Drug Manufacturer · FEI 3007163376

6 observations
Findings
  1. 1Laboratory records do not include complete data derived from all tests, examinations, and assay necessary to assure compliance with established specifications and standards.
  2. 2Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
  3. 3There is a failure to thoroughly review any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
  4. 4Jecheon, Chungcheonbuk, 27159, Korea (The Republic of) | Sterile Drug Manufacturer Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
  5. 5Batch production and control records do not include complete information relating to the production and control of each batch.
Show 1 more
  1. 6Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Check points
  • Are raw microbiology data (plate reads, photos, worksheets) recorded at the time of testing with a trail of later changes? (Observation 1)
  • When ineffectiveness complaints recur across batches of one product, is a cross-batch trend analysis used to find the root cause? (Observation 2)
  • When a Phase I OOS investigation blames lab causes like dirty glassware, is test evidence kept that proves that cause? (Observation 3)
Observation detail · 6 observations · From the source

Inspectors: Eileen A. Liu · Steven A. Brettler

Observation 1

Laboratory records do not include complete data derived from all tests, examinations, and assay necessary to assure compliance with established specifications and standards.

Specifically, A. During review ofthe bioburden and endotoxin tests performed on 1/03/2025 for theMMOMBL ings media FLLOy samples, we found the following. a) BE scone ob ank” and (OM Wy Tank Transfer Line” samples endotoxin out of speciticatio results obtained on 11/03/2025 were not recorded and reported. They were later replaced with the within acceptance results from different samples by QC Microbiology Team Lead. The passing results were reported in the final certificate of analysis (COA). b) as:lt at Transferoer bioburden test results obtained on /2025 were not recorded and reported. Specifically,na media plates that showed alert level colony forming units (CFU) at the completion of incubati 11/10/2025 were discarded. No worksheet was generated to document the positive bioburden data. On 11/12/2025 when inquired by the FDA investigator, the QC Microbiology Team Lead changed camera time and date to take photos of the plates with microbial growth. She also instructed a team member to create worksheets by backdating test information. B. The Incubator Usage Record logbook (INC-3 127) was manipulated to remove two entries of bioburden samples collected for deviation investigation regarding FI yyO OMWy during the vial sterilization in the Vial Line. The samples of concern were for Huons III OS Wy Injection SNP Batch POMP domestic market). Specifically, on 10/31/2025 pages 60 to 62 of the logbook containing information ofthe deviation samples were removed by the QC Microbiology Team Lead. She replaced the torn out pages with blank forms and instructed a team member to backfill log information, excluding information for the deviation samples. C. During the microbiology laboratory walkthrough on 11/12/2025, over thirty (30) different uncontrolled current good manufacturing practice (CGMP) blank document form types were identified as well as forms filled with original, raw data, Each blank form could be assessable to any personnel who had access to the microbiology laboratory without any additional controls and traceability. For example, one of the documents identified was a completed endotoxin gel clot test form (Analysis No. R251020004) for the following active pharmaceutical ingredient (API), OS W PPG BatchP [redacted] WH According to the laboratory personnel, the person identified an issue with the weight collected for the gel clot (power of 10), and the test was redone with a new, blank form two (2) days later. The original test form was not included with the test package for the raw material, there was no deviation or quality event initiated for the event, and no one reviewed the original form (no review signature). Batch{§ [redacted] WP) was released for use, and the API batch was utilized for at least atches that were intended for the U.S. Market such a O OI Vials and Ampoule OO

Observation 2

Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.

Specifically, From 01/2023 to date, a total of39 complaints from the U.S. market were received regarding IOV Injection USP being ineffective. No root cause was assigned for drug ineffectiveness. epicenter manufactured and shipped to the U.S. market, [redacted] Jbatches received ineffective complaints (each batch can receive multiple complaints). Additionally in 2023, out of the totalft faces manufactured and shipped the U.S., [redacted] batches received complaints. JOM Mis administered Your firm’s complaint investigations are inadequate in that to date no root cause(s) have been identified to assure product quality and patient safety.

Observation 3

There is a failure to thoroughly review any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, A. The firm’s OOS investigation OS-LC23-006 was inadequate. OS-LC23-006 was initiated following an OOS result for unknown substance in Injectio Batcl{ [redacted] finished product. The OOS for Batch{{{9§ found unknown purity of [redacted] % (Acceptance is [redacted] §% or less). The firm’s Phase I investigation assigned dirty glassware being the root cause. However, no scientific evidence was provided to confirm contaminated glassware was the cause for the OOS data. A new sample was tested using a “clean” glassware, the result was within acceptance, and the batch was released to the U.S. in 05/17/2023. Batch [redacted] g9y was manufactured in 04/05/2023 with an expiration date of(I [redacted] B. The firm’s OOS investigation OOS OS-LC23-010 was inadequate. OS-LC23-010 was initiated following MMPimpurity ir Injection ml USP OMY Batch POM WH The OOS for the above batch was ppm (acceptance is or less). The firm’s Phase I investigation assigned insufficient time being the root cause. However, the firm’s conclusion was based on a previous OOS investigation occurred in 10/12/2022. The firm has no scientific evidence to show insufficientJf was the cause tor the current OOS result. A new sample was tested and the batch was released to the U.S. market in 10/18/2023. Batch PPO vas manufactured in 08/31/2023 with an expiration date of(JOM C. Your Quality Control (QC) team failed to thoroughly document laboratory investigations such as, but not limited to Column Failure and Device Malfunction. Additionally, there is no documentation available to demonstrate that your Quality Assurance (QA) team reviewed and evaluated the laboratory investigations at the form utilized to document the investigation, at the batch release review and release stage, and the annual product quality review.

Observation 4

Jecheon, Chungcheonbuk, 27159, Korea (The Republic of) | Sterile Drug Manufacturer Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically, During the inspection, we watched videos of airflow visualization studies (smoke studies) performed for the Ampoule LineBitaed 08/03/2025 and for the Vial Filling Line dated 05/08/2025. The above filling lines manufacture injectable products for the U.S. market. The lack of adequate smoke coverage, turbulent airflow, or poor aseptic practice were observed. Examples including but were not limited to: A. The static smoke studies were not performed under true static conditions. Specifically, you captured and evaluated the airflow between filling machine movement and called it static conditions. You failed to provide a comprehensive baseline study of your cleanroom design and cleanroom airflow before personnel and operations were introduced. B. Per Ampoule Linc nterventions performed: a) Video TEC-25051-FIL-}001-A01/BO1 (Setting of filling machine) showed turbulent airflow inside the Grade B zone within th S enclosure. You failed to demonstrate that there was no ingress of the GradeB air into the GradeA filling line. b) Video TEC-2505 1-FIL-1001-A02/B02 (Breakage ofampoule during filling) showed an operator’s head and upper body extended inside of the Grade A area while performing intervention. This video also showed an updraft ofairflow adjacent to ihRABSMOM Parea in the Grade B room. You failed to demonstrate that the updraft airflow did not result in the ingress of the Grade B air into the Grade A filling line. c) Video TEC-25051-FIL-1001-A04/B04 (Resetting change part) showed an operator’s head and upper body inside the Grade A area while performing this intervention. d) Video TEC-25051-FIL-1001-A07/B07 (Resetting of(M4) showed an operator’s head and upper body inside the Grade A area while performing intervention “Remove rack for material” and intervention “Re-setting of Cay C. Per Vial Filling Line intervention performed: Si-Baik Kim, Manufacturing Colligation Division Head Huons Co., Ltd. 100 Bio-Valley-Ro CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSP 0 Jecheon, Chungcheonbuk, 27159, Korea (The Republic of) a) Video TEC-2505 1-FIL-1002-A02/B02 (Replacement o [redacted] showed the operator brought a replacement{POM WY from the Grade B room to inside ofthe Grade A filling area. The replacement (OMY was neither contained in AIPOMP bag nor sanitized before moving into the GradeA filling line. b) Video TEC-2505 1-FIL-1002-A03/B03 (Resetting onwy of(MM stopper) showed an operator’s head, arm, and shoulder inside the Grade A area while performing intervention. c) Video TEC-2505 1-FIL-1002-A04/B04 (Insertion of(stopper) showed addition of MM stoppers. In this video, we observed the operator placed the bag containing sterile stoppers directly over the stopper bowl blocking the clean first air. We also observed the outside surface of the bag touching the sterile stoppers inside the bowl. The firm confirmed the stoppers are single bagged, There was no video showing how the bags were transferred to the [redacted] L A HOG d) Video TEC-2505 1-FIL-1002-A05/B05 (Operator is moved under the conveyor belt) showed an operator crawling underneath the conveyor line inside the GradeA filling area. The firm stated this activity was conducted during machine setup. This operator was to transfer a JOM PHPHto the other si he filling line where a (POMP Pwas located. This video did not show the operator carrying a nit. Thus, the airflow cannot be adequately reviewed. e) Video TEC-25051-FIL-1002-A06/B06 (Re-settingf [redacted] IIy showed an updrafi of airflow to the left side of the conveyor line carrying stoppered vials in the Grade A area. There was no evaluation of the non-laminar airflow. This video also showed a wrench was brought inside the Grade A area without being sanitized. f) Video TEC-2505 1-FIL-1002-A07/B07 (Fallen vials onMOMMY showed operator’s hand and arm directly over sterile open vials on the) [redacted] P Impacted vials were not rejected. g) Video TEC-25051-FIL-1002-A08/B08 (Fallen vials on conveyor) showed operator’s hand and arm directly over sterile open vials on the conveyor after leaving the ee Impacted vials were not rejected. D. Aseptic process simulation (APS) or media fill for the U.S. Ampoule Linefgp lid not simulate the worst case commercial manufacturing conditions. Specifically, commercial filling intervention types, frequency, and duration were not tracked for adequate simulation studies during APS. Your firm lacked sterility assurance for your drug products if APS was not appropriately performed. E. During the walkthrough ofthe Ampoule Filling Lindllibn 11/19/2025, I observed the HEPA grill for FIL- 1004-HO2 appeared to be bent within the Grade A filling area. According to your firm management, the HEPA Grill appears to be bent approximately 2cm, and there is no documentation available to establish how long the grill was bent. No smoke study was completed for Ampoule Filling Lin Ge A area), and there was no risk assessment completed by your Quality Unit to scientifically justify the lack of a smoke study. Additionally, a piece of(was identified within the Ampoule Filling Lin Gra A area) on 1/19/2025. According to firm management, an employee was interviewed and explained that the("was applied to one of the bolts within the Grade A area to secure it; however, there was no documentation available to confirm. There is no written procedure to require documentation of the [redacted] "being(lMPH for the Ampoule Filling Line Grade A) for both static and operating conditions (interventions) for Terminal Sterilization (TS).

Observation 5

Batch production and control records do not include complete information relating to the production and control of each batch.

Electronic records are used, but they do not meet audit trail requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records, Specifically, Your Audit Trail Review procedure and practice is inadequate. The checklist currently utilized fot) audit trail reviews do not specifically require the identification and tracking of events logged within the audit trail such as, but not limited to abortion of injections, The audit trail log printout attached to each final product release record is incomplete where only the beginning of the laboratory testing is printed, There are no audit trail log printouts dedicated to stability testing. Additionally, the written procedure for audit trail reviews prior to July 2023 only require random equipment and time length of audit trail logs reviewed. There are a number of batches intended for the U.S. Market and within expiry where the audit trail review was not conducted to verify the reported laboratory data aligns with the audit log record. Sterile Drag Manufacturer

Observation 6

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

Specifically, Your firm lacked adequate justification for washing and sterilizing JOM gloves only To sanitize gloves before each batch, is used. Also, is used as needed and MMMM \ca sporicide) is used However, there is no written procedure on how toclean gloves. You also have no study to monitor cleaning effectiveness. At the end of each batch production, only the HPPOM WP glove is sampled per viable EM procedure. No fingers are monitored. You lacked justification for not monitoring gloves that are used during production and not sampling glove fingers. cr yw" jot!

See all 6 findings in this document
[FDA 483 observation · FDA]Bioclinica inc./Clario (eResearch Technology, Inc) — Unvalidated clinical data systems
FDA483

Clinical bone mineral density data were analyzed with unvalidated software

Published 2026-11-12 · Inspection date 02/27/2025 · Contract Research Organization · FEI 3032745961

1 observation
Findings
  1. 1Transfer of obligations to a contract research organization.
Check points
  • Is commercial software that processes or analyzes clinical data validated before use? (Observation 1)
  • Are edits and deletions made before data transfer captured in an audit trail? (Observation 1)
  • Is there a check that prior corrections are preserved in the final data transfer? (Observation 1)
Observation detail · 1 observation · From the source
Observation 1

Transfer of obligations to a contract research organization.

Specifically, 1. Your firm failed to validate computer systems used to process, manage, and report electronic data from clinical investigations to ensure accuracy, reliability, and consistent intended performance. For example: A) Your firm used unvalidated software applicationsfend ws to analyze clinical study bone mineral density data despite your June 2023 COTS assessments acknowledging Part 11 requirements. Critical data integrity gaps existed, as edits/modifications, reassessments, and deletions could be made in these systems with no audit trail before transferto)., B) Your validation approach failed to address critical upstream data processing activities, creating risk to data reliability. The absence of validation for these systems resulted in inability to generate complete audit trails, identify users making changes, document reasons for changes, prevent unauthorized modifications, and produce accurate and complete copies of records throughout the entire data lifecycle. 2. Your firm failed to establish and follow adequate procedures to ensure the integrity, accuracy, and reliability of clinical trial data for study Specifically, your firm did not implement effective validation controls, or adequate corrective and preventive actions. For Example: A) Quality Event DEV-06296 documents that correction factors were not properly applied to data in the final data transfer on June 26, 2024, affecting 31 subjects. “There was an IQC correction in prior transfer. In the Final/End of Study transfer, the prior IQC corrections were overwritten with the new data, instead of appended to the prior corrections which is our standard process (IM-SS-W027)." B) Quality Event DEV-06317 documents that hip data for three specific cases (DI) tbe were improperly excluded from the data transfer file, despite being required for analysis.

[FDA 483 observation · FDA]Nanovis LLC — Nano surface treatment validation and controls
FDA483

Acid concentration, a critical parameter, was measured only once at the start of the day

Published 2026-11-12 · Inspection date 03/19/2026 · Manufacturer · FEI 3009446038

6 observations
Findings
  1. 1Procedures for validation of processes did not adequately include statistical techniques with rationale for sample sizes and use of specific methods, procedures, and acceptance criteria.
  2. 2Production controls do not include implementation of monitoring and measurement of process parameters and product characteristics.
  3. 3Requirements for the work environment, and the procedures to monitor and control the work environment, were not adequately documented where conditions for the work environment can have an adverse effect on product quality.
  4. 4Purchasing information does not adequately describe or reference the product to be purchased, including requirements for product acceptance, procedures, processes, and equipment.
  5. 5Changes necessary to ensure and maintain the continued suitability, adequacy, and effectiveness of the quality management system and medical device safety and performance were not adequately identified and implemented.
Show 1 more
  1. 6Changes to quality management system processes were not adequately controlled in accordance with requirements and evaluated for their impact on the quality management system and the medical devices produced.
Check points
  • Is there a documented statistical rationale for process validation sample sizes? (Observation 1)
  • Are critical process parameters monitored for every lot against the validated range? (Observation 2)
  • Is there a microbial upper limit for process water that contacts finally cleaned product? (Observation 4)
Observation detail · 6 observations · From the source

Inspectors: Suyang Qin · Shawn Choi

Observation 1

Procedures for validation of processes did not adequately include statistical techniques with rationale for sample sizes and use of specific methods, procedures, and acceptance criteria.

Specifically, oMaster validation of the titanium anodize nano surface treatment for titanium implants and master validation adoption for the titanium anodize nano surface treatment of [redacted] do not adequately establish acceptance criteria to show that the anodize nano surface treatment will meet specification requirements. Per the [redacted] Engineering Drawing [redacted] 07 07/21/2022 note 10, nanotube anodize screw thread specifications are documented per SPE-00022. Per Spine Manufacturing Specification: Nanotube Anodization SPE-00022 Rev A 08/22/2025, page 2 section 7.2.1 through 7.3, parts are to be processed in general accordance with Nanovis work instruction NW 7.5.1.1-58 for titanium nanotube anodization and calcium phosphate deposition to yield the following physical properties: Calcitum phosphate does not cover nanotube openings, [redacted] tube diameter, if the entire part is not intended to be nanotube anodized, the feature(s) or zone(s) to be anodized with nanotubes should be defined on the engineering drawings. However, the following acceptance criteria were not established to show that these specifications are met. ‘|Your organization did not document acceptance criteria for how much of the surface intended to be nanotube anodized will be covered by nanotubes as an output of the process. Per [redacted] — Master Validation Adoption [redacted] 10/24/2025 pages 1-2, for the Highridge screws used in the process validation, you identified that between [redacted] and [redacted] of the [redacted] surface that was intended to be nanotube anodized is covered by nanotubes. Your organization did not provide a rationale for why [redacted] coverage of the intended area with nanotubes is sufficient for the product to meet its specification. Your organization did not document acceptance criteria for what percentage of nanotubes will be within the range of [redacted] tube diameter. Per [redacted] Master Validation Adoption [redacted] 09/12/2025 page 4, the acceptance criteria for nanotube diameter / morphology is documented as [redacted] (6)\(4)' nanotube structures between [redacted] and [redacted] measured using the [redacted] However, per [redacted] from [redacted] Master Validation Adoption (6) [redacted] 10/24/2025, a number of nanotubes can be observed to be at or greater than 100nm. Per the organization’s Principle Scientist the images were evaluated as passing results because the visual [redacted] " of all nanotubes present on the image appear within the specification range of [redacted] Your organization did not document the acceptance criteria can be an [redacted] " value. Spine Manufacturing Specification: Nanotube Anodization SPE-00022 Rev A 08/22/2025 does not document the [redacted] requirement as an [redacted] value. (|Process validations did not include a surface characterization to determine if the diameter of the nanotubes formed during the process are consistent and homogenous across the intended surface. Per Surface Characterization of nanoVIS Ti Surface on [redacted] Memo 08/29/2025, your organization documented that an analysis of [redacted] nanotubes show that the nanotubes created during the anodization average at [redacted] with an [redacted] standard deviation of [redacted] This surface characterization study shows that at greater than [redacted], the nanotubes would fall out of the acceptance range of [redacted] This surface characterization was not performed as part of a validation. Your organization does not have objective evidence that this surface characterization is repeatable at all ranges of acceptable process conditions. Your organization did not establish if this surface characterization establishes that the process is capable of producing a product with a consistent and homogenous surface. oMaster validation of the titanium anodize nano surface treatment for titanium implants and master validation adoption for the titanium anodize nano surface treatment of [redacted] do not adequately establish rationale for sample sizes. Per [redacted] Master Validation Adoption [redacted] 09/12/2025 page 4, nanotube diameter/morphology and calcium phosphate features are tested via [redacted] for visual attributes with a sampling frequency of [redacted] ™. Per the protocol page 3 section 8.1.3.4.1, [redacted] " representative image shall be captured for [redacted] determination. Your organization has not established in the validation that the diameters of the nanotubes are consistent and homogenous across the anodized surface. Your organization did not document a rationale for why a sample size of “image in each ofa samples is statistically significant to determine that anodization across the trial will meet nano surface specifications. Per [redacted] pFMEA Rev A 11/12/2025, nanosurface nonconformities are documented with a severity [redacted] out of™Per [redacted] Report RMR-10098 Rev B 01/24/2026, nanotube anodization nonconformities are documented with a severity [redacted]

Observation 2

Production controls do not include implementation of monitoring and measurement of process parameters and product characteristics.

Specifically, oCritical process parameters of the titanium anodize nano surface treatment for titanium implants validated process are not adequately monitored. Per 2025 Nano Process Master Validation Plan OQ Protocol [redacted] 08/22/2025 page 2 table 2.4A, critical process parameters include Acid Concentration and [redacted] Concentration. These process parameters are not adequately monitored in the following ways: Per Titanium Anodize Nanosurfacing Setup Sheet 206HXXX-00 [redacted] 11/20/2025 the monitoring for the Acid Concentration is reference only, performed only at the beginning of the day, and is a measurement by titration volume instead of concentration. Your organization produces multiple lots per production day, your monitoring does not provide assurance that the acid concentration is adequately maintained within the validated process range of [redacted] for each batch manufactured. Additionally, your organization has not adequately established that the titration reference range documented as [redacted] can be used to accurately monitor the acid concentration tolerance range of [redacted] _|Per Titanium Anodize Nanosurfacing Setup Sheet 206HXXX-00 [redacted] 11/20/2025 the monitoring for the [redacted] Concentration is reference only, performed only at the beginning of the day, and is a measurement by [redacted] instead of concentration. The process monitoring procedure does not document process limits for [redacted] value where it would indicate the process is operating outside of the validated range. Your organization produces multiple lots per production day, your monitoring does not provide assurance that the [redacted] is adequately maintained within the validated process range for each batch manufactured. Additionally, your organization has not adequately established how [redacted] relates to [redacted] concentration in a way that can be used to accurately monitor the process parameter. oProduct characteristics of the nanotubes formed in the anodization process are not adequately monitored. Per [redacted]: Nanotube Anodization SPE-00022 Rev A 08/22/2025, page 2 section 7.2.1 the nanotube specifications are Calcium phosphate does not cover nanotube openings, [redacted] tube diameter. Per Titantum Anodize Nanosurfacing Operation NW 7.5.1.1-58 Rev T 11/04/2025 page4 section 5.3 the product characteristic monitoring include sample [redacted] during the first production run and last production run of the day. Per Titanium Anodize Nanosurfacing Setup Sheet 206HXXX-00 [redacted] 11/20/2025, [redacted] are [redacted] production parts and representative samples. Per production records sampled, [redacted] is ran with the first and the last production run of the day. Per Attachment 6.2 Imaging Zones for Nano FortiFix Screws NW 7.5.1.1- 59 Rev A 11/05/2024, page 1 section 1.1, at least [redacted] ") on the sampling [redacted] or implant surface will be selected for magnification. Per Titanium Anodize Nanosurfacing Inspection NW 7.5.1.1-59 Rev F 11/05/2024 page 3 section 5.4.3, [redacted] mspection method, each [redacted] is inspected under [redacted] magnification for uniformly round nanotube structures between [redacted] and [redacted] and to assess if calcium phosphate is covering the nanotubes. Per the procedure page 3 section 5.4.2, 1 inspection image from each sample [redacted] is captured and saved. Your organization produces multiple lots per production day. You have not documented why your product characteristic monitoring of [redacted] out of [redacted], In [redacted] a production day is sufficient to demonstrate that all batches manufactured during that day conforms to product specifications. Per [redacted] pFMEA Rev A 11/12/2025, nanosurface nonconformities associated with incorrect processing times/parameters and inadequate process monitoring documented nanotube anodization nonconformities are documented with a severity [redacted].

Observation 3

Requirements for the work environment, and the procedures to monitor and control the work environment, were not adequately documented where conditions for the work environment can have an adverse effect on product quality.

Specifically, the titanium anodize nano surface treatment work environment does not have adequate requirements and is not adequately monitored and controlled. Per Spine Manufacturing Specification: Nanotube Anodization SPE-00022 Rev A 08/22/2025 page 2 section 6.1, all manufacturing and finishing processes, including final manufacturing cleaning, should occur [redacted] nanotube anodization. Per the specification page 2 section 6.3.1, [redacted] and/or [redacted] cleaning systems are prohibited following nanotube anodization and deposition; [redacted] " is recommended prior to final packaging. Per excerpt from [redacted] 09/26/2025, the product is sterilized via [redacted]. Per Facilities Resources NP 6.3 Rev E 01/09/2026 page 3 section 5.2.6.d, the nanosurfacing room work environment monitoring shall be controlled per Process Monitoring and Equipment Monitoring NW 7.5.1.1-66. However, there is no documentation of environmental monitoring requirements in Process Monitoring and Equipment Monitoring NW 7.5.1.1-66 Rev A 08/22/2025. Your organization has not documented environmental controls or monitoring requirements for an environment where product intended to be [redacted] sterilized and has been subjected to final manufacturing cleaning is processed. Product contamination within this work environment may compromise the product’s sterility assurance. Per [redacted] pFMEA Rev A 11/12/2025, nanosurface nonconformities associated with product contamination and improper environmental exposure are documented with a severity [redacted]. Per [redacted] 01/24/2026, product contamination with biological agents during nanotube anodization are documented with a severity [redacted]

Observation 4

Purchasing information does not adequately describe or reference the product to be purchased, including requirements for product acceptance, procedures, processes, and equipment.

Specifically, oYour organization did not adequately document purchasing requirements for [redacted] used in the titantum anodize nano surface treatment process. Per 2025 Nano Process Master Validation Plan [redacted] 08/22/2025 page 4, the [redacted] used in the titanium anodize nano surface treatment is [redacted]. Per the protocol, [redacted] is used for rinse tanks. Per Titanium Anodize Nanosurface Set-up NW 7.5.1.1-67 Rev C 11/04/2025 page 5, [redacted] y™™ is accessed from the [redacted] in the [redacted] room. Per the procedure page 5 section 5.2.8, [redacted] is used to fill all rinse tanks. Per Titantum Anodize Nanosurfacing Operation NW 7.5.1.1-58 Rev T 11/04/2025 page 9, section 5.4.10.c, in addition to the [redacted] rinse, an additional sink rinse may be performed for porous product. The [redacted] used during all steps of the titanium anodize nano surface treatment is from an external supplier and not controlled by the organization. Your organization has not documented purchasing requirements for the [redacted] " as a product, or the [redacted] generation as a process. Additionally, per Microbial Enumeration of Water Test Report 100148 02/16/2026, microbial enumeration of water from samples taken from implant sink, hose line, labware sink, deposition tank and deposition rinse tank resulted in between 22 CFU (colony forming units) and 451 CFU for HPC (heterotrophic plate count) and between 33 CFU and 528 CFU for yeast and mold. Your organization does not have a documented upper limit for the acceptable number of CFU in microbial enumeration in the [redacted] " supply. Per Spine Manufacturing Specification: Nanotube Anodization SPE-00022 Rev A 08/22/2025 page 2 section 6.1, all manufacturing and finishing processes, including final manufacturing cleaning, should occur prior to nanotube anodization. Per excerpt from [redacted] 09/26/2025, the product is sterilized via [redacted] Your organization has not documented whether exposure of final cleaned product to this water supply will result in nonconforming product or negatively impact the product’s sterility assurance. Per [redacted] pFMEA Rev A 11/12/2025, nanosurface nonconformities associated with product contamination are documented with a severity [redacted]. Per [redacted] 01/24/2026, product contamination with biological agents during nanotube anodization are documented with a severity [redacted] oYour organization did not adequately document purchasing requirements for the [redacted] as an input into your organization’s validated titanium anodize nano surface treatment process. Per [redacted] — Master Validation Adoption [redacted] 10/24/2025 pages 1-2, for the [redacted] used in the process validation, you identified that between [redacted] and (6) [redacted] bf the [redacted] surface that was intended to be nanotube anodized is covered by nanotubes. Per your organization’s Principle Scientist, the coverage of the surface of the [redacted] by the nanotubes is limited by the amount of exposed titanium. Per your organization’s Principle Scientist, the [redacted] titanium surface may be covered by nanoscale debris left over from [redacted] manufacturing processes. Your organization did not document a purchasing requirement for the amount of exposed titanium surface on the [redacted] necessary for the titantum anodize nano surface treatment to result in a nano coated surface that meets Spine Manufacturing Specification: Nanotube Anodization SPE-00022 Rev A 08/22/2025. Per [redacted] pFMEA Rev A 11/12/2025, nanosurface nonconformities are documented with a severity [redacted]. Per [redacted]) 01/24/2026, nanotube anodization nonconformities are documented with a severity [redacted]

Observation 5

Changes necessary to ensure and maintain the continued suitability, adequacy, and effectiveness of the quality management system and medical device safety and performance were not adequately identified and implemented.

Specifically, oCorrective actions implemented are not effective in documenting actions needed to ensure that nonconformities do not recur. For example, “JCAPA 130 documented a nonconformance where procedures were not updated to reflect the change in responsibilities when the organization took over nanosurfacing processes; the changes in responsibilities include the additional responsibilities related to work space, process equipment, preventive maintenance and calibration. Per the CAPA actions, corrections were implemented to revise Facilities Resources NP 6.3 and verify procedures, work instructions, and forms are in place for the responsibilities listed within the newly revised procedure. This CAPA was closed as effective on 05/08/2025. However, per Facilities Resources NP 6.3 Rev E 01/09/2026 page 3 section 5.2.6.d, the nanosurfacing room work environment monitoring shall be controlled per Process Monitoring and Equipment Monitoring NW 7.5.1.1-66. However, there is no documentation of environmental monitoring requirements in Process Monitoring and Equipment Monitoring NW 7.5.1.1-66 Rev A 08/22/2025. This CAPA did not result in establishing procedures to address all new responsibilities. _ICAPA 141 documented a nonconformance where the pFMEA for a product omitted process control documents established in the product’s control plan such as NW 7.5.1.1-65 Titanium Anodize Nanosurfacing Parameters and NF 7.5.1-08 Titanium Anodize Nanosurfacing SetupSheet. Per the CAPA actions, corrections were implemented to update pFMEAs from the scope to align with the control plan and update control of documents procedures and document approval procedures to prevent recurrence. The actions were completed on 11/07/2025 and the CAPA was closed as effective on 12/23/2025. However, the same nonconformance was identified in [redacted] pFMEA Rev A 11/12/2025 as this pFMEA did not include documents established in the [redacted] Control Plan Rev 07 11/03/2025 such as Spine Manufacturing Specification: Nanotube Anodization SPE-00022 and NW 7.5.1.1-65 Titanium Anodize Nanosurfacing Parameters. This CAPA did not result in preventing recurrence of the nonconformance. oCorrective actions are not implemented in accordance with established procedures; a rationale for not opening a corrective action was not documented in accordance with established procedures. For example, _|Corrective actions were not initiated to address nonconformances identified during internal audits. Per Internal Audits NP 8.2.2 Rev E 08/08/2025 page 4 section 5.1.1, identified audit nonconformances shall be processed through Corrective and Preventive Actions and entered as a CAPA workflow in [redacted] Per Quality Systems — Internal Audit (6y(4)) 10/06/2025, 2 nonconformances were documented. However, these nonconformances were not entered as a CAPA; your organization has not documented any corrective actions associated with these nonconformances. _|Corrective actions were not initiated to address negative trends in supplier monitoring and no rationale for the lack of action was documented. Per Supplier Management NP 7.4.1 Rev L 01/09/2026 page 6 section 5.4.2, supplier ratings and approvals are based on performance data from the previous [redacted] data is analyzed during management review to identify trends that may necessitate remedial action. Management shall determine and document any such actions or justify why no action is required. Per 2025 [redacted] Management Review data for critical supplier status monitoring, a critical supplier was identified to be conditionally approved with decreasing status scores for [redacted] However, no remedial action or rationale for no action was documented.

Observation 6

Changes to quality management system processes were not adequately controlled in accordance with requirements and evaluated for their impact on the quality management system and the medical devices produced.

Specifically, when moving your validated manufacturing equipment and changing the operation location for a validated manufacturing process, your organization did not adequately evaluate the impact of that change on medical devices in accordance with established procedure. Per Design and Development NP 7.3 Rev M 02/20/2025 page 12 section 6.7.4.1, initial releases and changes to design and development and engineering documents require formal documentation on the [redacted] and subsequent approval/release. Per the procedure page 13 section 6.7.4.5, during the review, the lead [redacted] evaluates if the change has any effect on product in process, already delivered, and/or constituent parts. Per Supplier Change Notification SQ-10416 01/07/2026, page 1, validated equipment used to qualify the anodize process is moved within the building and requalified. Per the change notification page 2, the nano processing room moved and is expanded. This change was sent to the organization’s customer for approval. However, your organization has not documented an [redacted] with an independent evaluation of the impact of the change on medical devices manufactured using the moved equipment in the new environment in accordance with procedural requirements. ‘Suyang Qin XSee uses

See all 6 findings in this document
[FDA 483 observation · FDA]AnaptysBio — Inadequate oversight of trial monitoring
FDA483

Electronic data queries remained unresolved for 9 to 13 months

Published 2026-11-06 · Inspection date 04/29/2026 · Sponsor · FEI 3020705743

1 observation
Findings
  1. 1Failure to provide investigators with the information needed to conduct the study properly and ensure proper monitoring of the study.
Check points
  • When monitoring is transferred between CROs, does a study-specific monitoring plan apply without a gap? (Observation 1)
  • Does the sponsor routinely track data queries that exceed the resolution timeline? (Observation 1)
  • Is it checked that monitoring visit reports are signed and approved within the required timeline? (Observation 1)
Observation detail · 1 observation · From the source

Inspectors: Farwa Z Razvi

Observation 1

Failure to provide investigators with the information needed to conduct the study properly and ensure proper monitoring of the study.

The inspection of clinical studies and revealed that the Sponsor failed to adequately oversee and monitor, the CROs responsible for monitoring. Specifically, 1. There was an absence of a study-specific monitoring plan between April 2022 and October 2022. In April of 2022, monitoring responsibilities were transferred fro to individual monitoring CROs based on region — These CROs followed the AnaptysBio Monitoring Plan which was developed in October 2022, resulting in an approximate 6 month gap in monitoring plans. 2. Data queries within the Medidata RAVE EDC were not resolved for a period of 9-13 months. Per the AnaptysBio Monitoring Plan (03Oct2022) the timeline for query resolution is approximately 3 business days from date of query issued. e For subjectshae andee. queries flagging anomalous FSH data entries were first opened in June 2022 and September 2022, respectively. Formal DM queries confirming that the FSH was not collected per protocol — an acknowledged protocol deviation — were not resolved until July 2023, representing resolution timelines of approximately 10-13 months. (6), query regarding incorrect childbearing potential classification —a data point directly relevant to subject eligibility and required protocol assessments — was opened in December 2022 and was not resolved until September 2023, a period of approximately 9 months. 3. Monitoring reports were not signed for various unblinded interim monitoring visits (IMVs). Per the AnaptysBio Monitoring Plan, the site visit report must be approved by the Report Reviewer and signed off by the CRA no later than 15 weekdays from the visit. e For site 10-101, six IMV reports were not signed by the CRA and/or a secondary reviewer. e For site 10-108, two IMV reports were not signed by the CRA and/or a secondary reviewer. 4. There was no site qualification documentation for site 42-107. Innovaderm was the CRO utilized for site selection prior to April 2022. Per the Jnnovaderm Monitoring Plan and Site Identification, Feasibility, and Selection SOP, each site must submit a Feasibility Questionnaire prior to the Site Qualification Visit (SQV), sponsor approval of the site must be obtained following the SQV, and sites must be provided with all essential documents prior to study initiation. These items could not be located in the TMF for site 42-107.

[FDA 483 observation · FDA]Protagonist Therapeutics Inc — Trial deviation reporting and monitoring gaps
FDA483

Monitoring found enrollment of subjects not meeting inclusion criteria up to 2 years later

Published 2026-11-06 · Inspection date 04/03/2026 · Sponsor · FEI 3013745424

1 observation
Findings
  1. 1Failure to provide investigators with the information needed to conduct the study properly and ensure proper monitoring of the study.
Check points
  • Are investigators given written instructions on initiating and reporting protocol deviations? (Observation 1)
  • Does the monitoring plan set a deadline for the first visit after the first subject is treated? (Observation 1)
  • How many weeks pass before monitors verify inclusion criteria after a subject is enrolled? (Observation 1)
Observation detail · 1 observation · From the source

Inspectors: Kristin M Abaonza

Observation 1

Failure to provide investigators with the information needed to conduct the study properly and ensure proper monitoring of the study.

Specifically, investigators did not receive information on how to initiate and report protocol deviations. Monitors, responsible for reporting deviations, did not ensure proper review of protocol compliance for a) The following subjects were enrolled and treated in the study despite not meeting inclusion criteria. Monitoring did not detect and report these protocol deviations until up to 2 years after the deviation occurred. The table below lists the protocol deviation and when the deviation was identified and reported by the monitor. Subject Protocol Deviation |Date Deviation} Date Identified Timeframe until Number (Inclusion Criteria Occurred Monitor not Met Identification No bone marrow 17-Feb-2023 18-Dec-2024 1 year, 10 months and biops 1 da Phlebotomy 8-Feb-2023 11-Feb-2025 2 years and 3 days timeframe b) The protocol deviations below were not detected by monitors. Protocol deviations were identified and recorded during a data listing review up to two years later. Subject Protocol Deviation Date Date Timeframe until (Inclusion Criteria not] Deviation... Number Identified Identification Met Occurred [redacted] Patient did not have stable dose of interferon 14-Apr-23 18-Feb-25 1 year, 10 months, and 4 at least 6 months prior days to randomization Patient did not have stable dose of interferon 26-Apr-23 14-Jul-25 2 years, 2 months, and 18 at least 6 months prior days to randomization c) For [redacted]. The Monitoring Plan, Version 2 (dated December 11, 2019) failed to address a timeframe for when the first monitoring visit should occur after the initial subject is enrolled and treated. The table below summarizes the delay in the first monitoring visit following treatment of the initial subject at each site. First Subject |Monitoring Visit} Timeframe until| # of Subjects Treated after First Monitoring Visit} Treated before Subject Treated after first Monitoring Visit Subject Treated 1508 30-Nov-2020 2-Feb-2021 2 months and 3 2 days 1512 26-Jan-2021 15-Jun-2021 4 months and 20 days 11-12 Feb 2021 3 months and 8 2 days At the above listed sites, protocol deviations and adverse events occurred before the first monitoring visit following treatment of the initial subject. For [redacted]. The Monitoring Plan addressed a timeframe for the first routine monitoring visit (RMV) to occur within 2 weeks of the site’s first randomized subject but may be increased to 3 weeks if deemed necessary. The table below summarizes the delay in the first monitoring visit following treatment of the initial subject at each site: Site First Subject |Monitoring Visit]Timeframe until} # of Subjects Treated after First |Monitoring Visit} Treated before Subject Treated after first Monitoring Visit Subject Treated 514 5-Dec-2022 6-Mar-2023 3 months and 1 2 day 570 29-Feb-2024 23-Apr-2024 1 month and 25 days At the above listed sites, protocol deviations and adverse events occurred prior to the first monitoring visit following treatment of the initial subject and were not reviewed by monitors for up to three months.

[FDA 483 observation · FDA]Implantica CE Reflux Limited — CAPA procedures and sample-size rationale
FDA483

CAPA scope limited to a single subcontractor and the one batch in question

Published 2026-10-27 · Inspection date 10/24/2025 · Bioresearch Sponsor, Manufacturer · FEI 3015217460

4 observations
Findings
  1. 1Procedures for corrective and preventive action have not been adequately established.
  2. 2Procedures to ensure that sampling methods are adequate for their intended use have not been adequately established.
  3. 3The organizational structure has not been adequately established and maintained to ensure that devices are manufactured in accordance with 21 CFR Part 820.
  4. 4Process validation activities have not been adequately documented.
Check points
  • Is CAPA scope extended to other batch records and subcontractors that may share the same omission? (Observation 1)
  • Do procedures define when an external standard overrides internal sample-size criteria, with statistical rationale? (Observation 2)
  • Are delays in open CAPAs and change requests tracked when key staff leave? (Observation 3)
Observation detail · 4 observations · From the source

Inspectors: John Sciacchitano · Kathryn Suttling · Lakecha N. Lewis

Observation 1

Procedures for corrective and preventive action have not been adequately established.

Specifically, the following deficiencies were found in these CAPA records: CAPA 00001: Inadequate Corrective Actions (ineffective training) and Effectiveness Check Plan (no interim checks) CAPA 00003: Inadequate Effectiveness verification plan for systemic QMS issue (no interim checks) CAPA 00002: 1. Investigation — Missing Process-Parameter Documentation The investigation does not contain any documented evidence that the) ay. tumbler was the equipment actually used throughout production. There is no record showing that the speed, rpm, and other parameters employed on the RS-300 devices match the values specified in the original validation reports (1O/OQ/PQ). 2. Corrective Action — Incomplete Batch-Record Amendment The corrective-action portion of the CAPA fails to provide documented proof that all affected batch records, including previously released batch records (job-router forms, batch-release sheets, and any downstream documentation) have been updated to include the tumbler model-number (e.g., isi as the equipment used for the tumbling operation. 3. Scope & Preventive Action — Insufficient Coverage The CAPA scope is limited to the single subcontractor ss and the one batch in question. The scope should be expanded to verify that the same omission (absence of equipment identification) does not exist in any other batch-record packages, whether they involve the same tumbler or other subcontractors, and appropriate preventive actions should be instituted to prevent recurrence. John eed

Observation 2

Procedures to ensure that sampling methods are adequate for their intended use have not been adequately established.

Specifically, the firm’s procedures for establishing sample sizes in validation activities lack clear guidance on when an external standard (such as an ANSI/ISO sampling requirement) can override or replace the organization’s own internal criteria. The procedures do not specify the necessary elements such as acceptance criteria, justification, rationale, approval process, methodology, or how to resolve any conflict between the two sources. Consequently, the choice of sample size in validation studies may be unsupported by statistical justification and applied inconsistently. For example: A sample size of six was initially selected in Protocol (DT_DVP0007 01) Manual Cleaning Validation Plan on the suggestion as per ANSI/AAMI ST98: 2022 [9]. ANSI/AAMI ST98: 2022. This sample size was changed to 9, a more conservative sample size, as reflected in the validation report DT_DVROOO7 03 Manual Cleaning Validation Report. Collectively, these validation reports did not adequately document the following: e the factors considered when selecting the initial six-unit size (expert judgment, industry practice, risk assessment, etc.). e the rationale or explanation why a sample size of 9 was sufficient, even if recommended by the standard that could include a clear, risk-based rationale for the sample size used, is sufficient for the specific device, process and risk level, and explain the deviation from your own internal SOP.

Observation 3

The organizational structure has not been adequately established and maintained to ensure that devices are manufactured in accordance with 21 CFR Part 820.

Specifically, between approximately December 2024 and September 2025, the firm’s approach to managing the quality system was, in part, triage-oriented rather than maintaining normal quality system operations. The departure of several key staff members resulted in delays and partial interruptions in the processing of CAPAs, change requests, nonconformances, and quality plans.

Observation 4

Process validation activities have not been adequately documented.

Specifically, the stated purpose of the validation protocol (test instructions) RS DVPO0004 "RefluxStop Radiopacity and Barium Sulphate," was not congruent with the conclusions in the corresponding output report RS DVROO04. The protocol documentation was inaccurate. John Dipkely Hone’byJohn

See all 4 findings in this document
[FDA 483 observation · FDA]L' Oreal Usa, Inc. — Label and rejected material control, no QC SOPs
FDA483

Printed drug labels stored in a general warehouse without segregation or control

Published 2026-10-26 · Inspection date 04/01/2026 · OTC Drug Manufacturer · FEI 3003763470

3 observations
Findings
  1. 1Labels and other labeling materials are not stored separately with suitable identification for each different drug product, strength, dosage form or quantity of contents.
  2. 2Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components, drug product containers, closures and labeling before disposition.
  3. 3The responsibilities and procedures applicable to the quality control unit are not in writing.
Check points
  • Is access to the printed label storage area limited to authorized personnel? (Observation 1)
  • Are rejected materials stored in an area physically separated from approved materials? (Observation 2)
  • Is there a written procedure for investigating and managing OOS results? (Observation 3)
Observation detail · 3 observations · From the source
Observation 1

Labels and other labeling materials are not stored separately with suitable identification for each different drug product, strength, dosage form or quantity of contents.

Specifically, Your firm failed to establish adequate controls for printed drug labels. During the walkthrough on 3/26/2026, I observed printed drug labels for “ [redacted] ” (lot # [redacted]) in the [redacted] general warehouse area. At the time of inspection, your firm had approximately ™different printed labels and printed tubes for the ™different OTC drug products and approximately [redacted] different cosmetic product labels stored in the [redacted] general warehouse area (designated for raw materials and packaging materials) and in the [redacted] general warehouse area (designated for tubes and other packaging components). The storage areas in both general warehouses were not segregated nor controlled for such critical components to prevent mix-ups between labels for different products. Access to the label storage area in the warehouse was not limited to authorized personnel. In addition, your firm also failed to have documented procedures for label management such as responsibilities, storage, issuance, use and reconciliation of the printed labels and tubes.

Observation 2

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components, drug product containers, closures and labeling before disposition.

Specifically, Your firm failed to provide separate or defined areas necessary to prevent contamination or mix-ups of rejected or damaged raw materials. Rejected materials were stored on the same shelves in the same general warehouse area as approved materials without physical separation or defined boundaries. The storage arrangement did not provide adequate control systems to prevent mix-ups between rejected and approved materials. As of 4/1/2026, there were approximately rejected components in the [redacted] warehouse area. Additionally, approximately ™rejected printed cosmetic labels were stored on shelves alongside approved drug and cosmetic printed labels in the [redacted] warehouse area. This practice creates a risk of cross-contamination and mix-ups between rejected and approved materials.

Observation 3

The responsibilities and procedures applicable to the quality control unit are not in writing.

Specifically, Your firm failed to establish documented procedures pertaining to the quality control unit at the firm. Specifically, during the inspection, you were unable to provide the following written procedures to ensure thorough investigations and proper procedures were followed and to ensure no mix-ups on the different formulas of OTC drug products your firm manufactured. Written procedures describing the roles and responsibilities of the Quality Control Unit, including Quality Assurance and Quality Control functions and responsibilities. Written procedures for the investigations and management of Out-of-Specifications (OOS) results. |_|Written procedures for the control and review of master and executed batch or packaging production records for the different formulas of the OTC drug products. 3/25/2026(Wed), 3/26/2026(Thu), 3/27/2026(Fri), 3/30/2026(Mon), 4/01/2026(Wed)

See all 3 findings in this document
[Regulatory news · EMA]Meeting highlights from the Committee for Medicinal Products… — CHMP November meeting recommends seven
EMARegulatory news

Human medicines committee recommended seven medicines for approval in November

EMA's human medicines committee (CHMP) recommended seven medicines for approval at its 2026-11-09 to 12 meeting, including Aumseqa (aumolertinib) for non-small cell lung cancer.

Published 2026-11-13 · Issuing authority EMA · Topic Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP…

Key facts · Basis: official index plus supporting sources
  • What changes: CHMP recommended seven medicines for approval
  • Applies to: Recommended medicines including Aumseqa (aumolertinib, non-small cell lung cancer)
[FDA 483 observation · FDA]Water-Jel Technologies, LLC — Delayed stability OOS probes, no study protocols
FDA483

Stability potency failure investigation for an ointment lot left open for 340 days

Published 2026-11-13 · Inspection date 09/20/2024 · Own Label Distributor/Repackager/Relabeler · FEI 1219592

2 observations
Findings
  1. 1There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
  2. 2The written stability testing program is not followed.
Check points
  • Are stability OOS investigations closed within a set deadline, with documented justification when exceeded? (Observation 1)
  • How many open non-conformances have remained unclosed for more than a year? (Observation 1)
  • Does every product have a stability protocol defining storage conditions, test intervals and sample numbers? (Observation 2)
Observation detail · 2 observations · From the source

Inspectors: Susan O Oladeji

Observation 1

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, you consistently fail to complete your stability OOS and non-conformance investigations in a timely manner without adequate justification. Examples are as follows: OTC Stability OOSs [redacted] Ointment Lot # [redacted] — [redacted] potency too low [redacted]. Investigation open for 340 days. [redacted] Ointment Lot # [redacted] — [redacted] _—potency too low [redacted] __. Investigation open for 340 days. [redacted] Gel Lot # [redacted] — [redacted] potency too high [redacted] too low [redacted]. Investigation open for 290 days. Lot # [redacted] — [redacted] potency too low [redacted] and [redacted]. Investigation open for 290 days. [redacted] Cream [redacted] (4). _. Investigation open for 163 days. Lot # [redacted] - [redacted] potency high [redacted] & [redacted]. Investigation open for 163 days. [redacted] Ointment Lot # [redacted] low potency [redacted] __. Investigation open for 93 days. [redacted] Ointment Lot # [redacted] - [redacted] potency too low [redacted] __. Investigation open for 49 days. [redacted] Ointment Lot # [redacted] — [redacted] high potency [redacted] — and [redacted] __. Investigation open for 39 days. OTC Non-Conformances Greater than 50% of the non-conformances you have initiated have been open for 156-681 days. The following investigations have been open for a year or more: [redacted] Pp (4) Packaging Error " [redacted] Cream [redacted] Short Count Ointment Manufacturer and Own Label Distributor [redacted] Short Count [redacted] Limit Change [redacted] Quarantine, Wrong Gel (b) (A) [redacted] Empty Doses 2) Cream [redacted] Leaking Cream [redacted] rong Item Printed Ointment [redacted]

Observation 2

The written stability testing program is not followed.

Specifically, you have failed to adhere to section 5.9 of your “Stability Design” SOP in that you did not establish a protocol for each drug product stating the parameters of a stability study including storage conditions, length of the study, testing time intervals, and the total number of samples to be tested. Manufacturer and Own Label Distributor 9/16/2024(Mon), 9/17/2024(Tue), 9/18/2024(Wed), 9/20/2024(Fr1)

[Guidance · FDA]Hematology and Pathology Devices; Reclassification of Immuno… — Proposed reclassification of IHC test systems
FDAGuidance

Proposal to reclassify immunohistochemistry tests used with approved oncology drugs

FDA proposed reclassifying immunohistochemistry test systems indicated for use with a corresponding approved oncology therapeutic product.

Published 2026-11-12 · Document no. 2026-23005 · Issuing authority FDA · Topic Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test…

Original text and translation
The Food and Drug Administration (FDA) is proposing to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SE…
Key facts · Basis: official source record kept by the collector
  • What changes: Proposed reclassification of these test systems, currently postamendments class III devices
  • Applies to: Test systems under product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER and SHF
[Regulatory news · PIC/S]Revision of the PIC Scheme (PIC/S 1/95 (Rev. 7)) — Revised PIC Scheme adopted and in force
PIC/SGMP News

The PIC/S Committee adopted the revised Pharmaceutical Inspection Co-operation Scheme (PIC/S 1/95 (Rev. 7)) at its 2026-11-02 meeting in Istanbul, Türkiye; it entered into force the same day.

Published 2026-11-12 · Issuing authority PIC/S

Key facts · Basis: official index plus supporting sources
  • What changes: The scheme document is revised to PIC/S 1/95 (Rev. 7)
  • Applies to: The Pharmaceutical Inspection Co-operation Scheme (PIC Scheme)
  • Effective date: 2026-11-02 (in force on adoption)

Korea 13 cards

GMP inspection
[GMP inspection · MFDS]ABIOGEN PHARMA S.p.A — Three findings on media, data, equipment
MFDS💊 Small moleculeGMP inspection

Inspectors required proper records of how culture media are managed

MFDS completed a post-approval GMP inspection of ABIOGEN PHARMA S.p.A's finished-product site in Italy and issued three deficiencies, all rated other.

Published 2026-11-10 · Inspection period 2026-05-19~2026-05-21

Other 3
Original text
평가 결과: 지적(보완)사항(Deficiencies) 있음 분야1) 구분2) 근거 법령 지적(보완)사항 요약 비고 시험실 기타 [별표 1] 제7.1호 배지에 대한 관리상황을 적절히 기록할 것 시험실 기타 [별표 1] 제7.1호 시험 판정에 대한 데이터 완전성 보완 대책 등을 마련할 것 시설장비 기타 [별표 1] 제2.1호 제조설비의 운전 적격성평가를 적절히 수행할 것 1) GMP 감시 분야(6개): 품질, 시설장비, 제조, 시험실, 원자재, 포…
Key facts · Basis: official source record kept by the collector
  • Finding 1: Properly record the management status of culture media (laboratory, other, [별표 1] item 7.1)
  • Finding 2: Establish measures to strengthen data integrity of test result decisions (laboratory, other, [별표 1] item 7.1)
  • Finding 3: Properly perform operational qualification of manufacturing equipment (facilities and equipment, other, [별표 1] item 2.1)
  • Outcome: Deficiencies found — 3 rated other
Check points
  • Do you keep records of the management status of culture media used in the laboratory? (Finding 1)
  • Are measures in place to strengthen data integrity of test result decisions? (Finding 2)
  • Has operational qualification been performed and documented for manufacturing equipment? (Finding 3)
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
At a glance 1 item · MFDS 1
Cosma S.P.ACosma S.P.A 외 3곳GMP inspections with no findings (4)—2026-11-10
[GMP inspection · MFDS]Cosma S.P.A 외 3곳 — GMP inspections with no findings (4)
Evidence AMFDSSignal Med · T2GMP inspection

MFDS published 4 GMP inspection results with no deficiencies raised. The sites and inspection dates are listed on this card.

Published2026-11-10
Document no.gmpinspect-1Q73JiEyqbl
SiteCosma S.P.A
Inspection period2026-05-12~2026-05-14
All 4 items
  • Cosma S.P.A · 2026-05-12~2026-05-14
  • Shilpa Pharma Lifesciences Limited Unit-2 · 2026-05-19~2026-05-21
  • Intas Pharmaceuticals Ltd. · 2026-05-19~2026-05-21
  • A. Menarini Manufacturing Logistics and Services s.r.l. · 2026-05-12~2026-05-14
Key facts · Basis: official source record kept by the collector
  • Count: 4 inspections with no deficiencies raised
  • Source: MFDS published GMP inspection results
Administrative action
[Administrative action · MFDS](주)휴온스 — Late narcotics handling reports
MFDSAdministrative action

Narcotics acquisitions, manufacture and sales were not reported within the deadline

MFDS suspended a domestic narcotics manufacturer's business for 3 days for failing to report narcotics handling records, and changes to them, within the reporting deadlines.

Published 2026-11-13 · Action (마약류제조업자) 업무정지 3일(2026. 11. 23. ~ 25.)

Shown in the original Korean: 1 value in this table.

Original text
○ 마약류 관리에 관한 법률」 제11조 및 같은 법 시행규칙 제21조에 따라 마약류 취급자는 마약류의 제조·판매 등 취급내역을 마약류통합시스템을 통해 기한 내 식품의약품안전처장에게 보고 및 변경 보고하여야 하나, - (삼응)_Zopiclone R-Isomer_(10mg), (식약처_표준품)_MFDS N-17-001_디에틸프로피온염산염_(100mg), (휴온스)_Eszopiclone_(원료)_(수입)_(시험연구용)_(1g), (휴온스)_펜…
Key facts · Basis: official source record kept by the collector
  • Violation: acquisitions, manufacture and sales of narcotics including zopiclone R-isomer, eszopiclone raw material, phentermine hydrochloride and a ketamine hydrochloride 50 mg/mL injection were not reported to the integrated narcotics system within the reporting or change-reporting deadlines
  • Sanction: 3-day business suspension as a narcotics manufacturer (2026-11-23 to 25)
  • Basis: violation of Article 11 of the Narcotics Control Act and Article 21 of its Enforcement Rule; sanction under [Annex 2] II, individual criteria item 9-d of the Enforcement Rule
More from the source · as stated in the source

Items reported late included an MFDS reference standard and an imported raw material for research testing.

Check points
  • Is the reporting date in the integrated narcotics system checked against the deadline for each acquisition, manufacture and sale?
  • Are research-use raw materials and reference standards managed under the same reporting procedure as products?
[Administrative action · MFDS]제이더블유중외제약(주) — Investigational product GMP violations
MFDSAdministrative action

Failure to follow written standards and investigational drug manufacturing rules

MFDS suspended a domestic pharmaceutical company's work on the clinical trial concerned for 1 month (first offense) for failing to follow its written standards and violating manufacturing and quality control standards for investigational drugs.

Published 2026-11-09 · Action 해당 임상시험 업무정지 1개월(2026.11.9.~2026.12.8.), 1차

Shown in the original Korean: 1 value in this table.

Original text
① 기준서 미준수 ② 임상시험용의약품 제조 및 품질관리기준 위반
Key facts · Basis: official source record kept by the collector
  • Violation: (1) non-compliance with written standards (2) violation of manufacturing and quality control standards for investigational drugs
  • Sanction: 1-month suspension of work on the clinical trial concerned (2026-11-09 to 2026-12-08), first offense
  • Basis: violation of Article 34(3)2 of the Pharmaceutical Affairs Act and Article 30(1)9 of the Rules on Safety of Pharmaceuticals; sanction under Article 76(1)3 of the Act, Article 95 of the Rules and [Annex 8] II, individual criteria item 15-e-4) and 15-e-6)
More from the source · as stated in the source

Two sub-items of individual criteria item 15-e in [Annex 8], 4) and 6), were applied together as the basis for the sanction.

Check points
  • Is consistency between the company's written standards and actual investigational drug manufacturing checked periodically?
  • Are investigational drug manufacturing and quality control requirements included as separate items in self-inspections?
[Administrative action · MFDS](주)안트로젠 — Unreported clinical trial plan changes
MFDSAdministrative action

Changes to the clinical trial plan were not reported or were reported late

MFDS suspended a domestic biotech company's work on the clinical trial concerned for 1 month (first offense) for unreported and late-reported protocol changes, investigational drug labeling violations, and clinical trial quality assurance and data quality control violations.

Published 2026-11-09 · Action 해당 임상시험 업무정지 1개월(2026.11.9.~2026.12.8.), 1차

Shown in the original Korean: 1 value in this table.

Original text
① 임상시험계획 변경 미보고 및 지연 보고 ② 임상시험용 의약품 표시기재 위반 ③ 임상시험 품질보증 및 임상시험자료 품질관리 위반
Key facts · Basis: official source record kept by the collector
  • Violation: (1) unreported and late-reported changes to the clinical trial plan (2) labeling violations for the investigational drug (3) violations of clinical trial quality assurance and trial data quality control
  • Sanction: 1-month suspension of work on the clinical trial concerned (2026-11-09 to 2026-12-08), first offense
  • Basis: violation of Article 34(1) and (3)2 of the Pharmaceutical Affairs Act and Article 24(5)1-2 and Article 30(1)9 of the Rules on Safety of Pharmaceuticals; sanction under Article 76(1)3 of the Act, Article 95 of the Rules and [Annex 8] II, individual criteria items 10-b, 15-e-5) and 16-f
More from the source · as stated in the source

Individual criteria items 10-b, 15-e-5) and 16-f of [Annex 8] were applied together for the three violations.

Check points
  • Is there a log tracking each clinical trial plan change by reporting requirement and deadline?
  • Is investigational drug label text checked against the requirements and approved before packaging?
[Administrative action · MFDS]재단법인아산사회복지재단서울아산병원 — Breach of informed consent procedures
MFDSAdministrative action

Procedures for obtaining consent from trial subjects were violated

MFDS suspended clinical trial work on the product concerned at a hospital trial site for 3 months and ordered a change of the principal investigator (first offense) for violating informed consent procedures for trial subjects.

Published 2026-11-09 · Action 해당 품목 임상시험 업무정지 3개월(2026.11.9.~2027.2.8.)과 임상시험 책임자 변경(1차)

Shown in the original Korean: 1 value in this table.

Original text
임상시험 대상자의 동의 절차 위반
Key facts · Basis: official source record kept by the collector
  • Violation: breach of consent procedures for clinical trial subjects
  • Sanction: 3-month suspension of clinical trial work on the product concerned (2026-11-09 to 2027-02-08) and change of principal investigator, first offense
  • Basis: violation of Article 34-2(3)3 of the Pharmaceutical Affairs Act and Article 30(1)4 of the Rules on Safety of Pharmaceuticals; sanction under Article 76-2(1)4 and 76-2(3) of the Act, Article 95 of the Rules and [Annex 8] II, individual criteria item 15-b
More from the source · as stated in the source

The sanction included replacing the principal investigator in addition to the work suspension.

Check points
  • Is the informed consent process checked before each subject is enrolled?
  • Is there a procedure to review the subject's data and trial conduct immediately when a consent breach is found?
[Administrative action · MFDS](주)녹원유통사업단 — Self-inspection not performed as required
MFDSAdministrative action

No self-inspection record up to the routine GMP inspection despite an annual rule

MFDS suspended all manufacturing at a domestic company for 1 month for failing to follow the self-inspection provision of its own written standards.

Published 2026-11-09 · Action ○ 전(全) 제조업무정지 1개월(2026. 11. 11. ~ 2026. 12. 10.)

Shown in the original Korean: 1 value in this table.

Original text
-자사 기준서 자율점검 관리규정에 ‘정기 점검은 원칙적으로 연 1회 실시하는 것으로 한다’라고 규정하고 있으나, GMP 정기감시일까지 자율점검을 실시한 이력이 없어 자사 기준서를 미준수한 사실이 있음
Key facts · Basis: official source record kept by the collector
  • Violation: the company's self-inspection rules called for a routine inspection once a year in principle, but there was no record of any self-inspection up to the date of the routine GMP inspection
  • Sanction: 1-month suspension of all manufacturing (2026-11-11 to 2026-12-10)
  • Basis: violation of Article 38(1) of the Pharmaceutical Affairs Act and Article 48-9-f of the Rules on Safety of Pharmaceuticals; sanction under Article 76 of the Act, Article 95 of the Rules and [Annex 8] I, general criteria item 6 and II, individual criteria item 25-c-3)
More from the source · as stated in the source

The suspension applies to all of the company's manufacturing rather than a single product.

Check points
  • Are self-inspections performed at the frequency set in the self-inspection rules, with records kept?
  • Is the planned self-inspection frequency compared with actual inspection dates at least once a year?
[Administrative action · MFDS]풍산주식회사 — Herbal product failed test specifications
MFDS▫️ OtherAdministrative action

Test results for the herbal medicine product did not meet specifications

MFDS suspended manufacturing of one herbal medicine product (product license No. 70) by a domestic manufacturer for 3 months because its test results did not meet specifications.

Published 2026-11-03 · Action 해당 품목 제조업무 정지 3개월(2026. 11. 18. ~ 2027. 02. 17.) 해당 품목: 풍산골쇄보(품목허가번호 : 제70호)

Shown in the original Korean: 1 value in this table.

Original text
해당 한약재 또는 한약제제의 시험 결과가 기준에 부적합 해당 품목: 풍산골쇄보(품목허가번호 : 제70호)
Key facts · Basis: official source record kept by the collector
  • Violation: test results for the herbal medicine material or preparation did not meet specifications
  • Sanction: 3-month suspension of manufacturing for the product concerned (2026-11-18 to 2027-02-17)
  • Basis: violation of Article 62 of the Pharmaceutical Affairs Act; sanction under Article 76 of the Act and Article 95 [Annex 8] II, individual criteria item 39-d-11) of the Rules on Safety of Pharmaceuticals
Check points
  • Are all items of each herbal material's test specification tested, with release only after a passing result?
  • Is there a procedure to quarantine and block release of herbal material lots whose test results fail specifications?
[Administrative action · MFDS]주식회사퓨어마인드농업회사법인 — Herbal materials failed cadmium limit
MFDS▫️ OtherAdministrative action

MFDS suspended manufacturing of three herbal medicine materials made by a domestic agricultural company for 3 months after market-sample testing found cadmium above the specification.

Published 2026-11-03 · Action 해당품목* 제조업무 정지 3개월(2026.11.18. ~ 2027.02.17.) 퓨어마인드곡기생(품목허가번호 : 제231호) 퓨어마인드절패모(품목허가번호 : 제128호) 퓨어마인드해방풍(품목허가번호 : 제138호)

Shown in the original Korean: 1 value in this table.

Original text
한약재 또는 한약제제의 시험 결과가 기준에 부적합 수거검사결과 : 카드뮴(ppm) 부적합 퓨어마인드곡기생(시험∙검사 기준 0.3이하 /결과 0.5) 퓨어마인드절패모(시험∙검사 기준 0.3이하 /결과 0.7) 퓨어마인드해방풍(시험∙검사기준 0.3이하 /결과 0.6)
Key facts · Basis: official source record kept by the collector
  • Violation: test results for herbal medicine materials did not meet specifications (cadmium in market samples)
  • Timeline: against a cadmium limit of 0.3 ppm or less, the three products tested 0.5, 0.7 and 0.6
  • Sanction: 3-month suspension of manufacturing for the products concerned (2026-11-18 to 2027-02-17)
  • Basis: violation of Article 62 of the Pharmaceutical Affairs Act; sanction under Article 76 of the Act and Article 95 [Annex 8] II, individual criteria item 39-d-11) of the Rules on Safety of Pharmaceuticals
More from the source · as stated in the source

The sanction is limited to the products under product license Nos. 231, 128 and 138.

Check points
  • Is cadmium and other heavy metal testing performed on every incoming lot of herbal raw material?
  • Is there a trigger to re-evaluate a supplier when heavy metal results approach the upper limit?
[Administrative action · MFDS](주)한수산 — Manufactured differently from notified method
MFDS▫️ OtherAdministrative action

Product made with an immediate container differing from the notification was shipped

MFDS suspended manufacturing of a bear bile herbal material by a domestic company for 1 month for shipping product made with a manufacturing method different from what was notified.

Published 2026-10-27 · Action ○ 해당 품목 제조업무정지 1개월(2026. 11. 17. ~ 2026. 12. 16.) - 해당 품목: ‘한수산웅담’

Shown in the original Korean: 1 value in this table.

Original text
- 제조 한약재 ‘한수산웅담’의 신고한 사항 중 신고사항과 다른 제조방법(직접 포장용기)으로 제조한 제품을 출하한 사실이 있음.
Key facts · Basis: official source record kept by the collector
  • Violation: shipped product manufactured with a method (immediate packaging container) different from the notified particulars
  • Sanction: 1-month suspension of manufacturing for the product concerned (2026-11-17 to 2026-12-16)
  • Basis: violation of Article 31(9) of the Pharmaceutical Affairs Act and Article 8(1) of the Rules on Safety of Pharmaceuticals; sanction under Article 76 of the Act, Article 95 of the Rules and [Annex 8] I, general criteria item 6 and II, individual criteria item 5-d
Check points
  • Does change control assess whether a change of immediate container requires a change to the notification?
  • Is the container actually used checked against the notified particulars before release?
[Administrative action · MFDS]대한약품공업(주) — Unreported psychotropic handling records
MFDSAdministrative action

MFDS issued a warning to a domestic narcotics manufacturer for failing to report 116 psychotropic drug handling records within the reporting deadline.

Published 2026-11-13 · Action (마약류제조업자) 경고

Shown in the original Korean: 1 value in this table.

Original text
○ 「마약류 관리에 관한 법률」 제11조 및 같은 법 시행규칙 제21조에 따라 마약류취급자는 마약류의 수출입․제조․판매․양수․양도․구입․사용․폐기등 모든 취급내역을 마약류통합관리시스템을 통해 보고기한 내 식품의약품안전처장에게 보고하여야 함에도 불구하고, - 동 업체는 향정신성의약품'‘(식약처_표준품)_MFDS 12-18 프로포폴(100mg)'등 116 건의 취급내역을 보고기한 내 보고하지 않은 사실이 있음
Key facts · Basis: official source record kept by the collector
  • Violation: 116 handling records, including an MFDS propofol reference standard (100mg), were not reported to the integrated narcotics management system within the deadline
  • Sanction: warning (as a narcotics manufacturer)
  • Basis: violation of Article 11 of the Narcotics Control Act and Article 21 of its Enforcement Rule; sanction under [Annex 2] II, individual criteria item 9-d of the Enforcement Rule
More from the source · as stated in the source

The reporting duty covers all narcotics handling, including import, export, manufacture, sale, transfer, purchase, use and disposal.

Check points
  • Are use and disposal records for psychotropic drugs, including reference standards, reported within the deadline?
  • Is the count of unreported handling records reviewed monthly and cleared before deadlines pass?
[Administrative action · MFDS](주)종근당 — Late narcotics handling reports
MFDSAdministrative action

Late reports under the raw material user, manufacturer and importer-exporter roles

MFDS issued a warning to a domestic pharmaceutical company, as a narcotics raw material user, manufacturer and importer-exporter, for failing to report narcotics handling records within the reporting and change-reporting deadlines.

Published 2026-11-13 · Action (마약류원료사용자, 마약류제조업자, 마약류수출입업자) 경고

Shown in the original Korean: 1 value in this table.

Original text
○ 「마약류 관리에 관한 법률」 제11조 및 같은 법 시행규칙 제21조에 따라 마약류 취급자는 마약류의 제조·판매 등 취급내역을 마약류통합시스템을 통해 식품의약품안전처장에게 보고하여야 하나, - (마약류원료사용자) (종근당)_디히드로코데인타르타르산염_(1g), 원풍덱스트로메토르판 브롬화수소산염수화물 (원료)(수입)_(25kg), 삼응)_삼응디히드로코데인주석산염_(원료)_(수입)_(5kg), 파일덱스트로메토르판 브롬화수소산염수화물 (원료…
Key facts · Basis: official source record kept by the collector
  • Violation: use of dihydrocodeine tartrate and dextromethorphan hydrobromide raw materials (raw material user), purchase, manufacture and use of etizolam and others (manufacturer), and transfer, use and sale of etomidate, clonazepam and others (importer-exporter) were not reported within the reporting and change-reporting deadlines
  • Sanction: warning (as narcotics raw material user, manufacturer and importer-exporter)
  • Basis: violation of Article 11 of the Narcotics Control Act and Article 21 of its Enforcement Rule; sanction under [Annex 2] II, individual criteria item 9-d of the Enforcement Rule
More from the source · as stated in the source

Late reports spanned imported raw materials, bulk materials, finished tablets and a reference standard.

Check points
  • Are reporting dates checked against deadlines for use, manufacture and sale under each narcotics license role?
  • Is use of imported and bulk raw materials reported to the integrated narcotics system on the same schedule as finished products?
[Administrative action · MFDS]비오신코리아(주) — Late reporting of drug supply records
MFDS💊 Small moleculeAdministrative action

Supply of an injection was not reported at shipment as required

MFDS suspended sales of a sodium selenite injection by a domestic supplier for 10 days for failing to report its 2026 first-quarter supply records on time.

Published 2026-11-10 · Action ○ 해당 품목* 판매업무정지 10일(2026. 11. 24. ~ 2026. 12. 3.) * 해당 품목: 셀레나제티프로주사(품목기준코드: 200610824) ※ 보고기한이 지난 날부터 1개월 이내 공급내역을 보고한 경우로 Ⅰ. 일반기준 제12호 하목에 따라 감경

Shown in the original Korean: 1 value in this table.

Original text
○ 의약품 공급내역 기한 내 미보고 - 의약품공급자는 「약사법」 제47조의3제2항 및 같은 법 시행규칙 제45조에 따라 완제의약품을 공급하는 경우 제품을 출하할 때 의약품관리종합정보센터의 장에게 보고하여야 하나, 동 업체는 2026년 1분기‘셀레나제티프로주사’의 공급내역을 기한 내* 보고하지 아니한 사실이 있음 * 출하일자: 2026. 2. 11., 보고일자: 2026. 2. 13.
Key facts · Basis: official source record kept by the collector
  • Violation: supply of finished drugs must be reported to the national drug information management center at shipment, but the product's 2026 first-quarter supply records were not reported on time
  • Timeline: shipped 2026-02-11, reported 2026-02-13
  • Sanction: 10-day suspension of sales for the product concerned (2026-11-24 to 2026-12-03)
  • Basis: violation of Article 47-3(2) of the Pharmaceutical Affairs Act and Article 45 of its Enforcement Rule; sanction under Article 76 of the Act, Article 95 of the Rules on Safety of Pharmaceuticals and [Annex 8] I, general criteria item 12-p and II, individual criteria item 36
More from the source · as stated in the source

The sanction was reduced under general criteria item 12-p because the supply records were reported within 1 month after the deadline.

Check points
  • Is the supply report date checked against the shipment date for every finished drug shipment?
  • Is there a follow-up procedure to complete any missed or late supply report within 1 month?

Recall 18 cards

[Recall / sales suspension · MFDS](주)에이프로젠바이오로직스 — Recall over pH failure in stability testing
MFDS💊 Small moleculeRecall

Oral solution recalled by the company after a pH failure in stability testing

An oral solution product was recalled after one stability test item (pH) failed specification (voluntary company recall).

Published 2026-11-12 · Product 이지롱내복액

Original text
안정성시험 일부 항목(pH) 기준일탈로 인한 영업자 회수
Key facts · Basis: official source record kept by the collector
  • Reason: One stability test item (pH) out of specification
  • Product and scope: One oral solution product
  • Type: Voluntary company recall
Check points
  • Do you measure and trend pH of oral solutions at every stability time point?
  • When pH fails in stability testing, do you assess the impact on other marketed lots of the same formulation?
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS]동성제약(주) — Recall over assay failure in stability testing
MFDS💊 Small moleculeRecall

Recalled by the company after a scopolamine assay failure in stability testing

A liquid product containing scopolamine hydrobromide hydrate was recalled after one stability test item (scopolamine hydrobromide hydrate assay) failed specification (voluntary company recall).

Published 2026-11-11 · Product 토스롱에스액

Original text
안정성 시험 일부 항목 (스코폴라민브롬화수소산염수화물 함량) 기준일탈로 인한 영업자 회수
Key facts · Basis: official source record kept by the collector
  • Reason: One stability test item (scopolamine hydrobromide hydrate assay) out of specification
  • Product and scope: One liquid product
  • Type: Voluntary company recall
Check points
  • Do you trend the scopolamine hydrobromide hydrate assay across stability time points?
  • Is there a procedure for deciding whether marketed lots must be recalled when a stability assay fails?
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall (Health Canada) · Health Canada]Pendopharm Division of Pharmascience Inc. — Recall over possible foreign matter
Health CanadaRecall

Affected nasal gel lot may contain foreign matter

Pendopharm's SECARIS NASAL GEL (macrogol 15%, propylene glycol 20%) was recalled for contamination because the affected lot may contain foreign matter (Type II).

Published 2026-11-13 · Document no. hc-82939 · Brand Pendopharm · Product SECARIS NASAL GEL · Type II

Original text and translation
Contamination
Key facts · Basis: official source record kept by the collector
  • Reason: Contamination — affected lot may contain foreign matter
  • Product and scope: SECARIS NASAL GEL (macrogol 15%, propylene glycol 20%)
  • Action: Consumers are told to verify whether their product is affected and consult a healthcare provider before stopping use or for any health concerns
Recall detail · From the source · Health Canada
Active ingredient · Macrogol 15% / w/w; Propylene glycol 20 % / w/wDosage form · Gel
What you should do
Original · Health Canada

Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada.

[Recall (Health Canada) · Health Canada]Pendopharm Division of Pharmascience Inc. — Recall over impurity out of specification
Health Canada💊 Small moleculeRecall

Diphenhydramine capsules recalled over an out-of-specification impurity

Pendopharm's PDP-DIPHENHYDRAMINE 25 mg and 50 mg capsules were recalled over an out-of-specification impurity result (Type II).

Published 2026-11-09 · Document no. hc-82928 · Brand Pendopharm · Product PDP-DIPHENHYDRAMINE · Type II

Original text and translation
Product quality
Key facts · Basis: official source record kept by the collector
  • Reason: Product quality — out-of-specification (impurity)
  • Product and scope: PDP-DIPHENHYDRAMINE 25 mg and 50 mg capsules
  • Action: Consumers are told to verify whether their product is affected and consult a healthcare provider before stopping use or for any health concerns
Recall detail · From the source · Health Canada
Active ingredient · 25 MGDosage form · Capsule
What you should do
Original · Health Canada

Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada.

[Recall · FDA]Huons Co., Ltd. — Eye drop recall over impurity failure
FDARecall

Polyethylene-related oligomers detected in single-use eye drops

Carboxymethylcellulose sodium 0.5% eye drops made by Huons Co., Ltd. in Jecheon, Korea were recalled for an impurities/degradation failure and detection of polyethylene-related oligomers (Class II, voluntary firm recall).

Published 2026-11-04 · Document no. D-0080-2027 · Product Carboxymethylcellulose Sodium, 0.5% Lubricant Eye Drops, Sterile, 30 Single-Use… · Class II

Original text and translation
Failed Impurities/Degradation Specification; detection of polyethylene (PE)-related oligomers
Key facts · Basis: official source record kept by the collector
  • Reason: Failed Impurities/Degradation Specification; detection of polyethylene-related oligomers
  • Product and scope: Carboxymethylcellulose sodium 0.5% eye drops, 30 single-use 0.5 mL containers, lots 2EQH501 to 2EQH513, 6,633,570 tubes, distributed nationwide in the U.S.
  • Action: Voluntary firm recall notified through two or more channels (initiated 2026-10-02)
More from the source · as stated in the source

The product was manufactured by Huons Co., Ltd. and marketed in the U.S. by GSMS Incorporated.

Check points
  • Does your impurity method separate and detect oligomers from the polyethylene of single-use eye drop containers?
  • Are substances leaching from the container material included in your stability test items?
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Status
Recall initiated · 2026-10-02FDA classification · 2026-10-26FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot: 2EQH501, Exp. 3/12/2027; 2EQH502, 2EQH503, 2EQH504, 2EQH505, Exp. 3/16/2027; 2EQH506, 2EQH507, Exp. 5/22/2027; 2EQH508, Exp. 5/26/2027; 2EQH509, Exp. 5/27/2027; 2EQH510, 2EQH511, 2EQH512, 2EQH513, Exp. 10/13/2028.

Recall size and scope

Quantity — 6,633,570 tubes

Distribution — Nationwide within U.S.

Company location — Jecheon, Korea (the Republic of)

[Recall · FDA]Meitheal Pharmaceuticals, Inc Vecuronium Bromide for Injecti… — Recall over missing warning or Rx legend
Evidence AFDASignal Med · T2💊 Small moleculeRecall

Vecuronium for injection labels lacked a warning or prescription legend

Vecuronium bromide for injection single-dose vials, 2 products in total, were recalled together because the label lacked a warning or Rx legend (Class III, voluntary firm recall).

Published2026-11-04
Document no.D-0108-2027
CompaniesMeitheal Pharmaceuticals, Inc
ProductVecuronium Bromide for Injection, 10mg, 10 Single-Dose Vials per carton, Sterile, Rx Only, Mfd. for Meitheal Pharmaceuticals, Chicago, IL. NDC: 71288-744-11 외 1품목
ClassClass III
All 2 products
  • Vecuronium Bromide for Injection, 10mg, 10 Single-Dose Vials per carton, Sterile, Rx Only, Mfd. for Meitheal Pharmaceuticals, Chicago, IL. NDC: 71288-744-11
  • Vecuronium Bromide for Injection, 20mg, 10 Single-Dose Vials per carton, Sterile, Rx Only, Mfd. for Meitheal Pharmaceuticals, Chicago, IL. NDC: 71288-745-21
Original text and translation · representative case
Labeling: Label Lacks Warning or Rx Legend
Key facts · Basis: official source record kept by the collector
  • Reason: Labeling: Label Lacks Warning or Rx Legend
  • Product and scope: 2 vecuronium bromide for injection single-dose vial products recalled for the same reason, 121,800 vials, distributed nationwide in the U.S.
  • Class: Class III
  • Action: Voluntary firm recall notified by letter (initiated 2026-10-08)
Check points
  • During label approval, do you check the warning and Rx legend line by line against the approved text?
  • Does incoming inspection of packaging materials include a check for missing warning text?
Recall detail · From the source · OpenFDA · Based on the representative product

This card groups 2 products into one entry. All values below refer to one representative product (including lots, quantity, and status).

Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-10-08FDA classification · 2026-10-29FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot# T1P0213A: Exp. 30-Apr-29 Lot# T1P0313A: Exp. 30-Apr-29 Lot# T1P0412A: Exp. 30-Sep-28 Lot# T1P0413A: Exp. 30-Apr-29 Lot# T1P0512A: Exp. 30-Sep-28 Lot# T1P0513A: Exp. 30-Apr-29

Recall size and scope

Quantity — 121,800 vials

Distribution — US. Nationwide

Company location — Chicago, IL, United States

Product identification

Brand name — VECURONIUM BROMIDE

Generic name — VECURONIUM BROMIDE

Route of administration — INTRAVENOUS

Application number — ANDA074688

[Recall · FDA]Brandywine Pharmaceuticals, LLC Theophylline Extended-Releas… — Recall over halted outsourced stability testing
Evidence AFDASignal Med · T2💊 Small moleculeRecall

Two products recalled after ongoing stability testing at a third-party lab was interrupted

Two theophylline extended-release tablet products were recalled together after the ongoing stability testing program at a third-party laboratory was interrupted (CGMP deviations; Class II, voluntary firm recall).

Published2026-11-04
Document no.D-0110-2027
CompaniesBrandywine Pharmaceuticals, LLC
ProductTheophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10 외 1품목
ClassClass II
All 2 products
  • Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10
  • Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.
Original text and translation · representative case
CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
Key facts · Basis: official source record kept by the collector
  • Reason: CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
  • Product and scope: 2 theophylline extended-release tablet products in 100-count bottles recalled for the same reason; lead product lot 405617, 1,620 bottles, distributed nationwide in the U.S.
  • Class: Class II
  • Action: Voluntary firm recall notified through two or more channels (initiated 2026-10-06)
Check points
  • Do you regularly track the time-point progress of ongoing stability studies outsourced to a contract laboratory?
  • Is there a procedure to transfer and continue stability testing at another laboratory if a contract laboratory stops testing?
Recall detail · From the source · OpenFDA · Based on the representative product

This card groups 2 products into one entry. All values below refer to one representative product (including lots, quantity, and status).

Status · OngoingVoluntary: Firm initiatedFirst notified · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Status
Recall initiated · 2026-10-06FDA classification · 2026-10-29FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot: 405617, Expiry: 03/31/2028

Recall size and scope

Quantity — 1,620 100-count bottles

Distribution — Nationwide within U.S

Company location — West Chester, PA, United States

At a glance 11 items · MFDS 1 · MHRA 1 · FDA 9
(주)한국파마파마레바미피드정possible foreign matter contaminationVoluntary recall2026-11-12
[Recall / sales suspension · MFDS](주)한국파마 — Recall over possible foreign matter
MFDS💊 Small moleculeRecall

A rebamipide tablet product was recalled over possible contamination with foreign matter (voluntary company recall).

Published 2026-11-12 · Product 파마레바미피드정

Original text
이물 혼입 우려에 따른 영업자 회수
Key facts · Basis: official source record kept by the collector
  • Reason: possible foreign matter contamination
  • Product and scope: one rebamipide tablet product
  • Type: voluntary company recall
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
Star Pharmaceuticals LtdClass 4 Medicines Defect Notification: Star Pharmaceuticals…Strength misprint on carton frontClass 42026-11-12
[Recall (UK) · MHRA]Class 4 Medicines Defect Notification: Star Pharmaceuticals… — Strength misprint on carton front
MHRA💊 Small moleculeRecall

Typographical error in the hydrochlorothiazide strength on the carton front

Star Pharmaceuticals Ltd's enalapril maleate/hydrochlorothiazide 20 mg/12.5 mg tablets became the subject of an MHRA Class 4 medicines defect notification over a strength misprint on the carton front.

Published 2026-11-12 · Class 4 · Star Pharmaceuticals Ltd

Original text and translation
①Star Pharmaceuticals Limited have informed the MHRA of a typographical error on the strength of hydrochlorothiazide printed on the front face of the carton which incorrectly states “12.
②mg” instead of “12.5 mg”.
Key facts · Basis: official source record kept by the collector
  • Reason: Carton front states the hydrochlorothiazide strength as “12. mg” instead of “12.5 mg”
  • Product and scope: Enalapril maleate/hydrochlorothiazide 20 mg/12.5 mg tablets (PLPI: 20636/1651), batches Y018198, Y019635, C125483 and C135541, 1740 packs distributed in the UK
  • Action: Healthcare professionals continue to dispense; patients continue to take the medicine as prescribed
Recall detail · From the source · MHRA
Full alert (Drug Alert)
Original · MHRA

DMRC reference number DMRC-41407584 Marketing Authorisation Holder Star Pharmaceuticals Ltd Medicine Details Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets PLPI: 20636/1651 Active ingredient: enalapril maleate / hydrochlorothiazide GTIN: 05050114165107 Affected Lot Batch Numbers Batch No. Expiry Date Pack Size First Distributed Y018198 30/06/2027 28 22/09/2026 Y019635 31/10/2027 28 05/12/2025 C125483 29/02/2028 28 05/03/2026 C135541 30/11/2028 28 08/06/2026 Background Star Pharmaceuticals Limited have informed the MHRA of a typographical error on the strength of hydrochlorothiazide printed on the front face of the carton which incorrectly states “12. mg” instead of “12.5 mg”. The strength is correctly presented on all other faces of the carton, the leaflet and the blister foil. The volume of affected stock distributed to the UK market is 1740 packs. Advice for Healthcare Professionals: Healthcare professionals are asked to note the information in this notification and should continue to dispense this product; the quality of the tablets is not impacted by this labelling defect. The risk associated with the labelling error is considered low because no corresponding strengths of the enalapril maleate / hydrochlorothiazide combination where the hydrochlorothiazide strength is expressed as 12 mg exist. Healthcare professionals are advised to reassure patients, if contacted, that the product is enalapril maleate 20 mg / hydrochlorothiazide 12.5 mg tablets as described in the Patient Information Leaflet. Advice for Healthcare Professionals to Provide to Patients: Patients should continue to take this medication as prescribed. This does not affect the quality of the tablets. If you are unsure or have any questions, please seek advice from your pharmacy or other healthcare professionals involved in your treatment. Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme . Additional information: For all medical information enquiries and information on this product, please email [email protected] or telephone 020 8423 2111. Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information. Yours faithfully Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU Telephone +44 (0)20 3080 6574 [email protected] Download document Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48

The Ritedose CorporationFormoterol Fumarate Inhalation Solution, 20mcg/2mL, package…Failed Impurities/Degradation SpecificationClass II2026-11-04
[Recall · FDA]The Ritedose Corporation — Recall over impurity/degradant failure
FDA💊 Small moleculeRecall

Formoterol inhalation solution recalled over an impurity specification failure

Formoterol fumarate inhalation solution 20mcg/2mL was recalled for failing its impurities/degradation specification (Class II, voluntary firm recall).

Published 2026-11-04 · Document no. D-0073-2027 · Product Formoterol Fumarate Inhalation Solution, 20mcg/2mL, packaged in cartons of 30 in… · Class II

Original text and translation
Failed Impurities/Degradation Specification
Key facts · Basis: official source record kept by the collector
  • Reason: Failed Impurities/Degradation Specification
  • Product and scope: Formoterol fumarate inhalation solution 20mcg/2mL, lot 25BL0, 3210 cartons, distributed nationwide in the U.S.
  • Action: Voluntary firm recall notified by letter (initiated 2026-10-15)
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-10-15FDA classification · 2026-10-23FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot: 25BL0, Expires: 02/28/2027

Recall size and scope

Quantity — 3210 Cartons

Distribution — Nationwide within the U.S

Company location — Columbia, SC, United States

Product identification

Brand name — FORMOTEROL FUMARATE INHALATION SOLUTION

Generic name — FORMOTEROL FUMARATE DIHYDRATE

Active ingredient — FORMOTEROL FUMARATE

Route of administration — RESPIRATORY (INHALATION)

Application number — ANDA216486

Glenmark Pharmaceuticals Inc., USAAbiraterone Acetate Tablets USP 500 mg, 60-count bottles, R…Labeling: Not Elsewhere ClassifiedClass II2026-11-04
[Recall · FDA]Glenmark Pharmaceuticals Inc., USA — Recall over a labeling defect
FDA💊 Small moleculeRecall

Abiraterone acetate tablets recalled by the firm over a labeling issue

Abiraterone acetate tablets 500 mg (60-count bottles) were recalled over a labeling issue (Class II, voluntary firm recall).

Published 2026-11-04 · Document no. D-0074-2027 · Product Abiraterone Acetate Tablets USP 500 mg, 60-count bottles, Rx only, Distributed b… · Class II

Original text and translation
Labeling: Not Elsewhere Classified
Key facts · Basis: official source record kept by the collector
  • Reason: Labeling: Not Elsewhere Classified
  • Product and scope: Abiraterone acetate tablets 500 mg, 60-count bottles, lot 13250135, 1296 bottles, distributed nationwide in the U.S.
  • Action: Voluntary firm recall (initiated 2026-10-09)
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiated
Status
Recall initiated · 2026-10-09FDA classification · 2026-10-23FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot #: 13250135, Exp. Date 11/2027

Recall size and scope

Quantity — 1296 bottles

Distribution — Nationwide within the United States

Company location — Elmwood Park, NJ, United States

Product identification

Brand name — ABIRATERONE ACETATE

Generic name — ABIRATERONE ACETATE

Route of administration — ORAL

Application number — ANDA209227

Safecor Health, LLCMetoclopramide Tablets, USP, 5 mg, 100 Tablets per bottle,…Manufacturer is recalling batches due to co-mingled tablet.Class II2026-11-04
[Recall · FDA]Safecor Health, LLC — Recall over co-mingled tablets
FDA💊 Small moleculeRecall

Metoclopramide tablet batches recalled over co-mingled tablets

Metoclopramide tablets 5 mg (100-count bottles) were recalled over co-mingled tablets (Class II, voluntary firm recall).

Published 2026-11-04 · Document no. D-0075-2027 · Product Metoclopramide Tablets, USP, 5 mg, 100 Tablets per bottle, Rx Only, Manufactured… · Class II

Original text and translation
Manufacturer is recalling batches due to co-mingled tablet.
Key facts · Basis: official source record kept by the collector
  • Reason: Manufacturer is recalling batches due to co-mingled tablet
  • Product and scope: Metoclopramide tablets 5 mg, 100-count bottles, lot 3116509, distributed nationwide in the U.S.
  • Action: Voluntary firm recall notified by email (initiated 2026-10-06)
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · E-Mail
Status
Recall initiated · 2026-10-06FDA classification · 2026-10-23FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot # 3116509, Expiry: 07/31/2027.

Recall size and scope

Distribution — US Nationwide

Company location — Rockford, IL, United States

Product identification

Brand name — METOCLOPRAMIDE

Generic name — METOCLOPRAMIDE

Active ingredient — METOCLOPRAMIDE HYDROCHLORIDE

Route of administration — ORAL

Application number — ANDA072801

MACLEODS PHARMA USA, INCOlmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide T…Failed Dissolution Specifications.Class II2026-11-04
[Recall · FDA]MACLEODS PHARMA USA, INC — Recall over dissolution failure
FDA💊 Small moleculeRecall

Olmesartan triple-combination tablets recalled over a dissolution failure

Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets 40 mg/10 mg/12.5mg were recalled for failing dissolution specifications (Class II, voluntary firm recall).

Published 2026-11-04 · Document no. D-0077-2027 · Product Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets 40 mg/10 mg/12… · Class II

Original text and translation
Failed Dissolution Specifications.
Key facts · Basis: official source record kept by the collector
  • Reason: Failed Dissolution Specifications
  • Product and scope: Olmesartan medoxomil/amlodipine/hydrochlorothiazide tablets 40 mg/10 mg/12.5mg, 3528 30-count and 216 90-count bottles, lots 12251163A and 12251163B, distributed nationwide in the U.S.
  • Action: Voluntary firm recall notified by letter (initiated 2026-10-07)
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-10-07FDA classification · 2026-10-26FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot #: a) 12251163A, Exp 05-31-2027; b) 12251163B, Exp 05-31-2027

Recall size and scope

Quantity — 3528 30-count and 216 90-count bottles

Distribution — Nationwide in the USA

Company location — Princeton, NJ, United States

Product identification

Brand name — OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE

Generic name — OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE

Active ingredient — OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE, HYDROCHLOROTHIAZIDE

Route of administration — ORAL

Application number — ANDA207088

ABC Compounding Co., Inc.Palm Antiseptic Hand Soap Net Contents: 1 Gallon (3.8 L). M…CGMP DeviationsClass II2026-11-04
[Recall · FDA]ABC Compounding Co., Inc. — CGMP deviations recall of 19 products
Evidence AFDASignal Med · T2Recall

Antiseptic hand soaps, body washes and other products from ABC Compounding Co., Inc., 19 in total, were recalled together for CGMP deviations (Class II, voluntary firm recall).

Published2026-11-04
Document no.D-0085-2027
CompaniesABC Compounding Co., Inc.
ProductPalm Antiseptic Hand Soap Net Contents: 1 Gallon (3.8 L). Manufactured by: ABC Compounding Co., Inc., 2600 Dogwood Dr., Conyers, GA 30013, UPC 711808196498 외 18품목
ClassClass II
All 19 products
  • Palm Antiseptic Hand Soap Net Contents: 1 Gallon (3.8 L). Manufactured by: ABC Compounding Co., Inc., 2600 Dogwood Dr., Conyers, GA 30013, UPC 711808196498
  • Aerocare Sani Mango Antiseptic Hand and Body Wash, Net Contents: 1 Gallon (3.8 L), Manufactured By: ABC Compounding Co., Inc., 2600 Dogwood Dr., Conyers, GA 33013, UPC 711808198249
  • Aero Foamy Mango Aloe Vera Antiseptic Hand & Body Wash, Net Contents: 1 Gallon (3.8 L), Manufactured by: ABC Compounding Co., Inc., 2600 Dogwood Dr., Conyers, 30013, UPC 711808198393
  • Certus Medical Satin Foam, 750 ml (25.4 fl. oz.), Manufactured for: Cartus Medical, 2600 Dogwood Dr., Conyers, GA 30013, UPC 711808250930
  • Freshhands Premium Foamy Antibacterial Hand Soap Antiseptic, Net Contents: 18 oz (532 mL), Sold By; Consolidated Chemicals, LLC, 3191 W Tharpe St. Tallahassee, FL 32303 USA, UPC
  • Delta Foremost Sani-Foam Mango, Net Contents: 1000 ML, 33.8 FL OZ, Manufactured Expressly For: Delta Foremost Chemical Corp., 3915 Air Park Street, Memphis, TN 38118,
  • Antiseptic Hand Soap, Net Contents: 1 Gallon (3.8 L) Distributed By: image supply, inc., P.O. Box 1108, 5081 Dawn Drive, Lumberton, NC28359
  • Lynx, LX0864 peachy-foam antiseptic handsoap, 1000 ML (33.8 FL OZ.) Manufactured by: ABC Compounding Co., INC., 2500 Dogwood Dr., Conyers, GA 30013, UPC 711808210804.
  • Lynx, antibacterial hand soap, Net Contents 1 Gallon, (3.8 L), Manufactured by: ABC Compounding Co., INC., 2600 Dogwood Dr., Conyers, GA 30013, UPC 711808199925.
  • Lynx, antibacterial hand soap, Refill, Net Contents 1 Gallon, (3.8 L), Manufactured by: ABC Compounding Co., INC., 2600 Dogwood Dr., Conyers, GA 30013, UPC 711808200027.
  • Handtastic Foamy Mango Antiseptic Foam Soap Hand & Body Wash, Net Contents : 18oz (532ml), Sold by, Momar Incorporated, 1880 Ellsworth Industrial Drive, N.W., Atlanta, Georgia, 80818.
  • People's FM-24 FOAMING High Foaming Antiseptic Hand and Body Wash, NET CONTENTS: 1000 ML 33.8 FL OZ, Distributed by: People's Janitorial Supply, 955 Main Street, Forest Park, GA 30298, 404-363-2226.
  • PRO CHEM Fresh Start, Antibacterial Hand Soap, Antiseptic Hand Soap, 800mL bag, Sold by: PRO CHEM, Inc.,1475 Bluegrass Lakes Parkway, Alpharetta, GA 30064.
  • PRO CHEM BAN AID, Antiseptic Hand Soap, Net Contents: 1 GALLON (3.8 L), Sold by: PRO CHEM, Inc.,1475 Bluegrass Lakes Parkway, Alpharetta, GA 30004.
  • Pro Chem Suds Hand Soap, Net Contents: 18 OZ (532 ml), Sold by Pro Chem Inc., 1475 Bluegrass Lakes Parkway, Alpharetta, GA 30004
  • Chemseptic, Net Contents: 1 Gallon (3.8 L), Distributed By: RMC Rochester Midland Corporation, 155 Paragon Drive, Rochester, NY 14624 USA, Made in USA
  • Spurrier, Antimicrobial Hand Soap, Net Contents: 1 Gallon (3.8 L), Manufactured by: ABC Compounding Co., Inc., 2600 Dogwood Dr., Conyers, GA, 30013, UPC 726133100508
  • SunCoast Paper Inc. Surgent Antiseptic Hand Soap, Net Contents : 1 Gallon (3.8 L), SunCoast Paper In., 4111 Community Rd., Brunswick, GA 31520, UPC 654441P10219
  • Wechem Hand Guard8/1000mL Bag, Manufactured by: ABC Compounding Co., Inc., 2600 Dogwood Dr., Conyers, GA, 30013
Original text and translation · representative case
CGMP Deviations
Key facts · Basis: official source record kept by the collector
  • Reason: CGMP Deviations
  • Product and scope: 19 products incl. antiseptic hand soaps and body washes recalled for the same reason, 9220 bottles, distributed nationwide in the U.S.
  • Class: Class II
  • Action: Voluntary firm recall (initiated 2026-09-22)
Recall detail · From the source · OpenFDA · Based on the representative product

This card groups 19 products into one entry. All values below refer to one representative product (including lots, quantity, and status).

Status · OngoingVoluntary: Firm initiated
Status
Recall initiated · 2026-09-22FDA classification · 2026-10-27FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

9220 bottles

Recall size and scope

Quantity — 9220 bottles

Distribution — US Nationwide

Company location — Conyers, GA, United States

Fei Fah Medical Manufacturing Pte. Ltd.ULTRA STRENTGH, ELECTRIC MIDICATED BALM (menthol 16% and me…CGMP DeviationsClass II2026-11-04
[Recall · FDA]Fei Fah Medical Manufacturing Pte. Ltd. — Topical balm recall over CGMP deviations
FDARecall

Menthol and methyl salicylate balm recalled by the firm over manufacturing deviations

A menthol 16% and methyl salicylate 32% topical balm made by Fei Fah Medical Manufacturing Pte. Ltd. in Singapore was recalled for CGMP deviations (Class II, voluntary firm recall).

Published 2026-11-04 · Document no. D-0104-2027 · Product ULTRA STRENTGH, ELECTRIC MIDICATED BALM (menthol 16% and methyl salicylate 32%)… · Class II

Original text and translation
CGMP Deviations
Key facts · Basis: official source record kept by the collector
  • Reason: CGMP Deviations
  • Product and scope: Menthol 16%/methyl salicylate 32% balm, 70 g and 10 g, lots 23FEBU7001-019, 24FEBU7001-020, 23FEBU1001-9 and 24FEBU1001-004, 171,120 units, distributed nationwide in the U.S.
  • Action: Voluntary firm recall notified by letter (initiated 2026-10-23)
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-10-23FDA classification · 2026-10-27FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot: a)23FEBU7001-019, Exp. Date: October 2028; 24FEBU7001-020, Exp. Date: November 2029. b) 23FEBU1001-9, Exp. Date: October 2028; 24FEBU1001-004, Exp. Date: November 2029.

Recall size and scope

Quantity — 171,120 units

Distribution — Nationwide within the U.S

Company location — Singapore, Singapore

Product identification

Brand name — MENTHOL AND METHYL SALICYLATE

Generic name — ELECTRIC MEDICATED BALM ULTRA STRENGTH

Active ingredient — MENTHOL, METHYL SALICYLATE

Route of administration — TOPICAL

Application number — M017

Eagle Pharma Outsourcing LLCPHENYLephrine HCL Infusion, 100 mg per 250 mL in 0.9% Sodiu…Lack of Assurance of SterilityClass II2026-11-04
[Recall · FDA]Eagle Pharma Outsourcing LLC PHENYLephrine HCL Infusion, 100… — Two infusions recalled over sterility assurance
Evidence AFDASignal Med · T2Recall

Two single-use infusion products recalled together over lack of sterility assurance

Two single-use infusion products from Eagle Pharma Outsourcing LLC were recalled together for lack of assurance of sterility (Class II, voluntary firm recall).

Published2026-11-04
Document no.D-0105-2027
CompaniesEagle Pharma Outsourcing LLC
ProductPHENYLephrine HCL Infusion, 100 mg per 250 mL in 0.9% Sodium Chloride (0.4 mg/mL), Sterile, Rx Only, Single-Use Container, EAGLE PHARMA OUTSOURCING, 2200 Riverchase Center, Suite 675, Hoover, AL 35244, UPC: 6985210025. NDC 69852-100-25 외 1품목
ClassClass II
All 2 products
  • PHENYLephrine HCL Infusion, 100 mg per 250 mL in 0.9% Sodium Chloride (0.4 mg/mL), Sterile, Rx Only, Single-Use Container, EAGLE PHARMA OUTSOURCING, 2200 Riverchase Center, Suite 675, Hoover, AL 35244, UPC: 6985210025. NDC 69852-100-25
  • OXYTOCIN, 30 USP UNITS, Added to 0.9% Sodium Chloride 500 mL - Single-Use Container, Rx Only, EAGLE PHARMA OUTSOURCING, 2200 Riverchase Center, Suite 675, Hoover, AL 35244, UPC: 6985203050. NDC 69852-030-50
Original text and translation · representative case
Lack of Assurance of Sterility
Key facts · Basis: official source record kept by the collector
  • Reason: Lack of Assurance of Sterility
  • Product and scope: 2 single-use infusion products in 0.9% sodium chloride recalled for the same reason; lead product lot PHENYL100-1004, 50 containers of 250 mL, distributed nationwide in the U.S.
  • Class: Class II
  • Action: Voluntary firm recall notified by email (initiated 2026-10-08)
Recall detail · From the source · OpenFDA · Based on the representative product

This card groups 2 products into one entry. All values below refer to one representative product (including lots, quantity, and status).

Status · OngoingVoluntary: Firm initiatedFirst notified · E-Mail
Status
Recall initiated · 2026-10-08FDA classification · 2026-10-28FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot: PHENYL100-1004, Expiry: 12/31/2026.

Recall size and scope

Quantity — 50 250 mL-containers

Distribution — Nationwide within the U.S

Company location — Hoover, AL, United States

Direct RxLidocaine Ointment USP, 5.0 % 50g JAR, Rx only, Packaged an…Subpotent DrugClass II2026-11-04
[Recall · FDA]Direct Rx — Recall over subpotency
FDARecall

Lidocaine ointment recalled by the firm as subpotent

Lidocaine ointment USP 5.0% in 50g jars was recalled as a subpotent drug (Class II, voluntary firm recall).

Published 2026-11-04 · Document no. D-0107-2027 · Product Lidocaine Ointment USP, 5.0 % 50g JAR, Rx only, Packaged and Distributed by: Dir… · Class II

Original text and translation
Subpotent Drug
Key facts · Basis: official source record kept by the collector
  • Reason: Subpotent Drug
  • Product and scope: Lidocaine ointment USP 5.0%, 50g jars, lots 03AP2511, 30AP2518, 18JU2519 and 18JU2520, 493 jars, distributed nationwide in the U.S.
  • Action: Voluntary firm recall notified by letter (initiated 2026-09-29)
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-09-29FDA classification · 2026-10-29FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

LOT#: 03AP2511, 30AP2518, 18JU2519, 18JU2520, Exp. Date 04/30/2027.

Recall size and scope

Quantity — 493 jars

Distribution — Nationwide within the United States

Company location — Dawsonville, GA, United States

MSN Laboratories Private Limited (Formulations Division, Un…Atorvastatin Calcium Tablets, USP, 40mg, 1000 tablets per b…Presence of Foreign Tablets/CapsulesClass II2026-11-04
[Recall · FDA]MSN Laboratories Private Limited (Formulations Division, Uni… — Recall over foreign tablets/capsules
FDA💊 Small moleculeRecall

Foreign tablets or capsules found in large atorvastatin bottles

Atorvastatin calcium tablets 40mg (1000-count bottles) were recalled for the presence of foreign tablets/capsules (Class II, voluntary firm recall).

Published 2026-11-04 · Document no. D-0113-2027 · MSN Laboratories Private Limited (Formulations Division, Unit-II) · Product Atorvastatin Calcium Tablets, USP, 40mg, 1000 tablets per bottle, Rx only, Manuf… · Class II

Original text and translation
Presence of Foreign Tablets/Capsules
Key facts · Basis: official source record kept by the collector
  • Reason: Presence of Foreign Tablets/Capsules
  • Product and scope: Atorvastatin calcium tablets 40mg, 1000-count bottles, lots DRF09618A and DRG02110A, 13,296 bottles, distributed nationwide in the U.S.
  • Action: Voluntary firm recall notified by letter (initiated 2026-10-21)
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-10-21FDA classification · 2026-10-29FDA published · 2026-11-04
Affected lots and expiry
Original · OpenFDA

Lot: DRF09618A, Exp 08-31-2029, DRG02110A, Exp 01-31-2030.

Recall size and scope

Quantity — 13,296 1,000-count bottles

Distribution — Nationwide in the USA.

Company location — Rangareddy District, India

Product identification

Brand name — ATORVASTATIN CALCIUM

Generic name — ATORVASTATIN CALCIUM

Active ingredient — ATORVASTATIN CALCIUM TRIHYDRATE

Route of administration — ORAL

Application number — ANDA211933

Trade press briefing 4 items

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.

AI Disclosure

How this content is produced, and caveats

1. Information generated by AI

Card titles, summaries, Korean translations, implications, check items, and detailed analysis are content generated automatically by generative AI from published primary official material.

2. Information provided as in the source

Figures, codes, dates, agency and company names in the fact table, quotations from the original text, source and official-document links, and findings tables (FDA Form 483 observations, MFDS routine inspection findings, and so on) are extracted mechanically from the source and are not reworded or rewritten.

3. Verification, limitations, and user notes

  • To improve accuracy, GRM provides evidence grades (A, B, C) and signal tiers (1–3). Evidence A means the information can be checked directly against a primary official document.
  • Summaries, translations, implications, check items, and detailed analysis generated by generative AI may contain mistranslations, omissions, misread context, or information that is not up to date.
  • This service is reference material intended to provide regulatory and quality information; it does not provide legal, regulatory, quality, or compliance advice or official interpretation.
  • Before using this material for decisions, quality system operation, regulatory response, or audit preparation, users must check the official source and the relevant agency's latest material themselves.

This digest is AI-generated from primary sources; interpretations are not official or legal advice — verify against the original before acting.